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Management Strategy for Open Innovation in Korean Biochip Industry 
Jeong-Woo Choi 
 
Abstract 
Due to the need to access external knowledge for new product development (NPD), open 
innovation has been widely used in the biochip industry. Since current resources owned by 
single firm do not have all the capabilities, NPD in biochip requires strong interdisciplinarity, 
wide diversity of technological knowledge, and integration capabilities. In the present study, 
management strategy for open innovation is investigated for NPD in the Korean biochip 
industry. Open innovation is classified in three steps: (1) switching phase about starting open 
innovation in the NPD initial stage; (2) implementation phase about open innovation 
management in the NPD middle stage; and (3) transition phase about change to close 
innovation in the NPD final stage. Three models for three phases are developed and then tested 
by carrying out surveys in the Korean biochip firms. In addition, the transition phase model is 
evaluated in the Korean bio-pharmaceutical firms. 
The switching phase model suggests that research capability and external trust are the main 
variables that affect switching cost, which relates to the perception of advantage of open 
innovation. The implementation phase model suggests that technological novelty affects degree 
of openness, which, in turn, relates to technological capability and firm performance. 
Furthermore, institutional-, environmental-, and firm characteristics affect the depth- and 
breadth of open innovation activity. The transition phase model suggests that knowledge 
connected with product innovation has an impact on the open-close transition tendency, which 
relates to perception of advantage of close innovation. Based on the results for three phases of 
open innovation, we propose the management strategy for open innovation during NPD. 
Therefore, based on the results of analyses of the proposed model, we can evaluate the factors 
that affect open innovation activity and develop an appropriate management strategy of open 
innovation for NPD of biochip. 
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1 
Chapter 1. Introduction 
 
1.1. Introduction 
 
Innovative product development in the leading-edge technology area has been subjected to 
two major pressures: reducing time-to-market and increasing the disintegration of product 
development processes into both production and development activities to get knowledge from 
the outside. Therefore, innovation for product development has been conducted with networks 
of partners outside organization and lead users all over the world, in the process that can be 
called open innovation (Chesbrough 2003a). In the process of coordinating the distributed 
innovative product development activities, project managers should use new network 
technologies. 
Due to the need of external knowledge for new radical product development, open 
innovation has been applied to the leading-edge technology in, for instance, the biotechnology 
and pharmaceutical areas (Nilsson 2009; Fetterhoff and Voelkel 2006). Owing to the 
characteristics of this area, such as the need of combination of various techniques and scarcity 
of resources inside a company, the application of network or external scientists is needed for 
the development of radical product in the nanotechnology and nanobiotechology fields (Lane 
and Kalil 2005; Conrad 2009). Furthermore, since biosensor and biochip are products of the 
nanobiotechnology field, a relevant strategy to handle application of network or external 
scientists as one way of open innovation is urgently required. However, the management 
strategy in nanobiotechnology in open innovation, especially for the biosensor and biochip 
industries1 has not been thoroughly investigated yet.  
To practice open innovation in the biochip industry, the following questions need to be 
addressed: 
̶ How can a company get various technologies from the outside to make biochips? 
̶ What would be a most appropriate management strategy for open innovation to get 
                                           
1 In what follows, the biosensor industry and the biochip industry will be referred to as the biochip industry, since 
the assembly of various biosensors on one chip has been described as biochip. 
2 
technologies from the outside world and to control the technology supply chain?  
 
The above questions are essential for the following reasons. The construction of a biochip 
needs a fusion of technologies, such as the biotechnology, electronics, chemistry, and the 
microelectromechical system (MEMS) technology. Therefore, firms want to get the 
technologies for product development from external partners, as firms cannot have all 
technologies and because there is a need to reduce the time for the development of technology. 
Open innovation is one way of outsourcing of technology. A new management strategy for 
open innovation is needed to efficiently get the technology from outside in order to effectively 
innovate in the biochip industry. The strategy should be made based on the combination of 
viewpoints of the technology supplier (external researcher) and the technology buyer (firm).  
To construct a relevant strategy to get the knowledge from the outside, appropriate 
technologies for major stages of innovation (e.g. initial, implementation, final) are investigated 
in this study. Specifically, we propose that the technology supply chain is constructed based on 
open networks and proprietary networks. 
In the initial stage, what is important is the decision to participate in open innovation and 
seeking participation of the technology supplier. To investigate the decision to participate in 
the open innovation, the switching cost from close innovation to open innovation is considered 
(Son et al. 2014; Matos 2009). Therefore, in this study, we investigate the firm’s willingness to 
participate in open innovation related to the switching cost and its perception of advantage of 
open innovation based on external trust and research capacity. To construct the management 
strategy, the switching cost theory is examined to verify the relations between the technology 
supplier (researcher) and the technology buyer (firm). Furthermore, we also investigate the 
relation between the supplier of technology, type of collaboration with other companies, reward 
for technology transfer, as well as coordinator of technology transfer to major and education 
levels. In the initial stage, the strategy of organization to adopt open innovation in the biochip 
industry is suggested and the relations between variables are analyzed.  
In the implementation stage, the management strategy for open innovation is related with 
the degree of open innovation (openness) and firm performance. The technology novelty and 
technology complexity affect openness and, in turn, openness is related to firm performance 
(Tatikonda and Rosenthal 2000; Vahter et al. 2014, Vahter et al. 2016). The resultant model for 
3 
relationships among technology novelty, technology complexity, openness, and firm 
performance is constructed and evaluated. Furthermore, breadth and depth of innovation 
related with firm performance that exits as a different form of open innovation is also 
investigated (Laursen et al. 2006; Greco et al. 2016). The factors that affect breadth and depth, 
such as environmental characteristics, firm characteristics, and organization characteristics, are 
also investigated. In the implementation stage, the strategy of organization to adopt open 
innovation in the biochip industry is suggested and the relations between variables are analyzed. 
In final stage, the transition of innovation type from open to close occurs and, therefore, a 
strategy to manage this transition is needed. The effect of technology development for 
transition from open innovation to close innovation is analyzed based on the stage of new 
development in the biochip industry. Transition point from close- to open- innovation is 
decided based on the stage of the commercial product opening. Repeat of transition from close- 
to open- innovation is performed as new product emerges in the biochip industry. This 
transition from close to open innovation is important in terms of devising a management 
strategy of new product development in biochip firms. The model for relation between the 
transition tendency among technology knowledge, product innovation stage, government 
approval stage, and close innovation is constructed based on semi-structured interview in the 
biochip industry and then extended to biotechnology industry. Finally, in the implementation 
stage, the strategy of organization to adopt open innovation in biotechnology firms is suggested 
and the relations between variables are analyzed.    
Research methodology used in the present study mainly involves data collection through e-
mail surveys and semi-structured interviews with researchers in the Korean biochip and 
biotechnology firms. Data analysis is performed by using quantitative statistical approaches 
and SPSS is used as the analytical software. Semi-structured interviews are used as a research 
method to investigate the issues of the switching cost, openness, and transition. The required 
management strategy of organization to adopt open innovation in the biochip industry is 
suggested and future directions of open innovation in leading-edge technology area are outlined. 
 
 
 
 
4 
1.2. Open Innovation 
 
1.2.1. Open innovation 
 
Nowadays, industrial innovations is becoming more open, requiring changes in how firms 
manage innovations (Edward 2016; Chesborough 2003a,b; Hodson 2016; Holmes 2016; von 
Hipper 1999, 2005). Accordingly, external sources of knowledge become more prominent, 
while external channels to market offer a greater promise. Based on open innovation concepts, 
in order to advance technologies, firms should use both internal and external paths to the market 
(Bender 2016; Owens 2016). 
Despite the growing body of evidence that supports how effective open innovation can be, 
companies still resist its ideas. Many researchers have explained open innovation as inbound- 
and outbound- innovation (Chesborough 2006b; Chesborough and Crowthther 2006; Savage 
2016; von Hipper and Krogh 2015). However, in recent years, industry leaders have had to face 
a new reality:  the situation when really good ideas are coming from the outside. Thus, 
deciding to open up to external ideas is a vital step towards stimulating a greater growth and 
innovation in firm. However, it is not just the first step. It was found that even committed 
companies believe in the myths and share the misconceptions that impair their ability to 
connect to useful external thinking (Chesborough 2004, 2006a). The four common myths about 
open innovation are as follows: (1) No one understands your needs; (2) There are no new ideas; 
(3) Response to your needs will be too academic to be useful; (4) Intellectual property issues 
make access to external innovation too complex. Once company overcomes these myths, it 
must face the reality: the prevalence of the Not Invented Here Syndrome. This syndrome should 
be overcome again to achieve open innovation.  
In such open innovation and uncertain circumstances, the firm needs to “play poker” 
(Chesborough 2004) and chess to compensate for the measurement error and manage risk such 
as “false negatives”. “Play poker” means that firms do not know all the information in advance 
and, therefore, have to decide whether to spend additional money to continue with the current 
project or to move to next projects, which makes new metrics for firms. New metrics could 
help a firm focus more upon external sources of innovation to enhance its business model. The 
concept of use of external sources based on new metrics in open innovation is one of the basic 
5 
principles of innovation in the new product development.   
In an investigation of recent trends and tendencies in open innovation, Gassmann (2005) 
shows that, although a trend towards open innovation can be observed, open innovation is not 
an imperative for every company and every innovator. Rather, there is a need for a contingency 
approach regarding the management of innovation with the focus on determining which of the 
factors that drive higher performance should be open and which should be closed. The nuclear 
and military industries are typical examples of close innovation industries where non-
proliferation of technology and protection remain important. Grassman (2006) reports that the 
more an industry’s idiosyncrasies correspond to the developments and trends, such as 
globalization, technology intensities, technology fusion, new business model, and knowledge 
learning, the more appropriate the open innovation model appears to be. 
To date, open innovation concepts have been regarded as relevant primarily to top ‘high-
technology’ industries, with examples that include Lucent, 3Com, IBM, Intel, and Millennium 
Pharmaceuticals (Chesbrough and Crowther 2006). Chesbrough and Crowther (2006) provide 
the explanation of the application of open innovation to outside high technology industry and 
report that, specifically, it was identified that organizations in industries outside ‘high 
technology’ are also early adopters of the concept. The investigation results reported by 
Chesbrough and Crowther (2006) demonstrate that many open innovation concepts are already 
in use in a wide range of industries. The authors document practices that appear to assist 
organizations in adopting these concepts and conclude that open innovation is not ipso facto a 
recipe for outsourcing R&D. Rather, open innovation has utility as a paradigm for industrial 
innovation beyond high tech to more traditional and mature industries. 
Furthermore, O’Conner (2006) suggests that radical innovation must be open innovation in 
large established firms. While growth and profit alternatives continue to erode many companies, 
the importance of radical innovation as a mechanism for organization rejuvenation is increasing 
(O’Conner and Ayers 2005). Some firms are building entire manufacturing systems to enable 
radical innovation over and over again. They are experimenting with different organizational 
structures that vary in terms of their relationship with R&D and in terms of how far down the 
commercialization path they oversee projects. To have a fully developed radical innovation 
capability, the firms should manage the following three sets of activities: discovery, incubation, 
and accelerated growth of new businesses. In addition, they should also ensure smooth 
transitions between these activities. In addition, there is a number of organization factors that 
6 
leverage the human side of making radical innovation happen that, if viewed systematically, 
could be more broadly used for a greater radical innovation success (O’Conner and McDermott 
2004). Specifically, O’Conner and McDermott (2004) outline gaps and mismatches that 
emerged between the expectation for radical innovation to happen and the mechanisms by 
which people are incented to do so (O’Conner and McDermott2004). 
In addition, Christensen et al. (2004, 2005) report how the open innovation concept can be 
analyzed from industrial dynamic perspectives. In these studies, the main proposition is that 
the specific models using which different companies manage open innovation with regard to 
an emerging technology reflect their differential positions within the innovation system in 
question, as well as the nature and stage of maturity of technological regime and the particular 
value position pursed by companies. This proposition was analyzed through an in-depth study 
of the current transformation of sound amplification from linear solid state technology to 
switched or digital technology within the consumer electronics system of innovation 
(Christensen et al. 2004, 2005). The results of this analysis suggest that there is a complex 
interplay between technology entrepreneurs and incumbents and that sometimes open 
innovation has to be conducted under the conditions of high transaction costs.  
Furthermore, Krischbaum (2005) reports an example of application of open innovation to 
company and suggests the optimal strategy of open innovation. By combining internal and 
external competencies and knowledge, both in R&D and marketing, the multinational life 
sciences and performance materials company Dutch State Mines (DSM) is opening up its 
innovation process. DSM recognizes that successful, profitable innovation depends upon team 
work and appropriate entrepreneurial culture. The presence of a business group dedicated to 
business development and venturing testifies to the increased importance of speeding up 
innovation at DSM, using both internal and external leads at all stages of new business 
development. During this process, different management styles are required, ranging from a 
scientific approach in early stages, through an entrepreneurial attitude in the early phase of 
commercialization, to a more risk-adverse mindset once the business has matured.  
Taken together, the results of the above studies suggest that management strategy should be 
needed for activity of open innovation.  
 
 
7 
1.2.2. Open source 
 
Goldman and Gabriel (2005) explain the open source approach, alternatively referred to as 
“innovation happens everywhere”, as s different way of doing business. There exists a large 
open-source community with established practices and cultures. Companies and other parties 
willing to start or join an existing open-source project need to understand the ground rules and 
established practices of this larger community, as there are the term open source sets 
expectations that need to be either met or explained. There are many definitions of what 
constitutes an open source. The basic idea is very simple: for open source software as an 
example, by opening the source code for a piece of software available to all, the programmers 
can modify it to better suit their needs and redistribute the improved versions to other users. 
By working together, a community of both users and developers can improve the functionality 
and quality of the software. Therefore, an open source requires that anyone can get and modify 
the source code and that they can freely redistribute any derived works created from it. Thus, 
the open-source community has been worked as the resource of the technology supplier in the 
open source computer. 
The “hybrid open source project” concept was first proposed by Goldman and Gabriel (2005). 
When companies start open-source projects, it is typical for those projects to be part of a 
company’s initiative for strategic purposes and aims. Since many companies use a more 
traditional or conventional development process, such companies starting open-source projects 
are likely to want to engage the open-source community with some of their traditional tools 
and in-house experts. When this happens, it can be called as “hybrid open-source project”. For 
example, while GE started its Visualization Toolkit open-source project, they wanted to 
establish a strong cultural value around testing and quality. Based on some ideas from Extreme 
Programming, they instituted a distributed, automatic testing system that kicks in every night 
on the changes submitted project that day.  
The open-source project has been applied as the concept of open innovation with a 
company’s initiative and use of external resources in biotechnology areas. A.R.A. Jefferson, an 
American-born molecular biologist, seeks to increase innovation in the life sciences by 
applying software’s open-source model to biotechnology (Broothaerts et al. 2005). His goal is 
to change the global patent system and how people use intellectual property, as well as to break 
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the grip of the big multinationals on the tool of innovation. Currently, open source movement 
in biotechnology has been done by CAMBIA, an international, independent non-profit research 
institute (www.cambia.org). CAMBIA has been creating new enabling tools to foster 
innovation and spirit of collaboration in the life sciences. CAMBIA’s BIOS InitiativeTM 
(Biological Innovation for Open Society) is exploring new R&D paradigms, practices, and 
policies that would address neglected priorities of disadvantaged communities. 
CAMBIA’s2 activities are as follows: (1) Open innovation depends on transparency in the 
patent system. CAMBIA’s Patent LensTM provides tools to make the world of patents and patent 
landscapes more transparent, to help focus paths leading to freedom to cooperate. These tools 
include one of world’s largest free-full text searchable life sciences patent databases, now 
expanding to include all technology classifications, as well as a variety of technology 
landscapes and intellectual property tutorials. (2) BiOS (Biological Open Source) Licenses 
have resonance with the licensing strategies that have evolved around free and open source 
software, but are uniquely crafted for the characteristic complexities, constraints, and business 
practices of modern life sciences. The BiOS Compliant Licenses are also designed to stimulate 
new opportunities, galvanize new groups of innovators, and achieve new efficiencies by 
encouraging a distinction between tools of innovation and the products and services. Biological 
Open Source Compliant Licenses create a dynamic protected technology commons where a 
material or invention can be improved by the ideas of many; however, access is maintained for 
all who agree to the terms without exclusive capture by anyone. CAMBIA has seeded this 
movement with its own technologies and other technology owners may also provide licenses 
to their technologies using this framework. 
Furthermore, BioForge,3 an online collaborative research platform for biological innovation, 
has been launched and developed in partnership with CollabNet Inc.4. In tradition of open 
source software, BioForge makes it possible for scientists to work together to craft new, 
deliverable technologies within a protected commons.  
Therefore, the open-source community in biotechnology should be the resource of 
technology supply in open innovation of the biotechnology field, which can be further applied 
to construct the technology supply diagram for the biochip field in the present study. 
                                           
2 For further detail, see www.cambia.org 
3 For further detail, see http://www.bioforge.net 
4 For further detail, see http://www.collab.net 
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1.3. Technology Development 
 
Currently, firms urgently need to reduce time-to-market in new product development (NPD) 
and, therefore, to get enough technology for commercial product-to-market inside the firm 
imports using knowledge from external partners. Thus, increasing NPD should be carried out 
with partners and lead users outside organizations, and then be distributed all over the world, 
transforming thus into distributed new product development (DNPD). The project managers 
should use new network technologies in the process of coordinating the DNPD activities. 
Since the innovation type is affected by the stage of new product development, the new 
product development in the biochip industry is related to the construction of management 
strategy of open innovation. The recombinant innovation, democratization and ‘connect and 
develop’ have been proposed as the way of open innovation in new product development as 
explained in the followings. 
 
1.3.1. Recombinant innovation 
 
Rather than cashing entirely new ideas, successful firms to achieve innovations focus on 
recombining old ideas in new ways by working with social networks during breakthrough 
innovation (Hargadon 2003a, 2004). Instead of insulating their innovation efforts from 
operating divisions, customers, and suppliers, these firms extensively rely on these partners. 
An intelligent recombination of existing technologies and innovations has driven the 
breakthrough in technologies. By spanning multiple, otherwise disconnected industries and 
markets, successful firms become the first to see how the existing technology in one market 
could be effectively used to create breakthrough innovations in another market. 
The technology brokering for recombinant innovation requires to bridge distant communities 
and to build new communities around those innovative recombination, which involves tapping 
the networks of innovation (Hargadon 2000). Bridging the otherwise disconnected 
communities in a firm’s external networks causes bringing the firm’s technical expertise to new 
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markets and industries. Devoting more resources to building new networks around a potential 
innovation can prove to be equally beneficial. Rather than nurturing individual geniuses, 
successful firms develop strong social networks both within and outside their groups 
(Hargadon 2004). This kind of social network base innovation should be the key principle of 
distributed new innovative product development in open innovation. 
However, pursuing the strategy of technology brokering does not mean throwing out the old 
R&D organization altogether (Hargadon 2003b). Aside from trying to invent the future, 
traditional R&D provide two critical competencies. First, these labs foster the expertise needed 
to evaluate existing technologies developed and used elsewhere. Second, the labs are best 
equipped to provide process innovations that fit within the organization’s particular constraints. 
To pursue a strategy of technology brokering means recognizing that a key role of corporate 
R&D is bridging the many different existing industries and markets and building the necessary 
combinations of technologies and people to enable potential breakthroughs. However, making 
this happen means moving the organization and the culture of R&D away from the leading 
edge pursuit of inventions.  
 
1.3.2. Democratization 
 
R&D has long been a costly and inexact process. Presently, some companies are trying a 
radically new approach by providing their customers with the tools to create, design, and 
develop their own products (von Hippel 1999; Thomke and Von Hippel 2002). For example, in 
their study of this democratization, Thomke and Von Hippel (2002) show that the customer, 
especially a lead user, has been emerged as innovators for a new way to create value. While 
trapping in top customer innovation can certainly generate tremendous value, capturing this 
value is hardly a simple or straightforward process. The companies should not only must 
develop the appropriate toolkit, but also revamp their business models and their management 
mind-sets. Now, with customers taking over more of the design task, companies should more 
closely focus on providing the best custom manufacturing. Said differently, as the location 
where value is both created and captured changes, the companies must reconfigure their 
business models accordingly. In addition, innovation development, production, distribution, 
and consumption networks can be built-up horizontally by and for users (Von Hippel 2005). 
11 
Furthermore, as suggested by Von Hoppel and Krogh (2006), free revealing of product and 
process designs is a defining characteristic of open innovation. Specifically, free revealing is 
the feature that facilitates collaborative design where all can participate, as in the well-known 
case of open source software projects. However, empirical research shows that free revealing 
of product and service designs is practiced far beyond the software industry. Therefore, a 
central tenant of open innovation is free revealing of the detailed workings of novel products 
and services, so that others may use them, learn from them, and perhaps improve them as well. 
Innovators frequently do freely reveal proprietary information and knowledge regarding both 
information-based products and physical products they have developed. On top of that, free 
revealing can make good economic sense for innovators and the society on the whole. Free 
revealing can be understood in terms of ‘private-collective’ model of innovation incentives. 
This model occupies a fertile middle ground between the traditional private and the collective 
action model of innovation incentives. This model explains conditions under which an 
innovation created by private funding may be offered freely to all. When these conditions are 
met, the society appears to have the best of both worlds: new knowledge is created by private 
funding and then the result is freely offered to all.  
 
1.3.3. Connect and develop 
 
Another process using open-source innovation strategy is “connect and develop” developed 
by Procter and Gamble Co. (P&G) (Dodgson et al. 2006; Huston and Sakkab 2006). “Connect 
and develop” is not a different type of innovation, but is rather an example of specific 
implementation choice of open innovation. As reported by Huston and Sakkab (2006), P&G 
created a technology brief that defined the problems needed to be solved and circulated it 
throughout the global networks of individuals and institutions to discover if anyone in the world 
had a ready-made solution. In 2000, realizing that P&G could not meet its growth objectives 
by increasingly spending more on R&D for less and less payoff, the reinvention of company’s 
innovation business model started. At that time, most of P&G’s best innovations had come 
from connecting ideas across internal businesses and, in this context, the external connection 
could provide highly profitable innovations. Betting that these connections were the key to 
future growth, P&G set the goal to acquire 50% of innovations from outside the company. As 
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outside source of innovation was studied, it was estimated that, for every P&G researcher, there 
were 200 scientists and engineering experts elsewhere in the world who were just as good, 
which amounted to a total of ca. 1.5 million people whose talents they could potentially use. 
The massive operational change and culture change have been implemented for tapping into 
the creative thinking of inventors and other external parties. This kind of innovation model was 
called as “connect and develop”. The model works and, today, over 35% of new products in 
the market have elements originating from outside P&G. Through “connect and develop” 
coupled with improvements in other aspects of invention related to production costs, design, 
marketing, R&D productivity has increased by nearly 60%. 
As specified by Huston and Sakkab (2006), the connect-and-develop strategy requires that a 
senior executive has day-to-day accountability for the company’s vision, operations, and 
performance. At P&G, the vice president for innovation and knowledge has this responsibility. 
Connect-and-develop leaders from each of the business units at P&G have dotted-line reporting 
relationships with VIP. The managers of virtual R&D networks (such as NineSigma and P&G’s 
virtual supplier network), as well as the technology entrepreneur and hub network, connect and 
develop legal resources and directly report on training resources. The VIP oversees the 
development of networks and new programs, managers the corporate budget, and monitors the 
productivity of networks and activities. This includes tracking the performance of talent 
markets, like NineSigma and InnoCentives (virtual open innovation web-site), as well as 
measuring connect and developing productivity by region evaluations, e.g. the costs and output 
(as measured by products in the market) of foreign hubs. Productivity measurements for the 
entire program are reported annually. 
Following the success of P&G, several other forward-looking companies like IBM and Eli 
Lilly started to experiment with the new concept of open innovation, leveraging one another’s 
competition assets – products, intellectual property, and people (Husto and Sakkab 2006). By 
now, the open innovation method of “connect and develop” has been widely spread worldwide 
due to its benefits for companies and their need of innovation (Dodgson et al. 2006). 
The main philosophy of the “connect and develop” method will be applied to construct the 
strategy for open innovation proposed in the present study.  
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1.4. Biotechnology 
 
1.4.1. Alliance characteristics of biotechnology industry 
 
Alliance is a way of collaboration that is the main activity of open innovation. In the 
biotechnology industry, strategic alliance including mergers and acquisitions (M&A) is 
essential for the survival and evolution of companies. Although strategic alliances are generally 
analyzed as planned and rational developments with clearly measurable outcomes, de Rond 
(2003) provides an important new explanation of how strategic alliances develop in the 
biotechnology industry. Since alliances in the biotechnology industry have become an 
important way of competing in our globalizing world to increase firms’ performance, their 
number has dramatically increased in recent years.  
In this respect, Williams (2005) argues that consolidation is a necessary activity for 
biotechnology companies and corporate development in biotechnology. The author considers 
consolidation as an important mean for biotechnology companies to acquire strong positions 
to enter into partnering negotiations in the spirit of combining their core competencies with 
those of partners with complementary skills (especially in sales), rather than to act as 
financially starved supplicants (Williams 2005).  
The numbers conspire to make finding a partner increasingly difficult. In 2004, there were 
4,500 biotechnology companies and only 15 large pharmaceutical companies, i.e. potential 
partners with near global reach. Therefore, a biotechnology company faces a strong 
competition and the partnership between a big pharmaceutical company and a biotechnology 
company is necessary for their mutual development. 
Previous data monitor analysis undertaken by Pavlou and Belsey (2005) has identified two 
key company categories currently shaping the biotechnology industry, namely, the leading 
biotherapeutics players and the emerging biotherapeutics players. The mergers and acquisitions 
(M&A)/licensing agreements and current-in-house-technology development by R&D are 
critical factors for the evolution of the leading and emerging biotherapeutics business model. 
Through consolidation, the emerging companies become to be fully integrated and gain 
sustainable profitability. Intrabiotechnology companies or biotechnology company-to-
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pharmaceutics company deals and commercially attractive technology acquisition activities 
should help to win the race of innovation and sustainable growth (Pavlou and Belsey 2005). 
Therefore, the alliance including M&A and technology development due to alliance are key 
factors enhancing the organization evolution in the biotechnology industry.. 
In sum, as suggested by the results overviewed above, the alliances between 
intrabiotechnology companies or biotechnology company-to-pharmaceutical companies are 
among the major factors to be considered for the development of the biotechnology industry.   
 
1.4.2. Innovation management in biotechnology 
 
Innovation is the fuel of the biotechnology industry; accordingly, biotech innovations arise 
from many fields, including biology, physics, computation, and engineering. However, all these 
fields share the common goal of the development of products or processes designed to improve 
our health, environment, or agriculture resources (Lőffler 2005). Clearly, not all innovations 
lead to the creation of good products, and not all good products build profitable companies. 
Innovations are particularly difficult to access because of the problems inherent in estimating 
all possible applications, market size, and time to market. Although quantitative assessments 
(such as net present values, risk-adjusted present values, and options) provide us with concrete 
numbers, they also yield an incomplete picture of the potential value of a technology. Using 
quantitative assessment alone may result in overlooking the most intriguing and 
revolutionizing biotechnologies. A more accurate assessment is possible when quantitative 
factors are also considered, such as inventive potential (i.e. whether the technology is 
revolutionary or evolutionary), applicability (i.e. whether the technology has a clear 
commercial application), and market environments (i.e. whether the public, regulatory, and 
policy environments are ready to deal with the innovation). Upon integration of qualitative and 
quantitative measurements, a quadrant emerges where, depending on their relative qualitative 
versus quantitative scores, different technologies can be compared and categorized as 
“winners”, “promising”, ”dogs”, and “low-hanging fruit” (Lőffler 2005).  
Since the nanobiotechnology to be investigated in this study is a revolutionary emerging 
technology, the proposed analysis (qualitative versus quantitative score) will be performed for 
nanobiotechnology. 
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As explained by Shohet (2004), biotechnology companies are under intense scrutiny and 
unremitting pressure from shareholders and inventors to overt their costly R&D inputs into 
value-creating outputs. However, the techniques and tools to influence and manage R&D 
productivity are often weakly developed and are rarely fully deployed in many early-stage and 
mid-cap biotech businesses. There are many reasons for this trend, not least of which is that 
biotech companies often have a strong-science-led heritage and ethos, where the anarchic 
elements of research are encouraged. In big pharmaceutical companies, diagnostics, and 
medical technology companies, the disciplined tools for research management and product 
development are not at first seen as necessary and are frequently overlooked as the company 
grows. In fact, as will be argued in the present study, there is a considerable opportunity for 
biotech managers to strengthen R&D performance productivity through deploying more robust 
management tools that would enhance strategic, organizational and operational processes. This 
will lead to a better allocation and use of resources, as well as ensure that the right products are 
developed in the right way and at the right time. In relation to R&D, there are many ways for 
the senior managers of biotech companies to achieve a better practice, even if the best practice 
in biotech has yet to be well defined and validated. As the business grows, robust systems for 
R&D management become essential, not just to help allocate resources, but also to organize 
the company and to minimize risks and properly exploit the product opportunities. Managing 
these opportunities using a better R&D practice will help to ensure the sustainability of the 
business and deliver the growth and success required by shareholders and investors.  
In the present study, the open innovation in R&D of the biochip industry will be proposed to 
be managed based on the concepts outlined above. 
 
1.4.3. Open innovation in biotechnology 
 
In the increasingly competitive landscape, there is a growing demand for companies to be 
innovative. However, the concept of innovation in a product innovation is confused by the 
development of technology to make product. If innovation is defined as the commercialization 
of an enabling technology that provides the customer with a new capability, then there are two 
key requisites for innovation: customer insight to identify unmet need, on the one hand, and 
technology awareness to identify the respective enabling technology, on the other hand. Drivers 
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for innovation can be thought of as any force that links customer need uniquely with an 
enabling technology solution; this region of overlap is described as the innovation space. As 
shown by a report Fetterhoff and Voelkel (2006), Roche Diagnostics manages the challenges 
of sourcing external technologies by leveraging these drivers through comprehensive 
technology evaluation.  
Although most companies understand the need for external innovation, only few capture the 
full value of partnership with external technology providers. Value can be progressively built 
throughout the process of managing external innovation. This external innovation value chain 
can be thought of as consisting of the following five key stages: (1) Seeking opportunities; (2) 
Evaluating the market potential and inventiveness of a given opportunity; (3) Recruiting 
potential partners by building a convincing argument; (4) Capturing value through 
commercialization; and finally (5) Extending the innovation offering. Each stage offers a 
unique opportunity for value creation, but presents different challenges requiring unique skills 
and responsibilities. At Roche Diagnostics, for the start stage of external innovation, seeking 
and evaluating were mainly considered. 
At Roche Diagnostics, a process built upon six axes for technology assessment has been 
established (Fetterhoff and Voelkel 2006). These six axes, resembling a hexagonal ring, are as 
follows: (1) Customer utility; (2) Competition, or uniqueness of the opportunity; (3) Commerce, 
or market size; (4) Capital, or cost of opportunity; (5) Copyright, an intellectual property; and 
(6) Company fit, or strategy. Moreover, the space created by the corresponding axes defines 
perspectives from which the market potential for a given technology can be assessed. This six 
axis chart and the space created within it define multiple perspectives that offer a 
comprehensive approach to the assessment of the market potential for a given opportunity. If a 
given technology opportunity is positively evaluated, then recruitment, value capture, and 
extending processes have been done for external innovation. Roche Diagnostics manages 
external innovation by creating a vision of future based on customer insight and provides a 
comprehensive assessment of enabling technologies through multiple perspectives. 
Implementing the process outlined in the above within Roche Diagnostics has led to a 
successful value creation through multiple technology partnership and technology acquisition. 
In the present study, the technology assessment skill proposed above will be applied to 
evaluate the market potential and inventiveness of a given opportunity in open innovation in 
the field of nanobiotechnology. 
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Another relevant company of open innovation in biosciences is InnoCentive5. InnoCentive 
was created to foster innovation and efficiency in the area of R&D for major companies around 
the globe. The company was launched in 2001 as a start-up business venture incubated through 
a division of Elli Lily and Company. InnoCentive is an unbiased knowledge broker between 
major global companies and the worldwide scientific community, enabling them to collaborate 
and solve difficult problems. Global companies post their tough R&D problems on the 
confidential InnoCentive website6 for more than 22,000 leading scientists and researchers in 
125 countries to solve these problems for financial reward (Demir 2003). 
Solution-seeking companies, called Seekers, post their scientific problems on the 
InnoCentive website for the global community of registered scientists, called solvers, to access 
and have the opportunity to submit solutions. After a careful review by InnoCentive and the 
seeker’s company, awards are issued by InnoCentive only for the best solution that met the 
seeker’s requirement. Award amounts range from US$5,000 to $100,000. In exchange, 
intellectual property rights are transferred from the solving scientist to the anonymous solution-
seeking company. In addition to network of scientists that make up global Solver base, 
InnoCentive has a core team of top scientists and business executives in Andover, 
Massachusetts, and Indianapolis, Indiana. To date, InnoCentive is working with leading global 
companies such as BASF, DOW Chemical, P&G, Syngentra, and others, enabling them to 
confidentially post their tough R&D problems on the InnoCentive website. In addition, 
InnoCentive collaborates with a number of academic and research-based institutes around the 
globe. Initially, InnoCentive began with a focus on chemistry challenges (organic, inorganic, 
bio-organic, medicinal, biological, structural, etc.), but, in the past year, it has been expanded 
into other scientific disciplines including biology (microbiology, genetics, proteomics, 
genomics, pharmacology, bioengineering), biochemistry, and material science. 
Therefore, InnoCentive has introduced open innovation in biotechnology, such as in the 
bioscience and bioengineering areas, which can be applied for open innovation of 
nanobiotechnology to be investigated in this study. 
Furthermore, as concerns the pharmaceutical industry, Nilsson (2006) has reported open 
innovation in the pharmaceutical industry as follows. Since the pharmaceutical industry is both 
                                           
5 For further detail, see www.innocentive.com 
6 For further detail, see www.innocentive.com 
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one of the most research-intensive industries and a big industry in terms of revenue, it is 
important to acquire a deeper understanding of the trends in localization of R&D facilities. The 
open innovation strategy, where companies’ R&D crosses over corporate and national borders, 
becomes popular in the pharmaceutical industry. A challenge in pursuing open innovation 
strategy is the coordination of R&D sites. In localized R&D sites, it is important to optimize 
the use of technologies, systems, and processes so that to ensure the collaboration across the 
organization.  
Leading research-based pharmaceutical and biotechnology companies in the United States 
spend on an overwhelming percentage of R&D dollars in the U.S. At the same time, the number 
of R&D laboratories that these companies locate outside the U.S. is growing, alongside with 
their overall spending on R&D. The increased complexity of the science used to develop 
today’s medicine drives more pharmaceutical companies to establish laboratories close to 
research hotbeds around the world.  
While acknowledging the need for an open innovation strategy and sharing the belief that 
this strategy will grow increasingly prevalent within the pharmaceutical industry, involved 
actors also point out that costs and coordination difficulties create constrains in implementing 
the strategy. Moreover, the time necessary to get a new laboratory up and running is 
considerable. Therefore, there are reasons to expect the process of establishing R&D facilities 
in new places to move slowly and to depend on the financial situation of the companies.  
Cookie (2009) reported that micro-economic geography related to knowledge capabilities of 
firms, and their network in open innovation of biotechnology industry as follows. R&D 
outsourcing and open innovation economic geography for biotechnology have been 
investigated and collaborative relations between firms or between firms and clusters are 
focused in research. In UK’s biotechnology sector, there is considerable asymmetry in the 
location of research-driven clustering. Innovation attracts distant networks of cooperation in 
UK’s biotechnology sector, which well matches the characteristic feature of biotechnology 
where R&D is related to collaboration between external partner firm and inside laboratory. 
In the present study, the results on open innovation in the biotechnology industry overviewed 
above will be applied to construct the strategy of open innovation in the biochip industry. 
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1.4.4. Innovation management in nanobiotechnology 
 
At present, since the nanobiotechnology-based products are in the developing stage at 
laboratories and commercial products have not been made, few reports are available about the 
management of innovation and case study of open innovation in nanobiotechnology.  
According to Adhikari (2005) the convergence of technology with biology at the nano level 
is called nanobiotechnology. Nanobiotehnology has immense implications for medicine. 
However, while it works well in laboratory conditions, the transition of therapeutic concepts 
from mice to men is not easy to make. Four key areas of nanobiotechnology are therapeutics, 
drug delivery, tissue reconstruction, and imaging and diagnostics. Although the benefits of 
nanobiotechnology are huge, there are certainly many hurdles ahead to lead 
nanobiotechnology-based new products to become approved therapies. 
In the present study, a strategy of innovation in nanobiotechnology so that make commercial 
products will be proposed. 
According to Thomas and Acuna-Narvaez (2006), nanotechnology offers a promise to 
revolutionize the life sciences, because it equips biologists with tools and materials that can 
interact directly with the studied biomolecules. Both biotechnology and nanotechnology have 
matured to the point where their convergence offers opportunities for novel solutions to the 
unmet needs in biology. Although nanotechnology has always held a great promise as a 
platform for biotechnology applications, this convergence has taken longer than anticipated. 
Nevertheless, the pace of this convergence is now accelerating. Although there are a number 
of factors that have probably catalyzed this convergence, the primary ones relate to the 
increasing maturity of biotechnology and nanotechnology, greater opportunities for public 
funding and collaborations, and increasing interest and funding from the private sector, which 
is helping to convert technological advances into commercial applications.  
In this study, in order to design the strategy of innovation of nanobiotechnology, the key 
factors to catalyze the convergence of biotechnology and nanotechnology will be considered. 
Furthermore, in their report on the application and commercialization strategies in 
nanobiotechnology, Amurthur et al. (2005) distinguish between two forces that are driving 
applications in nanobiotechnology: the sheer force of the scientific advances that provide 
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revolutionary enabling technologies, on the one hand, and the tremendous need to surmount 
specific medical and pharmaceutical hurdles, on the other hand. In general, these applications 
can be divided into three main categories: detection, diagnosis, and therapeutics. The 
commercialization of nanobiotechnology is characterized by three distinguishing factors: (1) 
boundaries between research and commercialization are blurred; (2) transformation agents 
need to be highly technical; and (3) conversion agents need to devise multiple strategies. 
Advances in enabling technologies have accelerated the onset and development of 
nanobiotechnology. Compelling scientific and business drivers will accelerate the pace of 
innovation in this field and create significant commercialization opportunities. It is widely 
assumed that university and research labs are playing a decisive role in closing the gap between 
research and commercialization frontiers for nanobiotechnology applications. 
Therefore, in the present study, the commercialization strategies will be be combined with 
open innovation strategy of nanobiotechnology. 
Furthermore, as reported by Conrad (2006), the National Cancer Institute (NCI) recognizes 
the needs of physicians and basic research scientists to collaborate and, therefore, has 
established a new “team science” model for cancer research by aligning funding mechanisms, 
organization culture, and strategic investments to accelerate interdisciplinary research. This 
team-oriented model lies at the core of new programs that form the Alliance for 
Nanotechnology in Cancer. The model includes teams of experts who can not only view the 
many elements of the cancer progress, but can also integrate that knowledge and design in an 
innovative and targeted strategy of drugs, biologics, and even devices that can be used in all 
phases of the cancer process in an integrated fashion.  
In the present study, the concepts for open innovation in the nanobiotechnology industry 
outlined above will be applied to construct the strategy of open innovation of the biochip 
industry. 
 
1.4.5. Development of the biochip technology 
 
The biochip technology has been developed from biosensor array to DNA chip or protein 
chip. Recently, cell chip is being developed, which will be followed by the development of 
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organ chip. Microarray technology such as MEMS (microelecromechanical system), has been 
applied to the fabrication of all kinds of biochip.  
A DNA chip is a technology used in molecular biology and biosensor fields that consists of 
an arrayed series of thousands of micro/nanoscopic spots of single stranded DNA 
oligonucleotides, known as probes (Lenoir and Giannella 2006). The probes are 
complementary gene sequence of desired targets, which can be hybridized to cDNA or cRNA 
of the analysis target. Depending on the high specificity of complementary DNA strands, an 
array of several targets can be used to detect multiple targets at the same time. Therefore, 
micro/nanoarrays have dramatically accelerated many types of investigation in the DNA chip 
field. DNA chips can be used to measure changes in expression levels, detect single nucleotide 
polymorphisms (SNPs), as well as genotype or re-sequence mutant genomes (Ramsey 1988). 
They also differ in sensitivity, selectivity, and cost effectiveness as compared to traditional 
detection techniques.  
A protein chip provides a multiplex approach to identify protein-protein interactions, 
transcription factor protein-activation, and the targets of biologically active small molecules 
(Zhu and Snyder 2003). Sometimes it is referred to as a protein microarray. The protein chip is 
a piece of glass on which different molecules of protein or specific antibody binding for specific 
binding DNA sequences (as capture probes for the proteins) have been affixed at separate 
locations in an ordered manner, thus forming a microscopic array. The most common protein 
chip is the antibody microarray where antibodies are spotted onto the protein chip and are used 
as capture molecules to detect proteins from cell lysate solutions. Also, protein chip has not 
been used instead of protein microarray (Seong and Choi 2003). The protein chip was was 
originally used by electronics to describe small solid blocks containing various electrical 
circuits. Along the same lines, protein chip denotes an integrated circuit which electrical and 
logical functions performed by protein molecules when appropriately manipulated. However, 
we now call all solid membranes (glass slide, wafers, and polymers) biochips when 
biomolecules, such as DNA, proteins, lipid, carbohydrates, or conjugates between them are 
attached by covalent or noncovalent bonding. In addition, mechanical fluidic devices for the 
analysis of biomolecules in terms of quantity and quality are also called biochips or Lab-on the 
chip (LOC). Since the term ‘protein chip’ has also been used to denote biochips attached with 
proteins for biosensors, the terminology gets confusing. In addition, some of the chips show 
different patterns of protein arrays that are not observed in the fields of DNA chips.  
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Cell chip is a progressive type of biochip that can analyze the data of cell itself (Yea et.al. 
2007). This is an integrated technology that combines surface modifications to allow in vitro 
cell culture within the micro-chip and subsequent conversion of the physiological phenomena 
of these cells to a readable signal (El-Ali et al. 2006). This technology can be used to detect 
materials and measure microbial phenomena that cannot be detected by conventional 
biosensors used for the analysis of DNA and proteins, as well as an in vitro analysis not 
available in normal environment due to multiple cues that vary in time and space, including 
gradients of cytokines and secreted proteins from neighboring cells. Over the last several years, 
the interest in biochemical experiments and analysis of living cells has increased for studying 
effects of drug and external stimuli on cell behavior. To meet the needs for proper cell analyzing 
tools, various analytical techniques, such as resistance-, enzyme-, or fluorescence-based 
methods, have been developed to detect cellular signals in a simpler way with a high sensitivity. 
Label-free electrical techniques have also been tried for detecting changes of action potentials 
or electrochemical properties of target cells. Recently, extracellular action potential of cardiac 
myocytes and neuron cells derived from stem cells was successfully measured using a micro 
electrode array, which is not available with the optical or fluorescence based technique. 
Furthermore, the MEMS technology was also integrated to cell chip for further cell treatment 
or cell separation process, which can be included in the ‘lab-on-a-chip’ or ‘micro-total-analysis-
system(μTAS)’ field. These various kinds of cell chips that can integrate many different 
techniques for different purpose can be usefully applied to cellular research. 
The microfabrication technology has been applied to construct DNA chip, protein chip, and 
cell chip (Šášik et al. 2004). The first widely used technology was the spotted cDNA microarray, 
which consists of numerous probes of PCR-amplified cDNA fragments deposited in a matrix 
pattern of spots. A microarray is a structure that consists of sequential dots and plays an integral 
role in gene expression profiling. The substrate material is plastic, glass, or a silicon chip. A 
microarray can be made using various methods. The simple way is to merely drop the DNA 
onto glass slides using pins. More sophisticated methods use photolithography, electrochemical 
approaches, and inkjet printing. While the array technology was in use as early as in the 1980s, 
it did not come into prominence until the mid-1990s, when biotechnology really began to take 
off. Today, microarrays are widespread in genomic research and have a diverse range of 
applications in biology and medicine (Hoheisel 2006). This technique allows a researcher to 
simultaneously perform a sequence of tests on all of the samples, which dramatically speeds 
up research, as traditional biological experimentation works on samples one at a time.  
23 
Therefore, considering that the innovation type can be changed based on the stage of new 
product development, in the present study, the history of development of new products in the 
biochip industry will be considered to construct the strategy of open innovation in the biochip 
industry. 
 
1.5. Research Questions and Objectives of the Present Study 
 
The two basic research questions addressed in this study are as follows:  
̶ How can a company get various technologies from outside to make biochip?  
̶ What is an appropriate management strategy for open innovation to get technologies 
from outside by co-managing technology supply?   
 
Although there are some investigations on management strategy for open innovation in the 
biotechnology industry, the management of technology for open innovation in the biochip 
industry has not been properly addressed yet. In this study, the management of technology in 
biochip is investigated for each step of new product development (NPD) in open innovation, 
such as the switching phase in the initial stage of NPD, the implementation phase in the middle 
stage of NPD, and the transition stage of the last stage of NPD. The switching phase refers to 
the period when a firm wants to change from close innovation to open innovation; here, the 
switching cost refers to the cost of the change from close to open innovation. Furthermore, the 
implementation phase refers to open innovation that is actively being done; likewise, the degree 
of open innovation refers to the level of openness to external partners. The transition phase 
refers to the period of time when a firm wants to stop open innovation and start to close 
innovation, while the transition of innovation type refers to the change from open innovation 
to close innovation. 
Each step is investigated using the model based on the switching cost, the model based on 
the degree of open innovation, and the model based on the transition of innovation type, 
respectively.  
 
24 
1.5.1. Research questions in the switching phase 
 
In the initial stage of NPD, the decision to start open innovation is important, and then the 
seeking and evaluating the technology supplier should be considered. The decision can be 
described as the firm’s willingness to participate in open innovation.  
With regard to the switching phase, the following questions will be addressed: (1) Which 
influential factors should be considered to make decision to either start open innovation or not 
in the initial stage of new product development? (2) What is the relation among influential 
factors including the switching cost related to the perception of advantage of open innovation? 
(3) What is the strategy of facilitating the initiation process in open innovation? 
The firm’s willingness to participate in open innovation is related to the switching cost (Son 
et al. 2014; Matos 2009), i.e. the cost of the change from close innovation to open innovation; 
therefore, the switching costs can be investigated based on a number of different factors, 
including commitment-trust, research capacity, and the perception of advantage of open 
innovation. To construct a relevant management strategy, the model for switching costs is 
constructed. Furthermore, the relations among the switching cost, influential factors, and 
perception of advantage of open innovation are evaluated based on the proposed model 
To analyze the switching cost, the following hypotheses are explored in the present study: 
• There would be a positive relationship between trust with the existing research partner 
and the switching cost. 
• There would be a positive relationship between trust with existing research partners and 
the perception of advantage of open innovation. 
• There would be a positive relationship between trust with internal research team and 
switching cost. 
• There would be a negative relationship between trust with internal research team and 
the perception of advantage of open innovation. 
• There would be a positive relationship between research capacity of the firm and 
switching cost. 
• There would be a positive relationship between research capacity and the perception of 
advantage of open innovation. 
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• There would be a negative relationship between the switching cost and perception of 
advantage of open innovation. 
The investigation of the above hypotheses will be undertaken based on the survey 
conducted in the Korean chip industry.  
  
1.5.2. Research questions in the implementation phase 
 
In implementation of open innovation, openness is the key factor to increase the technology 
ability for NPD. Openness is related to technology characteristics, such as novelty and 
complexity (Tatikonda and Rosenthal 2000; Vahter et al. 2014; Verhoeven et al. 2016). Thus, 
the relationship among technology characteristics, openness, technology ability, and firm 
performance in the biochip industry should be evaluated. Also, breadth and depth of innovation 
activity are proposed during implementation of open innovation (Laursen et al. 2006; Laursen 
and Salter 2014; Greco et al. 2016). The factors affecting the breadth and depth of openness in 
the biochip industry will be investigated. 
 
1.5.2.1. Model for openness related to novelty and complexity of technology 
The following questions emerge with regard to openness related to novelty and complexity of 
technology: (1) Which influential factors should be considered regarding the optimal degree of 
open innovation during the implementation process in new product development? (2) What is 
the relation among factors including the technology characteristics with the openness? (3) What 
is the strategy to control the openness to increase the firm performance? 
To construct an appropriate management strategy, the model for openness related to 
technology- novelty and -complexity is constructed. Furthermore, the relations among 
openness, technology ability, and firm performance are evaluated based on the proposed model. 
To analyze the openness, the following hypotheses are formulated in the present study: 
• There would be a positive relation between technology novelty and openness. 
• There would be a positive relationship between technology novelty and technology 
ability. 
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• There would be a positive relationship between technology complexity and openness. 
• There would be a positive relationship between openness and technology ability. 
• There would be a positive relationship between technology ability and firm 
performance 
The investigations of the above hypotheses will be undertaken based on the survey in 
conducted the Korean chip industry.  
 
1.5.2.2. Model for breadth and depth of openness 
Openness is an important factor to make NPD. The breadth of openness is related to the 
number of knowledge sources, while the depth of openness is related to the number of 
collaboration with one knowledge source. A model for breadth and depth of openness is 
constructed. Furthermore, the relations among environmental characteristics, firm 
characteristics, and organization characteristics to openness are evaluated based on the 
proposed model.  
To analyze the breadth and depth, the following hypotheses are formulated in the present 
study: 
• Environmental characteristics would affect the depth and breadth of openness. 
• Firm characteristics would affect the breadth and depth of openness. 
• Institutional characteristics would affect the depth of openness 
The investigation of the above hypotheses will be undertaken based on the survey 
conducted in the Korean chip industry.  
 
1.5.3. Research questions in the transition phase 
After producing NP in the final stage, the firm considers the continuation of open or the 
transition to close innovation. The decision for close or open innovation is crucial, since it 
affects the firm performance (Felin and Zenger 2014). The transition tendency depends on 
knowledge for NP, product development stage, government approval stage, and product 
innovation stage. Furthermore, the transition tendency depends on willingness of close 
innovation or the perception of advantage of close innovation. The management strategy to 
decide the transition of innovation type should be made based on the relation between transition 
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tendency and the above mentioned factors.  
In this context, the following questions emerge: (1) What factors should be considered in 
making the decision on either closing open innovation or not at the final stage of new product 
development? (2) What is the relation among factors including the transient tendency related 
with the perception of advantage of close innovation? (3) What is the strategy to control the 
openness to increase frim performance? 
When commercializable product is made during NPD, a firm in the biochip industry has to 
decide on the type of innovation. Since all the technology to produce commercial product is 
acquired, keeping the open status needs more expense and poses a risk of leakage of knowledge. 
Therefore, to transit to close innovation might be a better choice to increase the interest of the 
firm. However, considering the modification of product for new application and more 
improvement of product for advanced function, the open innovation should be preserved. In 
this study, the relations among transition decision, product stage, and product innovation stage 
will be evaluated.  
To analyze the innovation transition, the following hypotheses will be addressed: 
• The transition to close innovation would occur after attaining the commercial-level 
product. 
• The transition tendency of innovation would depend on firm size. 
• Emergence of a new innovative product derived from the current new product would 
affect the repetition of transition tendency. 
The investigation of the above hypotheses will be undertaken based on the semi-structured 
interviews with researchers in the biochip industry.  
Based on semi-structured interviews with researchers in the biochip industry, the model 
based on innovation transition will be proposed. The transition tendency relates to knowledge, 
product development stage, government approval stage, and product innovation stage. Thus, 
firm’s willingness to change to close innovation and the perception of advantage of close 
innovation are related to the transition tendency. Although the model is constructed based on 
research in the biochip industry, the evaluation of model will be done in the bio-pharmaceutical 
industry for the extension of the model. 
To analyze the transition tendency from open innovation to close innovation, the following 
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hypotheses are formulated. 
• There would be a positive relationship between product development stage and 
accumulation of knowledge. 
• There would be a positive relationship between product development stage and 
transition tendency to close innovation. 
• There would be a positive relationship between knowledge and transition tendency to 
close innovation. 
• There would be a negative relationship between product innovation stage and transition 
tendency to close innovation. 
• There would be a negative relationship between government approval stage and 
transition tendency to close innovation. 
• There would be a positive relationship between transition tendency to close innovation 
and the perception of advantage of close innovation. 
The investigation of the above hypotheses will be undertaken based on the survey 
conducted in the Korean bio-pharmaceutical industry.  
Taken together, the case studies outlined above aim to construct the management strategies 
for open innovation in the Korean biochip industry. Investigation of biochip is important, since 
the biochip is an emerging high technology product and the product of fusion technologies, 
such as nanobiotechnology. In this context, a relevant management strategy is urgently needed 
in the biochip industry for effective new product development. 
The overall scheme of the process of innovation and NPD and model- related phases 
explored in this study is shown in Figure 1.1.   
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Figure 1.1. Process of open innovation and new product development 
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Chapter 2. Management Strategy for the Switching Phase of Open Innovation in New 
Product Development of Biochip 
 
In the initial stage of new product development (NPD) in the biochip industry, due to the 
technology novelty and complexity of biochip, the need of external technology has emerged. 
Therefore, open innovation is being considered as an effective innovation method for new 
product development. Fetterhoff and Voelkel (2006) report managing open innovation in 
biotechnology based on the experience of open innovation in Roche and the external value 
chain can be thought of as consisting of five key stages. ‘Seeking opportunities’ is the first step 
to be considered here (Fetterhoff and Voelkel 2006). To seek opportunities in open innovation, 
the decision to start open innovation and seeking of external partners are the first step. This 
step investigated in this chapter. 
At first, in the initial stage of new product development, the firm should decide whether or 
not to start open innovation. In this paper, this phase is defined as the switching phase, since, 
in this phase, the innovation mode switches from close to open. Although the firm understands 
the need for external innovation, the factors and relations to produce value are not clearly 
understood and then it is difficult to make the decision. Thus, in this chapter, the factors 
affecting the perception of advantage of open innovation are investigated and the model based 
on the switching cost is proposed. Based on the results of model evaluation with the data from 
the Korean biochip firms, the strategy for the decision of open innovation adoption is proposed.  
 
2.1. Introduction 
 
Due to the rapid development of high-tech technology, trends of industrial innovation have 
rapidly changed. Accordingly, firms have sought to diversify their innovation mode in order to 
increase profitability from product innovation and to survive in competitive environments. 
During this process, collaboration between firms, especially in related researching fields, has 
emerged as an important issue. After the conceptual introduction by Chesbrough (2003), open 
innovation has received a huge attention of both academic research circles academies and firms. 
According to Chesbrough (2003), open innovation is the methodology of innovation that opens 
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the innovation process, including research, development, and commercialization and uses 
external resources so that to reduce innovation cost, increasing thus the possibility of success 
and maximizing the added value creation (Chesbrough 2003, 2006a,b).  
Both worldwide and in Korea, owing to such characteristics as the need of combining 
various techniques and limitation of resources in different techniques inside a firm, open 
innovation has been widely used in the biochip industry (Fuji-Keizai 2008; Kim 2008, 2013; 
Impact Co 2013; Hyun 2013, Kwon 2015). Since the biochip field is a fusion between 
biotechnology and information technology, the knowledge distribution should be recognized 
and the importance of knowledge integration should be considered more than in any other area 
in biotechnology. Considering that the sources of knowledge are wide-spread and that, unlike 
specialists in one specific area, experts in fusion technology are rare, the interactive innovation 
between internal and external experts should be prioritized. Therefore, the innovation in 
biochip should be done based on the recombinant technology concept, network learning, 
technology supply chain, and combination of internal and external resources in fused open 
innovation settings. The innovative product development with hybridization of internal sources 
and external resources in technology development structure should play the key role in 
innovation in markets for biochip. 
To achieve open innovation in the biochip industry, a systematic strategy of management 
in radical innovative new product development is needed. To clarify the resources for open 
innovation, the core network and resources should be depicted, since global networks are a 
platform for activities that constitute open innovation strategy in innovative product 
development.  
Although most firms understand the need for external innovation, only few of them know 
how to develop partnerships with excellent external technology providers (Fetterhoff and 
Voelkel 2006). In this respect, Fetterhoff and Voelkel (2006) suggest that the external 
innovation value chain consists of five key stages: 1) seeking opportunities; 2) evaluating the 
market potential and inventiveness of a given opportunity; 3) recruitment potential partners by 
building a convicting argument; 4) capturing value through commercialization; and finally 5) 
extending the innovation offering (Fetterhoff and Voelkel 2006). Approaches to increase the 
likelihood of finding suitable innovation partners include placing multiple technology scouts 
and allowing first rights on new product development. 
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In view of the above, as a first step, the decision whether or not to initiate open innovation 
should be made by considering the current internal and external status of the firm. In this study, 
the relation with the switching cost and the perception of advantage of open innovation is 
investigated to provide evidence on this decision. In addition, we also consider the factors that 
affect the switching cost. The model for relations is proposed and a survey is performed in the 
Korean biochip firms to evaluate the model. Finally, based on the results of model evaluation, 
the strategy for decision to start open innovation is suggested. 
 
2.2. Theoretical Considerations 
 
2.2.1. Open innovation in the biotechnology industry 
In what follows, some instances of open innovation in the biotech industry are overviewed. 
 According to Fetterhoff and Voelkel’s (2006) report on managing open innovation in 
biotechnology based on the case study of Roche, on the increasingly competitive landscape, 
there is a growing demand for companies to be innovative in the bio-pharmaceutical sector. 
However, the concept of innovation is confused with product innovation. If innovation is 
defined as the commercialization of an enabling technology that provides the customer with a 
new capability, then there are two key requisites for innovation: customer insight to identify 
unmet need, on the one hand, and technology awareness to identify the respective enabling 
technology, on the other hand. Drivers for innovation can be thought of as any force that 
uniquely links a customer need with an enabling technology solution; this region of overlap is 
described as the innovation space. Roche Diagnostics manages the challenges of sourcing 
external technologies by leveraging these drivers through a comprehensive technology 
evaluation.  
Another relevant company of open innovation in biosciences is InnoCentive7 (Demir 2003). 
As mentioned in Chapter 1 of the present paper, InnoCentive was created to foster innovation 
and efficiency in the area of R&D for major companies around the globe. The company was 
launched in 2001 as a start-up business venture incubated through a division of Elli Lily and 
                                           
7 See www.innocentive.com 
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Company. InnoCentive is an unbiased knowledge broker between major global companies and 
the worldwide scientific community, enabling them to collaborate and solve difficult problems. 
Global companies post their tough R&D problems on the confidential InnoCentive website 
where more than 22,000 leading scientists and researchers from 125 countries try to solve them 
for financial reward. 
Furthermore, in his report on open innovation in the pharmaceutical industry, Nilsson (2006) 
notes that, since the pharmaceutical industry is one of the most research-intensive industries as 
well as a big industry in terms of revenue, it is important to acquire a deeper understanding of 
the trends in localization of R&D facilities. The open innovation strategy, where companies’ 
R&D crosses over corporate and national borders, becomes popular in the pharmaceutical 
industry. A challenge in pursuing open innovation strategy is the coordination of R&D sites. In 
localized R&D sites, it is important to optimize the use of technologies, systems, and processes 
so that to ensure collaboration across the organization. The partnership and innovation in life 
science has also been reported by Kleyn et al. (2007) that shows that the government support 
for partnering between bio-pharmaceutical companies and universities is growing in the UK 
and some European countries. Partnering helped industry and university to increase innovation 
in R&D and led them to adopt more open approaches to innovation. 
Open innovation approaches in biotechnology, such as bioscience and bioengineering, can 
be applied for open innovation of biochip to be investigated in this study.  
 
2.2.2. Technology and innovation in biochip 
Biochip can be classified to DNA chip, protein chip, and cell chip. DNA chip was first 
developed from Affymaetrix8 which, based in Santa Clara, is a pioneer and market leader 
among the companies developing revolutionary biotechnology that helps doctors identify 
diseases and develop drugs likely to help patients by analyzing genetic level data. The main 
product of Affymetrix is DNA chip, also called a gene microarray or gene chip, which is a 
breakthrough tool that derives from the genetic revolution. Although Affymetrix is a market 
leader, the market in DNA chip has recently become highly competitive due to the entrance of 
new venture companies and large companies, such as Agilent and Motorola. Recently, the new 
                                           
8 See www.affymetrix.com 
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applications of DNA chip, such as genome-wide epigenetic analysis and on-chip synthesis, 
have also emerged (Hoheisel 2006). 
In recent years, the markets of protein chip and cell chip have rapidly increased due to the 
high application fields, such as diagnosis and high throughput screening in drug delivery 
(Seong and Choi 2003; Zhu and Snyder 2003; El-Ali et al. 2006). Accordingly, markets of 
nanobiochip and lab-on-a-chip chip based on new nanotechnologies are now emerging and will 
rapidly grow and expand in the future. 
Furthermore, in their report on the open system of innovation in DNA biochip’s development, 
Lenoir and Giannella (2006) note that the open character of network economics is what makes 
them truly innovative. The emergence of diffusion of microarray technologies, biochip, 
provides an example of an open system of innovation. The inventors make the biochip to be 
commercial product based on knowledge resources from all parts of the network. The 
knowledge spillovers go both ways: at first from industry to academy and then from academy 
to industry. However, while Lenoir and Giannella’s (2006) study focused on knowledge 
diffusion based on the relation between industry and academy, the strategy of open innovation 
process in the entirety of internal and external resources has not been reported.  
In addition, Verboven and et al. (2004) analyze the innovation in high-tech sector, such as 
that concerned with medical devices and develop the model of innovation by small firms in 
high-tech sectors such as biopharmacy, medical devices in healthcare, and nanomaterials. 
According to the authors, there are two major innovation processes: firstly, product 
manufacturing, i.e. when fundamentally new knowledge is translated into a first application, 
and, secondly, strategic shift when new knowledge is applied to other areas, i.e. different from 
the one where its first application occurred. 
The technology status and the analysis of innovation status in the mainstream biochip 
technology can be applied to construct the strategy of open innovation in the biochip industry. 
 
2.2.3. Switching costs  
 The term ‘switching cost’ refers the cost of the change from one system to the other system; 
the switching cost is reported to be a significant antecedent of both attitudinal and behavioral 
loyalty (Matos et al. 2009). Specifically, according to Das and Teng (2002), the alliance 
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constellation should consider the role of generalized exchange partners according to the social 
exchange theory. Firms are willing to maintain their current relationship and not to move to 
new ones by replacing the current partner (Dwyer et al. 1987; Weiss and Anderson 1992). 
Focusing on switching cost, Matos et al. (2009) develop and empirically test the antecedent, 
mediating and moderating role of switching costs on the relationship between satisfaction and 
loyalty. The authors suggest that competing models are proposed based on the investigation of 
the influence of the switching cost on satisfaction and loyalty (Matos et al. 2009). Their results 
demonstrate that consumers with different switching cost levels will manifest a distinct 
relationship between satisfaction and attitudinal loyalty and the moderating effect if the 
switching cost is stronger in the relationship between satisfaction and behavior royalty. 
Therefore, the different switching cost level affects the level of change of current goods or 
relations. 
Based on different types of innovation, such as branching innovation (technological 
innovation along a particular path) and recombinant innovation (fusions of multiple paths), 
different models of technological transition are constructed (Frenken et al. 2012). For example, 
Frenken et al. (2012) suggest that recombinant innovations create short-cuts which reduce 
switching costs, allowing agents to escape a technological lock-in. As a result, recombinant 
innovation speeds up technological progress, allowing transitions from close innovation to 
open innovation. Therefore, the reduction of the switching cost relates to speeding up 
technological progress, allowing transitions based on the connection of internal and external  
According to Huang and Hsieh (2012) report that consumer’s perceived innovative attributes 
(such as relative advantage, compatibility, and complexity) directly affect their acceptance 
behavior, as well as influence their behavior via their perception of the costs (procedural, 
financial, and relational switching costs). Additionally, complexity is a key antecedent to 
switching costs. Economides and Katsamaka (2006) report the relation of the switching cost to 
an expansion of open source program in PC. In their study, the switching cost from dominant 
Windows operating system is shown to make it difficult for Linux market-share to grow fast. 
However, the existence of other open source applications (such as OpenOffice, the Mozilla 
Firefox browser, etc.) may reduce the switching cost to Linux in the long run. Thus, the factors 
affecting the switching cost should be investigated to find the way to increase the change to a 
new product. 
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In a similar fashion, Wu (2014) investigates the service innovation for digital service on 
loyalty. Specifically, the authors examine service innovation loyalty from the consumer 
perspective: namely, taking into account technology leadership, service leadership, and 
switching cost. Wu (2014) proposes that switching costs have a significant positive impact on 
consumers’ loyalty; consequently, higher switching costs can differentiate a service provider 
from its competitors. The relations among client discretion, switching costs, and financial 
innovation are further investigated by Bhattacharyya and Nanda (2000). The authors suggest 
that, due to the large and well-known banks’ varied expertise, they may face lower switching 
costs when they market a product to the clients and that the switching cost would depend on 
financial exchange. Furthermore, Yi and Lee (2005) investigate the antecedents and 
consequences of the switching cost by considering the moderating role of service subscription 
types. The authors demonstrate that switching costs have a positive effect on keeping the 
current service firm and that the increase of the switching cost is not the only factor to change 
the current service firm. In view of the above, the factors affecting switching cost should be 
investigated to find the way to increase the change to a new product. As suggested by the results 
of previous studies, owing to various influencing factors, switching costs can affect the 
tendency to maintain the current product or partner.  
The switching cost in open innovation refers to the cost of the change from close innovation 
to open innovation. If the switching cost is high, the willingness of a firm to change would be 
low. Therefore, evaluating the factors for the switching cost and assessing the relation of the 
switching cost and the perception of advantage of open innovation can facilitate the decision 
to start open innovation in the initial stage of NPD in the biochip industry. 
 
2.3. Research Model and Hypotheses 
In this study, the three important factors to decide on starting open innovation for the initial 
stage of new product development are constructed, namely: (1) trust to current internal and 
external partners; (2) research capacity; and (3) switching cost. Based on this, the model is 
proposed where the perception of advantage of open innovation is related to (1) level of trust 
to the current external partner; (2) level of trust to the internal research team; (3) level of 
internal research capacity; and (4) the switching cost of the change from close innovation to 
open innovation. The theoretical model is shown in Figure 2.1. In what follows, we provide a 
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description of the relationships between the variables.  
(1) External Trust and Internal Trust 
Changing from current alliances, including the current external partner and internal research 
team, to new alliances for open innovation requires trust to new partners. The trust to alliances 
is related to the construction of a network and belief for collaboration for a new product 
development. According to Newell and Swan (2009), trust facilitates the firms to establish 
inter-organizational networks to overcome the isolation of small and medium enterprises. 
Likewise, Doney and Cannon (1997) suggest that trust contributes to reducing transactional 
uncertainty through previous collaborative experience with the third parties and expectation 
towards untrusted parties. Trust fosters long-term orientation between exchange partners by 
shifting the focus to future conditions and a strong trust decrease propensity to leave, i.e. the 
perceived likelihood that a partner will terminate the relationship in near future (Ganesan 1994; 
Morgan and Hunt 1994). Based on the above results, trust to external partner influences the 
continuation of current collaboration.   
When a firm trusts the existing partner in research capability and innovation capability, the 
firm wants to keep the current partner, despite the fact that a change to a new partner can result 
in the new technology and yield economic benefit. Therefore, a firm is reluctant to change from 
close innovation to open innovation with new partners because of high switching costs. It can 
be suggested that trust to the current external partner is positively related to the switching cost. 
Based on the above, the following hypothesis is proposed. 
H1: There would be a positive relationship between trust with existing research partner and 
switching cost. 
In addition, the superior research ability of external partner affects the development of new 
product which makes the economical outcome. When open innovation starts and a new product 
is developed, the superior research ability of external partner positively affects the development 
of a new product, which yields economic benefit. Thus, it can be expected that the trust to 
existing external partner is related with perception of advantage of open innovation. In view of 
the above, the following hypothesis is proposed. 
H2: There would a positive relationship between trust with existing research partner and the 
perception of advantage of open innovation. 
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When a firm trusts internal research team in the development of a new product, the firm 
wants to continue working only with current research team, despite the fact that a change to a 
new partner through inflow and outflow of technology can result in the new technology and 
yield economic benefit. Therefore, a firm is reluctant to change from close innovation to open 
innovation to new external partners because of high switching costs. It can be suggested that 
the trust to existing internal research team is positively related to the switching cost. 
Furthermore, the trust to internal research team affects the development of a new product, 
which yields economic benefit. Accordingly, it can be expected that the trust to internal 
research team is related to the perception of advantage of open innovation. Based on these 
considerations, the following hypotheses are proposed. 
H3: There would be a positive relationship between trust with internal research team and 
switching cost. 
H4: There would a negative relationship between trust with internal research team and the 
perception of advantage of open innovation. 
(2) Research Capacity 
The firm’s internal research capability related to technology is essential in new product 
development, since a new technology or reconfiguration of the current technology are needed 
for new product development. For the adoption of a technology, the characteristics of internal 
resources, such as knowledge, are an influential factor (Roth et al. 1996). Specifically, Rogers 
(1995) suggests that the existing knowledge and internal resources can improve the speed of 
learning about new technology and lower the amount of extra investment to adopt the 
technology. Therefore, based on the above, the following hypothesis is proposed.  
H5: There would a positive relationship between research capacity of the firm and switching 
cost. 
Absorptive capability can be classified as a firm’s internal research capability. Absorptive 
capability to effectively learn from other firms is related to implementation of open innovation 
(Vanhaverbeke et al. 2008). Returns from open innovation are the greatest when firms maintain 
their internal research capacity, employ a dedicated incentive system for innovation, and 
advocate strong cross-functional collaboration (Tidd and Bessant 2015). Thus, it can be 
predicted that the firm’s internal research capability is positively related to the perception of 
advantage of open innovation. If internal research capacity is high, firm can absorb the external 
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technology well after starting open innovation, since internal research team has the ability to 
accept external technology and make product well. Based on these considerations, the 
following hypothesis is proposed. 
H6: There would be a positive relationship between research capacity and the perception of 
advantage of open innovation. 
(3) Switching costs 
As concerns the role of the switching cost in open innovation, Reed et al. (2012) report that 
open innovation affects the drivers of competitive advantages and that the firm that get 
advantages from switching risks to lose advantages in open innovation. In new ventures based 
on open innovation, for instance, in open source software, the market entry barrier is related to 
the low switching cost for users (Gruber and Henkel 2006). Therefore, Baldwin and Hippel 
(2011) suggest that a paradigm shift occurs from producer innovation to user and open 
collaborative innovation, in which open collaborative innovation project avoids the transaction 
costs. Also, in classical mass production, a change of designs requires a setup of manufacturing 
facility and associated switching costs; however, in the new collaborative innovation, the 
switching cost by changing of designs decreases. On line contests for open innovation—i.e. 
seekers posting innovation projects to which solvers submit solutions—have been developed 
into a new online commerce model (Yang et al. 2009). According to Yang et al. (2009), choices 
of solvers in a contest can be estimated by evaluating the switching cost, and a contest with a 
higher learning cost will have a higher switching cost. The above results suggest that the 
performance enhancement by open innovation is related to switching cost. Also, the presence 
of switching costs can lead to insufficient adoption of a new technology (Chen and Foreman 
2006). Based on the above, the following hypothesis is proposed. 
H7: There would be a negative relationship between the switching cost and the perception 
of advantage of open innovation. 
Based on the above hypotheses and relations, the model is constructed as shown in Figure 
2.1.  
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Figure 2.1. Model for relation between switching cost and open innovation 
 
2.4. Research Method 
(1) Questionnaire Design 
The biochip industry, one of high technology industries, is a fusion of various technologies 
including biochip, nanotechnology, biosensor, and bioinformatics. In general, due to secure 
competition for patent and intellectual property, open innovation activity has been hardly 
accomplished in high technological industries. However, since life cycle of a high technology 
has recently decreased, the need for open innovation activity has increased in the process of 
rapid development and commercialization of new products (Ahn and Lee, 2011). In this context, 
it can be predicted that open innovation has happened in the biochip industry because of its 
high intensive level of technological research and, for that reason, the biochip industry in Korea 
is selected as the target industry of the present study. 
The aim of this research is to investigate the start of open innovation and switching cost 
during the initial stage of the new product development process. To achieve this aim and to 
ensure the validity of findings, a questionnaire survey is done. Previous studies on the 
switching cost and open innovation have also performed a questionnaire survey, which is an 
established research technique for technology management studies (Al-Zu’bi and Tsinopoulos 
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2012; Pick and Eisend 2014, 2016)   
The questions were designed as follows. The interview to construct questions was done with 
three interviewees: CTO of two small biochip firms (BioDiatech and NSB Postech), CTO of 
one medium-size biochip firm (NanoEnTek), and manager of the biochip team of a large firm 
(Samsung Advanced Institute of Technology) in Korea, from October 10 to October 24, 2012. 
The discussion for open innovation in the initial stage of new product development in biochip 
was held. Specific attention was paid to the factors affecting the start of open innovation so 
that to find the relation of factors for open innovation and advantage of open innovation. The 
discussion results for the start of open innovation in the initial stage of new product 
development of biochip were analyzed and the main variables were classified as three factors 
(internal trust, external trust, research capacity) switching cost, and perception of advantage of 
open innovation (see Table 2.1).  
The scales used in the survey were seven as used in the literature (Son et al. 2014); however, 
the scales were later modified for this study. To ensure the validity of questions and scales, a 
panel of experts consisting of three interviewees and two professors of Sogang University, 
Korea (major: biochip and biosensor) were asked to review them. This process led to 
modification and clarification of the questions.  
The main question concerns the switching cost to start open innovation in the initial stage of 
new product development of biochip. Here, three aspects are important to address, namely: (1) 
Does open innovation start based on switching cost? (2) Do factors such as internal trust, 
external trust, and research capacity affect switching cost? (3) Does the switching cost relate 
to the perception of advantage of open innovation? The survey constructed based on these 
questions is described in the next section.  
Table 2.1. Questions for open innovation in initial stage of new product development (NPD). 
(1) How would you characterize external trust in the initial stage of NPD?  
1.1. External collaborative partners keep the promise with our firm. 
1.2. External collaborative partners are honest with us. 
1.3. We trust the information provided by our external collaborative partners. 
1.4. External collaborative partners are genuinely interested in the business success of  
our firms. 
1.5. External collaborative partners are well aware of our concerns. 
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(2) How would you characterize internal trust in initial stage of NPD? 
2.1. Internal researchers keep the promise with our firm. 
2.2. Internal researchers are honest with us. 
2.3. We trust the information provided by internal researchers. 
2.4. Internal researchers are well aware of our concerns. 
2.5. Internal researchers are trustworthy. 
(3) What is the level of research capacity in the initial stage of NPD? 
3.1. Our firm has well-equipped infrastructure for research and development. 
3.2. We have enough researchers to develop our new products. 
3.3. We have sufficient capital to develop our new products. 
3.4. We have integrated information system for communication between departments. 
(4) How would you characterize the switching cost in the initial stage of NPD? 
4.1. We are facing obstacles in switching to open innovation. 
4.2. Switching to open innovation is costly. 
(5) How would you characterize the perception of advantage of open innovation in the 
initial stage of NPD? 
5.1. Open Innovation will provide accurate information at the right time in decision 
 making. 
5.2. Open innovation will improve the ability to manage technical knowledge. 
5.3. Open innovation will help technological diversification. 
5.4. Open innovation will help improve competitiveness. 
5.5. Open Innovation allows many researchers to communicate simultaneously. 
 
(2) Survey Administration 
The survey in the Korean biochip firms, conducted from October 24, 2011 to November 17, 
2012, targeted decision makers in 70 firms. The respondents were contacted by e-mail and visit. 
At that time, the total number of bio-diagnostics firms in the Korean Association of Bio-
diagnostics was about 70. At first, from October 24, 2011 to February 24, 2012, the survey was 
done for 50 firms; the number of collected surveys was 35, which was not sufficient for data 
validation. Then, from August 17, 2012 to November 17, the survey was done for additional 20 
firms and the number of collected surveys was 15. Thus, the total number of collected surveys 
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amounted 50 firms. Due to the long period of data collection (approximately one year), there 
may have a time-related bias, though all firms were alive during one year. Biochip firms 
included biosensor firms, biochip firms to produce DNA chip, protein chip, cell chip, biosensor 
array firms, biochip fabrication firms including MEMS (microelectromechanical system), 
bioinformatics firms, and instrument firms (arrayer and detector). Through the survey, a total 
of 50 survey results were acquired, reaching the response rate of 71 %, and further analysis 
was carried out with 47 surveys (in 3 surveys, the responses were incomplete). 
 
(3) Demographic characteristics 
Demographic characteristics of the respondents are shown in Table 2.2.  
 
Table 2.2. Characteristics of demography of sample 
Division Content Number Percentage (%) 
Personal  
employment term 
below 5 years 16 32 
6~10 years 15 30 
11~15 years 13 26 
16~20 years 3 6 
21~25 years 2 4 
above 26 years 1 2 
Personal position 
CEO 23 46 
Research Director 4 8 
General Manager 11 22 
Deputy General 
Manager 
6 12 
Manager 4 8 
Missing value 2 4 
Personal age 
20~29 1 2 
30~39 14 28 
40~49 23 46 
50~59 11 22 
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Missing value 1 2 
Firm's Age 
below 5 years 9 18 
6~10 years 14 28 
11~15 years 19 38 
16~20 years 7 14 
Missing value 1 2 
Number of 
employees 
below 10 15 30 
11~50 16 32 
51~100 6 12 
101~200 5 10 
200~300 4 8 
1800 1 2 
Missing value 3 6 
Number of 
researchers 
1~10 24 48 
11~20 12 24 
21~50 5 10 
51~100 3 6 
above 100 3 6 
Missing value 3 6 
 
 
(4) Statistical analysis of variables 
The definition of variables and measurement method of the variables in the research model 
are shown in Table 2.3. A seven-point scale was used for the variables. 
Table 2.3. Denotation and measurement of variables 
ET 1 External collaborative partners keep the promise with our firm. 
ET 2 External collaborative partners are honest with us. 
ET 3 We trust the information provided by our external collaborative partners. 
ET 4 External collaborative partners are genuinely interested in the business success of 
our frim. 
ET 5 External collaborative partners are well aware of our concerns. 
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IT 1 Internal researchers keep the promise with our firm. 
IT 2 Internal researchers are honest with us. 
IT 3 We trust the information provided by internal researchers. 
IT 4 Internal researchers are well aware of our concerns. 
IT 5 Internal researchers are trustworthy. 
RC 1 Our firm has well-equipped infrastructure for research and development. 
RC 2 We have enough researchers to develop our new products. 
RC 3 We have sufficient capital to develop our new products. 
RC 4 We have integrated information system for communication between departments. 
SC 1 We are facing obstacles in switching to open innovation. 
SC 2 Switching to open innovation is costly. 
AO 1 Open Innovation will provide accurate information at the right time in decision 
making. 
AO 2 Open innovation will improve the ability to manage technical knowledge. 
AO 3 Open innovation will help technological diversification. 
AO 4 Open innovation will help improve competitiveness. 
AO 5 Open Innovation allows many researchers to communicate simultaneously. 
ET: External trust, IT: Internal trust, RC: Research capacity, SC: Switching cost, AO: 
Perception of advantage of open innovation 
 
Based on the data acquired by the survey, analysis was performed using SPSS 18.0 program 
and PLS 2.0. The hypotheses were tested by applying the partial last square (PLS) method to 
the collected data. This study used PLS, rather than other SEM methods (i.e. LISREL, AMOS, 
etc.), because the PLS approach places minimal restrictions on sample size and residual 
distribution (Phang et al. 2006). First of all, analysis of descriptive statistics quantity was 
accomplished and the results were investigated. To verify the reliability of the samples, items 
measuring each comprising concepts were investigated using Cronbach’s alpha test. Also, to 
verify the validity of the samples, factor analysis was performed in the hypothesis testing 
process. 
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2.5. Results 
 
2.5.1. Validation  
To validate the model, three types of validity—content validity, convergent validity, and 
discriminant validity—were assessed. (1) Content validity was evaluated based on Cronbach 
alpha value (see Table 2.4). Cronbach’s alpha test to individual scale and the overall measures 
was used to assess internal consistency. The threshold value of Cronbach alpha is 0.7 (Nunally 
and Berstein 1994). As shown in Table 2.4, the Cronbach alpha values were 0.908 for external 
trust, 0.940 for internal trust, 0.883 for research capacity, 0.841 for switching cost, and 0.928 
for the perception of advantage of open innovation. Therefore, all variables are valid.  
  Table 2.4. Confirmatory factor analysis 
Constructs Composite Reliability AVE* Cronbach’s Alpha 
External Trust (ET) 0.931 0.730 0.908 
Internal Trust (IT) 0.952 0.799 0.940 
Research Capacity 
(RC) 
0.919 0.741 0.883 
Switching Cost (SC) 0.923 0.857 0.841 
Perception of 
Advantage of open 
innovation (AO) 
0.945 0.776 0.928 
* Average variance extracted 
 
  (2) Convergent validity was assessed by composite reliability and average variance 
extracted (AVE) from the measures (see Table 2.4). The acceptable values of composite 
reliability for reliable construct is 0.7 (Chin 1988). The composite reliability values in our 
sample were 0.931 for external trust, 0.952 for internal trust, 0.919 for research capacity, 0.923 
for switching cost, and 0.945 for the perception of advantage of open innovation. Therefore, 
all variables are valid. The acceptable value of AVE is over 0.5 (Fornell and Larcker 1981). 
The AVE values in our sample were 0.730 for external trust, 0.799 for internal trust, 0.741 for 
research capacity, 0.857 for switching cost, and 0.776 for the perception of advantage of open 
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innovation. Therefore, all variables are valid.  
(3) Discriminant validity is verified by evaluating the square root of AVE (Fornell and 
Larcker 1981; Lee et al., 2014). In our results, the square root of AVE for each construct as 
greater than the levels of correlation involving the construct (see Table 2.5). Also, each 
construct showed a larger variance with its own measures than those with other measures (see 
Table 2.5). Threshold value of absolute value pairwise correlation is 0.6 (Nunally and Berstein 
1994) and the highest absolute value of pairwise correlation in our sample was lower than that 
(0.559). Variance inflation factors (VIF) were calculated to detect the multicollinearity among 
the explanatory variables. Threshold value of VIF is 10 (Nunally and Berstein 1994) and the 
highest VIF value in our sample was 0.4.732, which is far lower than 10. Thus, all variables 
are valid.  
 
Table 2.5. Correlation between constructs 
 AO ET IT RC SC 
AO 0.881*     
ET 0.181 0.854*    
IT 0.066 0.559 0.894*   
RC 0.392 0.252 0.113 0.861*  
SC 0.122 0.497 -0.197 0.398 0.926* 
* Square root of AVE 
 
Other analyses based on statistical results are as follows. The descriptive statistics including 
standard deviation are reported in Table 2.6. Kaiser-Meyer-Olkin measure of sampling 
adequacy was 0.737. The results suggest that 5 factors explain 80.522 % of the total variance 
(see Table 2.7). Since all 5 factors are well-distributed over 0.6 in factor analysis, the validity 
requirement was satisfied (see Table 2.8).  
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Table 2.6. Descriptive Statistics 
 N Min Max Mean Std. Deviation 
IT 1 47 1 7 5.72 1.155 
IT 2 47 1 7 5.74 1.188 
IT 3 47 1 7 5.83 1.167 
IT 4 47 1 7 5.72 1.210 
IT 5 47 1 7 5.85 1.122 
ET 1 47 3 7 4.98 .944 
ET 2 47 2 7 4.74 .943 
ET 3 47 3 7 4.98 1.032 
ET 4 47 2 7 4.70 1.413 
ET 5 47 2 7 4.57 1.281 
RC 1 47 3 7 5.28 1.192 
RC 2 47 1 7 4.57 1.441 
RC 3 47 1 7 4.43 1.778 
RC 4 47 1 7 5.13 1.361 
SC 1 47 -1 6 4.04 1.615 
SC 2 47 1 6 4.40 1.378 
AO 1 47 2 7 4.79 1.178 
AO 2 47 2 7 5.15 1.302 
AO 3 47 3 7 5.45 1.157 
AO 4 47 1 7 5.53 1.316 
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AO 5 47 1 7 5.04 1.429 
Effective Number 47     
Table 2.7. Total Variance Explained 
Extraction 
Sums of 
Squared 
Loadings 
Total 
Rotation Sums of Squared Loadings 
% of Variance Cumulative % Total 4 5 
7.068 33.657 33.657 4.293 .008 .046 
4.365 20.785 54.441 4.021 -.033 -.295 
2.762 13.151 67.593 3.626 -.001 -.275 
1.700 8.093 75.686 3.317 .228 -.071 
1.016 4.836 80.522 1.653 .248 -.079 
    .205 -.077 
    -.058 -.107 
    -.106 .059 
    .067 -.004 
    -.168 -.079 
    .869 -.145 
    .905 -.084 
    .872 -.015 
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    .612 -.265 
    -.466 .694 
    -.140 .908 
    .082 -.009 
    .301 .052 
    .250 .170 
    -.003 .000 
    .092 -.117 
Extraction Method: Principal Component Analysis 
Table 2.8. Rotated Component Matrix 
 
Component 
1 2 3 4 5 
ET1 .272 .245 .789 .008 .046 
ET2 .321 .272 .723 -.033 -.295 
ET3 .172 .204 .805 -.001 -.275 
ET4 .289 -.136 .811 .228 -.071 
ET5 .340 .045 .757 .248 -.079 
IT 1 .891 .095 .099 .205 -.077 
IT 2 .885 -.028 .281 -.058 -.107 
IT 3 .870 .005 .243 -.106 .059 
IT 4 .820 .118 .271 .067 -.004 
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2.5.2. Hypothesis testing 
To validate the model, the structural equation model was applied and Partial Least Square 
(PLS) was used. Since PLS requires minimal demands on sample size (Chin 1998) to validate 
a model and our data set had 47 questionnaires, the PLS method was used to evaluate the 
proposed model and hypotheses. When t-value is over 1.96, the hypothesis is significant at 5% 
level of significance (provided the number of surveys is sufficiently large). Cramer suggests 
that the approximation is usually good for samples larger than 30 (Cramer 1946) and, thus, 
statistical inference is appropriate for our dataset. As shown in Table 2.9. Only t-values for the 
relation between external trust and switching cost, the relation between research capacity and 
switching cost, the relation between research capacity and the perception of advantage of open 
innovation, and the relation between the switching cost and the perception of advantage of open 
IT 5 .842 -.107 .294 -.168 -.079 
RC 1 .030 .173 .060 .869 -.145 
RC 2 -.053 .104 .154 .905 -.084 
RC 3 -.147 .172 .040 .872 -.015 
RC 4 .347 .332 .049 .612 -.265 
SC 1 -.028 .067 -.407 -.466 .694 
SC 2 -.082 .049 -.170 -.140 .908 
AO 1 -.055 .849 .167 .082 -.009 
AO 2 -.042 .841 .123 .301 .052 
AO 3 .051 .866 .080 .250 .170 
AO 4 .025 .865 .126 -.003 .000 
AO_5 .109 .823 -.044 .092 -.117 
Extraction Method: Principal Component Analysis 
Rotation Method: Varimax with Kaiser Normalization: a. Rotation converged in 6 iterations 
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innovation were over 1.96 and thus only these four relations are satisfied. Values of path 
loadings were calculated and the sign related to correlation with the switching cost was 
reversed, since the reverse coding for switching cost was performed. As R2 for the switching 
cost is 0.253 and R2 for the perception of advantage of open innovation is 0.315, the model is 
acceptable, since acceptable range of R2 is over 0.1.  
 
Figure 2.2. Model result for relation between switching cost and open innovation 
Table 2.9. Path Coefficients 
 
Original 
Sample 
Sample Mean 
Standard 
Deviation 
T Statistics P Values 
ET → AO 0.337 0.350 0.223 1.509 0.132 
ET → SC 0.483 0.489 0.146 3.309 0.001** 
IT → AO -0.086 -0.111 0.212 0.407 0.684 
IT → SC -0.106 -0.086 0.143 0.744 0.457 
RC → AO 0.505 0.513 0.157 3.222 0.001** 
RC → SC 0.288 0.284 0.132 2.188 0.029* 
SC → AO 0.473 0.467 0.155 3.050 0.002* 
*** p<0.001, ** p<0.01, * p<0.05 
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As further analysis for the model, group difference between two groups with different position is 
conducted. The two group data have 44 values that omitted missing value from initial 47 values as shown 
in Table 2.10. Group 1 has 23 data (49%), which represented by CEO and Research Director of the firm 
and Group B has 21 data (51%), which represented by General Manager, Deputy General Manager, and 
Manager of the firm. In the analysis of Group 1 in Table 2.11, only relation between switching cost and 
perception of advantage of open innovation is valid since t value is 2.358 and acceptable t value is larger 
than 2.07 for 23 data. In the analysis of Group 2 in Table 2.12, only relations between external trust and 
switching cost, and between research capacity and switching cost are valid since t value is 2.816 and 2.080, 
respectively, and acceptable t value is larger than 2.08 for 21 data. It looks that there might be difference 
between Group 1 and Group 2. But if the analysis for difference of Group 1 and Group 2 is done, all p-
values are not in the acceptable range (p is larger than 0.05) in Table 2.13. This result suggest that there is 
no difference in the analysis of Group 1 and Group2, and thus the results with 47 data have validity. 
 
Table. 2.10. Group based on position difference 
 Content Number Percentage (%) 
Group 1 
CEO 20 42.6 
Research Director 3 6.4 
Group 2 
General Manager 8 17.0 
Deputy General Manager 2 4.3 
Manager 11 23.4 
Missing value 3 6.4 
Total 44 100 
 
Table. 2.11. Analysis of Group1. 
 
Original 
Sample 
Sample Mean 
Standard 
Deviation 
T Statistics P Values 
ET → AO -0.321 -0.155 0.313 1.027 0.305 
ET → SC -0.215 -0.240 0.388 0.554 0.579 
IT → AO 0.322 0.187 0.336 0.959 0.337 
IT → SC -0.149 -0.008 0.374 0.400 0.690 
RC → AO 0.465 0.406 0.248 1.876 0.061 
RC → SC -0.002 -0.072 0.348 0.006 0.995 
SC → AO 0.570 0.547 0.242 2.358 0.018 
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Table. 2.12. Analysis of Group2. 
 
Original 
Sample 
Sample Mean 
Standard 
Deviation 
T Statistics P Values 
ET → AO 0.703 0.609 0.372 1.892 0.059 
ET → SC -0.671 -0.612 0.238 2.816 0.005 
IT → AO -0.156 -0.135 0.364 0.430 0.667 
IT → SC 0.211 0.083 0.233 0.904 0.366 
RC → AO 0.697 0.650 0.362 1.925 0.054 
RC → SC -0.467 -0.446 0.225 2.080 0.038 
SC → AO 0.572 0.418 0.315 1.814 0.070 
 
Table.2.13. Analysis of difference of Group 1 and 2 
 Path Coefficients difference (G1-G2) p-value (G1-G2) 
ET → AO 1.024 0.971 
ET → SC 0.456 0.136 
IT → AO 0.479 0.164 
IT → SC 0.360 0.787 
RC → AO 0.231 0.756 
RC → SC 0.465 0.117 
SC → AO 0.001 0.504 
*** p<0.001, ** p<0.01, * p<0.05 
 
In the results of analysis of the model with path coefficient, t-value and R2 values are 
reported in Figure 2.2. The results in Figure 2.2 suggest the followings. The trust to current 
external partner is positively related to the switching cost, which means that as external trust 
becomes higher, the switching cost to open innovation increases. This result suggests that the 
firm with strong trust in the current external partner is reluctant to do open innovation with a 
new external partner. This supports Hypothesis 1. Furthermore, trust to current external partner 
is not directly related to the perception of advantage of open innovation. Our results suggest 
that the current external partner does not affect the enhancement of performance by open 
innovation of firm, since current external partner is not directly related to new external partner. 
Therefore, Hypothesis 2 has to be rejected.  
The trust in current internal research team is not directly related to the switching cost, which 
means that, although internal trust becomes higher, the switching cost to open innovation is not 
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changed. Our results suggest that the current internal trust does not affect the enhancement of 
performance by open innovation of firm, since trust to current research team is less important 
than the research capacity of current research team. Thus, Hypothesis 3 has to be rejected. 
Furthermore, trust to current internal research team is not directly related to the perception of 
advantage of open innovation, meaning that, although internal trust becomes higher, the 
switching cost to open innovation is not changed. Our results suggest that trust to current 
external partner does not affect the enhancement of performance by open innovation of firm, 
since internal trust is not directly related to the transfer of technology from new external partner, 
which causes the enhancement of performance by open innovation of firm. Therefore, 
Hypothesis 4 is not supported by our results.     
Furthermore, the research capacity is positively related to the switching cost, meaning that, 
as internal research capacity becomes higher, the switching cost to open innovation increases. 
The results suggest that the firm with high research ability is reluctant to do open innovation. 
Therefore, Hypothesis 5 is supported by our data analysis. The research capacity is positively 
related with the perception of advantage of open innovation, meaning that, as internal research 
capacity gets higher, the benefit due to increases after open innovation starts. Our results show 
that the firm with high research ability can get a better result due to being open to external 
partners. These results suggest that firm with a high research capacity can get, absorb, and 
adapt external technology. Thus, Hypothesis 6 is substantiated by the results.    
Next, the switching cost is negatively related to the perception of advantage of open 
innovation, meaning that, as the switching cost becomes higher, the perception of advantage of 
open innovation decreases. A high switching cost means a low willingness to open innovation 
(Lee et al. 2014). The results provide evidence that, when a firm expects a high switching cost, 
it is less likely to participate in open innovation, which causes the decrease the perception of 
advantage of open innovation. Thus, Hypothesis 7 is supported by the results of our analysis.   
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2.6. Conclusion and Discussion 
The summary of the research results is shown in Figure 2.3. 
 
Figure 2.3. Summary of model result for relation between switching cost and open innovation 
 
The purpose of this study is to investigate the factors to decide to start open innovation. The 
factors that relate the switching cost to the perception of advantage of open innovation affect 
the decision on new product development. Based on our data analysis results, we can conclude 
that the switching cost has a negative relation with the perception of advantage of open 
innovation. If the switching cost is low and thus the perception of advantage of open innovation 
is high, the firm starts to open and get knowledge from external collaborators, meaning that the 
technology-sharing and -transfer from current external partner and internal research team 
decreases. If the switching cost is high and, due to this, the perception of advantage of open 
innovation decreases, the firm will not want to open the technology flow between inside and 
outside. In addition, the trust to current external partner and the level of research capacity in 
the firm affects the switching cost. It is found that trust to current external partner and the level 
of research capacity in the firm have a positive relation with the switching cost. 
The innovation strategy is needed to effectively do innovation, since the problem with 
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innovation improvement efforts is rooted in the lack of innovation strategy (Pisano 2015). 
Based on the results reported above, the following strategy to manage open innovation is 
suggested. The decision to start open innovation or not in the initial stage of new product 
development should be made based on the consideration of the switching cost and the 
perception of advantage of open innovation. At first, the factors such as trust to current external 
partner and internal research capacity to affect switching cost should be considered. If the trust 
to current external partner or the level of research capacity in the firm is high, the switching 
cost is too high, the firm should keep the current external partner and internal research team in 
close innovation.  
Alternatively, if the switching cost is within acceptable value, the firm should decide to start 
open innovation with a new external research partner. The relation with the current external 
partner should be reduced to reduce the switching cost. The research capacity should be 
reduced by the reduction of number of researchers or Ph.D. level researchers, which causes a 
decrease of the switching cost. However, the internal research capacity should be kept over the 
medium level, since the internal research capacity affects the performance of open innovation 
activity. Internal research team with a good research capacity can efficiently manage the 
technology transfer from the outside the firm. By reducing the switching cost, the perception 
of advantage of open innovation increases, causing an acceleration of implementation of open 
innovation.  
To summarize, the results reported above allow us to draw the following conclusions: (1) 
Switching should be considered to make decision on starting open innovation or not in the 
initial stage of new product development; (2) Current internal research capacity and external 
partner are important factors, since the current situation is the key factor to decide whether or 
not to start open innovation by introducing new partners; (3) Based on the insights of the 
relation of current situation with the switching cost and that of the switching cost with the 
perception of advantage of open innovation, firms decide whether or not to start open 
innovation.  
Since, the extended period of data collection (ca. a year) could have caused a time-related 
bias in the present study (although all firms that responded to the survey were alive during one 
year), a reduction of time for the survey is recommended.   
Though only trust and research capability are considered as key factors for switching cost in 
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this study, the various factors to affect switching cost should be encountered for accurate 
analysis. Switching cost is affected by antecedents such as firm-related, buyer-related and 
market-related and the relation between antecedents and switching cost is modulated by 
moderators such as culture, product characteristics and others (Pick and Doreen 2014). Thus in 
future for biochip industry the effect of market-related antecedents on switching cost should be 
investigated to clarify the switching to open innovation in the initial stage of new product 
development.   
In this study the internal- and external- trust are selected as the key factors for switching cost 
since the trust is one of the most important factors for collaboration work due to culture of 
Korea (Kim et al. 2008). This approach can be considered as reasonable since the cultural 
variations relate to the effect of relationship variables such as switching cost in and the 
relationship between switching cost and behavior loyalty is established (Pick and Doreen 2016). 
But, since the trust is a subjective factor, if more objective factors such as research capability 
of external partners and current market situation are considered for switching cost, the research 
findings should be more appropriate and clear to understand the open innovation in the initial 
stage of new product development. 
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Chapter 3. Management Strategy for Implementation of Open Innovation in New 
Product Development of Biochip 
 
Since open innovation is considered to be an effective innovation method for new product 
development (NPD) of biochip, the start of open innovation can be decided based on the 
analyses as shown in Chapter 2. After the open innovation process is started, during the 
implement stage of open innovation, a strategy to increase the firm performance is needed in 
product development of the biochip industry. During the implementation of open innovation 
activity, the following questions need be addressed: (1) Does an increase of openness affect 
firm performance in new product development? (2) Which level of openness is needed for new 
product development? (3) How can we implement the open innovation process in practice? In 
this chapter, we seek to answer the above questions by investigating the influential factors 
affecting openness based on both technological and non-technological points of view.  
At first, the firm must decide about the optimal level of openness to enhance its performance. 
Although the firm understands the need for external innovation, relations between influential 
factors and openness necessary to enhance firm performance are not clearly understood, 
making it difficult to make the decision related to the appropriate degree of openness. Thus, in 
Section 3.1., the factors affecting the openness based on the technical characteristics, such as 
technology novelty- and -complexity, and the factor’s relation to enhance the firm performance, 
are investigated. The model based on technology characteristics is proposed. Based on the 
results of model evaluation with the data from Korean biochip firms, the strategy regarding 
openness and firm’s performance enhancement is proposed from the technology point of view.  
In the next step, the firm must decide about the way of breadth and depth of open innovation 
activity. The variety of the external seeking in open innovation is measured by breadth and 
depth of open innovation. The breadth of open innovation can be measured by a number of 
collaborators, while the depth of open innovation can be measured by the frequency (number 
of collaboration) of a single target in open innovation. Laursen and Salter (2006) used the 
concept of depth and breadth to measure the degree of open innovation. Although the firm may 
want to implement an open innovation strategy, relations of influential factors necessary to 
enhance the open innovation activity are not clearly understood yet. Thus, in Section 3.2., the 
influential factors affecting the open innovation activity will be investigated based on the non-
technical characteristics, such as environmental characteristics, firm characteristics, and 
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institutional characteristics. A set of hypotheses regarding the factors affecting open innovation 
is proposed. Based on the results of hypotheses evaluation with the data from Korean biochip 
firms, the strategy for the decision of open innovation will be proposed from the non-
technology point of view.  
To sum up, in this chapter, the factors affecting open innovation, such as the environmental 
characteristics, firm characteristics, and institutional characteristics, are investigated for the 
first time. The goal is to evaluate the effect of these factors on breadth and depth of innovation 
activity. This case study is also the first to address the breadth and depth of open innovation 
activity in the biochip industry. 
 
3.1. Openness Based on Technology Characteristics  
 
3.1.1. Introduction 
 
Due to the need of combination of various techniques and limitation of resources in 
different techniques inside firms, both worldwide and in Korea, as well as the need of external 
knowledge for new radical product development, open innovation has been widely applied to 
the biochip industry (Fuji-Keizai 2008; Kim 2008; Impact Co 2013; Kim 2013, Hyun 2013; 
Kwon 2015). Since the biochip technology results from a fusion between biotechnology and 
information technology, the knowledge distribution in different types of firms should be 
recognized and the importance of knowledge integration should be considered more than in 
other areas of biotechnology.  
To achieve open innovation in high technology products, a novel management strategy is 
needed in order to manage the development of novel and complex technology characteristics 
(Fetterhoff and Voelkel 2006; Igartua et al. 2010; Pisano 2015; Slowinski and Sagal, 2015; 
Tidd and Bessant 2015; Vanhaverbeke et al. 2008). Although most companies understand the 
need for external innovation, only few of them can establish partnerships with external 
technology providers (Fetterhoff and Voelkel 2006). Fetterhoff and Voelkel (2006) suggest that 
research external innovation value chain consists of five key stages: 1) seeking opportunities; 
2) evaluating the market potential and inventiveness of a given opportunity; 3) recruitment of 
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potential partners by building a convincing argument; 4) capturing value through 
commercialization; and finally 5) extending the innovation offering. Furthermore, Slowinski 
and Sagal (2015) suggest the stages for open innovation as (1) want phase; (2) find phase; (3) 
get phase; and (4) manage phase to success. Slowinski and Sagal (2015) report that the model, 
which emerged within the pharmaceutical industry in the 1990s, is developed to bring rational 
thinking from the fast-paced world of biotechnology industry to chemical industry in open 
innovation activities. In this model, a firm pursues open innovation activities through a four-
phase lifecycle from want- to find- and get- phase. Finally, firm must manage the open 
innovation relationship to success. Thus, to increase firm’s performance and make profit by 
producing a new product, the management of innovation for success is important in the 
management phase for commercialization. The management strategy during open innovation 
is urgently needed for a radical innovative new product development in fusion technology areas, 
such as the biochip technology. 
In the implementation stage of open innovation in new product development (NPD), the 
decision regarding the level of openness to external partners is important, since open innovation 
is considered to be an effective innovation method for new product development. In this study, 
the decision regarding the level of openness based on technology characteristics is investigated 
in a case study of the Korean biochip industry. Technology characteristics, such as technology 
novelty and technology complexity, are related to openness and, consequently, the openness 
and innovativeness in firms has been investigated in previous research (Tatikonda and 
Rosenthal 2000; Vahter et al. 2014). This study is the first to focus on the relation between 
openness and technology ability to make commercial products, on the relation between 
technology ability and firm performance, and, more generally, on open innovation in the 
biochip industry. A model linking technology characteristics and performance is developed to 
suggest a relevant management strategy for open innovation during the implementation stage. 
The model to link these relationships is proposed and a survey is carried out among the 
Korean biochip firms to evaluate the model. A total of 47 Korean biochip firms are included in 
the survey. Finally, a strategy regarding the degree of openness to increase the firm’s 
performance is proposed. 
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3.1.2. Theoretical Considerations 
 
3.1.2.1. Open innovation in biotechnology industry 
Chiaroni et al. (2009) report managing open innovation in bio-pharmaceutical industry based 
on the experience of open innovation. The authors focus on the adoption of the open innovation 
paradigm in the bio-pharmaceutical industry and investigate which organizational modes (i.e. 
collaborations, in- and out-licensing) pertaining to open innovation have been implemented 
and how those modes are interwoven with the different phases of drug discovery and 
development processes. Furthermore, Bianchi et al. (2011) discuss how bio-pharmaceutical 
firms have used different organizational modes (i.e. licensing agreements, non-equity alliance, 
purchase and supply of technical and scientific services) to enter into relationship with different 
types of partners (i.e. large pharmaceutical companies, product biotech firms, platform biotech 
firms and universities) with the aim to acquire (inbound open innovation) or commercially 
exploit (outbound open innovation) technologies and knowledges.  
Similarly, Al-Belushi et al. (2015) argue that, in a knowledge-based high tech industry such 
as the marine biotechnology industry, the ability to innovate is a key factor for increasing 
organizational competitiveness and this may be achieved using open innovation. The research 
results of Al-Belushi et al. (2015) demonstrate that the extent of openness in the marine 
biotechnology companies is higher towards market side activities and the use of open 
innovation to increase collaboration between companies, universities, and government research 
institutes needs to be significantly strengthened. In a similar fashion, Michelino et al. (2015) 
investigate the relationships between the adoption of open innovation by companies and firm’s 
status, such as internal R&D and financial performances. the authors suggest that open 
innovation is a very pervasive behavior among smaller and younger companies, for which 
internal R&D is complementary to openness: still being in the development phase, they drive 
most of their revenues from open innovation itself and show negative financial performances.  
Furthermore, Puslecki (2016) investigates the development of modes of cooperation in the 
Polish biopharmaceutical industry, referring to the data provided by the Association of 
Strategic Alliance Professionals. Puslecki (2016) suggests that biopharmaceutical companies 
try to implement new strategies to transfer their research processes to a higher level, often using 
open innovation model as an additional tool for developing new products and services. 
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Liekwise, Slowinski (2004) develops a model based on six steps for open innovation, namely: 
(1) determining what you need to know; (2) assembling the due diligence team; (3) preparing 
the partner for the due diligence process; (4) managing interaction between firms; and (5) 
conducting due diligence on intellectual assets.  
According to Nilsson (2006), since the pharmaceutical industry is one of the most research-
intensive industries, as well as a big industry in terms of revenue, it is important to acquire a 
deeper understanding of the trends in localization of R&D facilities. The open innovation 
strategy where companies’ R&D crosses over corporate and national borders has become 
popular in the pharmaceutical industry. For instance, Kleyn et al. (2007) investigate the 
partnership and innovation in biopharma companies and find that partnering helps the firm to 
increase innovation and lets them adopt more open approaches to innovation. On top of that 
Kleyn et al. (2007) also report that organizational structures to coordinate and support 
partnerships (flexibility, leadership, developing organizational capabilities of universities) and 
a creation of enabling environment by governments are critical success factors for partnering. 
The results of previous studies overviewed above suggest that, first, the management 
strategy is urgently needed in the implementation of open innovation in the biotechnology 
industry and, second, that openness is affected by various factors and is related to firm 
performance. Therefore, open innovation approaches in biotechnology, such as bioscience and 
bioengineering, can be applied for open innovation of biochip. These approaches will be 
investigated in this chapter. 
 
3.1.2.2. Technology novelty and innovation 
Technology novelty is an important factor for open innovation implementation, since 
novelty level can influence the amount of required technology transferred from external 
partners (Rampersad et al. 2010). Takiconda and Rosenthal (2000) investigate the relation 
between project characteristics and project outcomes, as well as characterize product 
development projects in terms of technology novelty and project complexity levels (. the 
authors report that technology novelty contributes to project task uncertainty and is, in turn, 
associated with project execution outcomes; at the same time, projects with high levels of 
technology novelty are associated with special project outcome elements (Takiconda and 
Rosenthal 2000). 
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Furthermore, Bogers and West (2012) investigate the managing of distributed innovation 
projects based on strategic use of open and user innovation. The authors report that a given 
innovation is typically classified across two orthogonal dimensions of technical novelty, 
namely: (1) technology novelty refers to whether the innovation constitutes a discontinuous (or 
radical) or an incremental technology changes; and (2) the scope of novelty refers to whether 
the innovation is new to the world or new to a specific producer or adopter. Similarly, 
Verhoeven et al. (2016) propose a more comprehensive measurement of technology novelty 
with patent-based indicators. Specifically, the authors characterize inventions ex ante along the 
following two dimensions of technology novelty: novelty in recombination and novelty in 
knowledge origins. 
Next, Nieto and Santamaria (2007) focus on the importance of diverse collaborative 
networks for the novelty of product innovation. This study shows that competition today is 
driving firms to introduce products with a higher degree of novelty and, consequently, there is 
a growing need to understand the critical success factors behind more novel product 
innovations. The role of different types of collaboration networks is analyzed and it is found 
that the greatest positive impact on the degree of innovation novelty comes from collaboration 
networks comprising different type of partners (Nieto and Santamaria 2007). 
In a different study, Tidd and Hsieh (2004) explore the influences of project novelty on the 
effectiveness of open service innovation. The obtained results demonstrate that the relationship 
between the intensity of supplier integration and development outcome varies with different 
degrees of project newness. Specifically, the authors find that (1) development projects with a 
higher novelty content are associated with higher levels of interaction with existing suppliers 
to communicate the requirements of more novel inputs; (2) development projects with a higher 
novelty content are associated with higher interaction with additional suppliers and new 
partners to expand the scope and function of new services; and (3) development projects with 
a higher novelty content are associated with mechanisms that have a higher degree of 
information richness to exchange and share knowledge with supplier and partners, such as 
project meeting and/or peer-to-peer discussion (Tidd and Hsieh 2014). Similarly, Mooty and 
Kedia (2014) report that transfer capability is necessary when there is a low degree of novelty 
and complexity arising from the lack of incongruence between accessed knowledge domain.  
The results of previous studies overviewed above suggest that technology novelty is an 
important factor to open innovation and the relation between technology novelty and openness 
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should be clarified. The effect of technology novelty on openness should be investigated and a 
relevant strategy of open innovation management related to technology novelty should be 
constructed in the biochip industry. 
 
3.1.2.3. Technology complexity and innovation 
Technology complexity is an important factor for open innovation implementation, since 
complexity level influences the amount of required technology transferred from external 
partners. In this respect, Wei and Wei (2011) investigate the impact of product complexity and 
heterogeneity on online open innovation practices and report how product complexity and 
heterogeneity influence the way in which companies carry out online open innovation. The 
authors also stress that facilitating communication among innovators is critical to innovation 
when the product at stake is complex.  
Furthermore, Brant and Lohse (2014) suggest that a wide range of factors, including 
globalization, advances in information and communication technology (ICT), and growing 
technological complexity, has induced business to increasingly engage in innovation 
collaborations, i.e. open innovation. This study proposes that key factors driving the 
ascendance of open innovation models include accelerated globalization, increasing 
technology complexity, and greater connectivity resulting from the ICT advancements. 
Next, in an investigation of project-based perspectives on complex product development in 
open innovation, Becker et al. (2013) outline the specific nature of complex product 
development processes and acknowledge the need to rely on external sources of innovation. 
The authors also focus on the challenges of leveraging, such dispersed knowledge, pointing to 
the specific problems brought by the crucial role of “leaning by doing” in complex product 
innovation processes.   
In another relevant study, Bahemia and Squire (2010) abstractly examine open innovation 
on the project level, rather than on the firm level, and develop a conceptual framework of 
inbound open innovation on the new product development project level to access factors that 
help determine the degree of openness along three dimensions (see also Tidd 2014). Bahemia 
and Squire (2010) find that the appropriate calibration of the three dimensions of inbound open 
innovation is determined by the types of innovation (radical versus incremental), product 
complexity (discrete versus complex), and the appropriate regime (tight versus weak). 
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Furthermore, Mooty and Kedia (2014) suggest that the complexity of knowledge exchange 
arise when the information and knowledge necessary to develop the innovation is new and 
unfamiliar to the focal firms. According to the results of this study, translation capability is 
necessary when there is a moderate degree of complexity arising from partial incongruence 
between accesses knowledge domain, and transformation capability is necessary when there is 
a high degree of complexity arising from high level of incongruence. 
In another research pertinent to the topic, Hobday (1998) reports that complex products and 
systems (CoPS) affect the innovation and industrial organization and that there is a wide variety 
of innovation paths in CoPS projects. Adding nuance to these conclusions, Hansen and Rush 
(1998) report that there has been a shift to complex products and systems in industrially 
developed countries due to the increase of industrial output.  
The results of the studies overviewed above demonstrate that technology complexity is an 
important factor to open innovation and the relation between technology complexity and 
openness should be clarified. The effect of technology complexity on openness should be 
investigated and the strategy of open innovation related to technology complexity should be 
constructed in the biochip industry, since the biochip itself is very complex product. 
 
3.1.3. Research Model and Hypotheses 
In this chapter, the following four important factors related to firm performance in open 
innovation will be considered: technology novelty, technology complexity, openness, and 
technology ability. The model is proposed, in which openness is related to (1) level of 
technology novelty; (2) level of technology complexity; (3) level of technology ability; and, 
related to (3), we will focus on (4) the level of technology ability. A theoretical model based on 
the proposed hypotheses is shown in Figure 3.1. In what follows, the relationships between the 
four variables are described in further detail.  
 
(1) Technology novelty 
For new product development in the biochip technology, novelty is very high and thus new 
technologies must be transferred from external partners. Since the way to get new technologies 
from external partners is open innovation and considering that a higher novelty in product 
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demands a higher novelty in technology, the degree of technology novelty affects the quality 
and amount of external technology flow that, in turn, affects the degree of open innovation. 
Therefore, it can be predicted that the technology novelty is directly related to openness. 
According to Tidd and Hsieh (2014) who investigated the influence of project novelty on the 
effectiveness of open service innovation, the more novel development projects demand a higher 
level of interactions with existing suppliers to communicate, while the more novel development 
projects are associated with interaction with additional suppliers and new partners to expand 
the scope and function of new services. These results suggest that the technology novelty is 
related to the level of open innovation and the higher the level of technology novelty, the higher 
the level of degree of openness. Based on this expectation, the following hypothesis can be 
formulated: 
H1: There would be a positive relationship between technology novelty and openness. 
The complexity of knowledge exchange arises when the information and knowledge 
necessary to develop an innovation is new and unfamiliar to the focal firm due to the high level 
of technology novelty (Mooty and Keida 2014). The complexity relates to the knowledge 
exchange capabilities, one of technology abilities. Therefore, technology novelty can be related 
to the technology ability of a firm. Based on the above, the following hypothesis can be 
formulated: 
H2: There would be a positive relationship between technology novelty and technology 
ability. 
(2) Technology complexity 
Complexity level of biochip is very high, since various technologies are combined to 
produce biochips. In this context, inflows of various external technologies are needed to 
provide sufficient technologies to make commercial product inside the firm and, in open 
innovation, the degree of openness can control the amount of various inflowing technologies. 
Therefore, the technology complexity can be related to the degree of openness. According Wei 
and Wei (2011) product complexity and heterogeneity influence the ways in which companies 
carry out online open innovation; when the product is complex, facilitating communication 
among innovators is essential. Based on the above considerations, the following hypothesis can 
be formulated: 
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H3: There would be a positive relationship between technology complexity and openness. 
(3) Openness  
Dahlander and Gann (2010) clarify the definition of openness currently used in various 
reports and literature on open innovation and indicate that openness consists of two inbound 
processes (sourcing and acquiring) and two outbound processes (revealing and selling) 
Furthermore, Love et al. (2011) investigate the openness, knowledge, innovation and growth 
in the UK business service and their results underscore the importance of external openness in 
the initial and exploratory phases of innovation process, as well as the importance of internal 
openness in the later phase of innovation process. In addition, Love et al.’s (2011) results 
demonstrate that learning from openness is based on the dynamics of breadth in external 
innovation linkage and indicate that openness in external knowledge sources includes a process 
of interaction and information processing.  
Furthermore, Roper et al. (2013) investigate externalities of openness in innovation in the 
Irish plant-level data from the manufacturing industry. The results of this study show that 
openness can itself generate positive externalities by enhancing knowledge diffusion. The 
authors also report that externalities of openness in innovation are positively related to the 
firm’s innovation performance. Likewise, in their investigation of the relation between 
openness and innovation performance, especially with the focus on the difference between in 
small firms and large firms based on Irish manufacturing plants, Vahter et al. (2014) find that 
small firms have a lower level of openness due to a lower level of external linkage and a lower 
level of breadth of openness as compared with those of large firms. Similarly, in a study of the 
reasons why openness drives innovation in IT companies, States (2003) finds that open culture 
accelerates the development and diffusion of new technologies.  
Next, Lichtenthaler and Lichtenthaler (2009) identify the following six ‘knowledge 
capacities’ as firm’s critical capabilities of managing internal and external knowledge in open 
innovation process: inventive, absorptive, transformative, connective, innovative, and 
desorptive capacity. Innovative firms have to acquire new skills and routines to develop the full 
real option potential of open innovation practices (Vanhaverbeke et al. 2008). Vanhaverbeke et 
al. (2008) suggest that a firm has to acquire new skills to materialize the benefits of the extended 
flexibility. In this context, development of absorption capacity is needed to effectively learn 
from other firms (Vanhaverbeke et al. 2008). Furthermore, organizing inbound open innovation 
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in traditional industries requires building absorptive capacity; therefore, the ability to absorb 
external knowledge has become a major driver of competition (Spithoven et al. 2011). Thus, 
openness is related to technology ability and the increase of the level of the degree of open 
innovation causes an increase of technology ability. Therefore, it can be predicted that openness 
is positively related to a firm’s internal technological capability to make commercial products. 
Based on the above, the following hypothesis can be formulated: 
H4: There would be a positive relationship between openness and technology ability. 
(4) Technology ability  
In a study on Taiwan’s electronics industry, specifically, with regard to nonlinear 
characteristics of accumulation of technology capability, Tsai (2004) reports that the 
technological capability affects firm performance. The technological innovation increases the 
long-term firm performance (Dieguez-Soto et al. 2016; Takiconda and Montoya-Weiss 2001). 
Thus, it can be predicted that a firm’s internal research ability is positively related to firm 
performance. Therefore, the following hypothesis can be formulated: 
H5: There would a positive relationship between technology ability and firm performance. 
Based on the above hypotheses and relations, the model is constructed as shown in Figure 
3.1. 
 
Figure 3.1. Model for relation between technology characteristics and open innovation 
 
70 
3.1.4. Research Method 
 
(1) Questionnaire Design 
The biochip industry, one of high technology industries, is a fusion of various technologies 
including biochip, nanotechnology, biosensor, and bioinformatics. In general, due to secure 
competition for patent and intellectual property, open innovation activity was barely 
accomplished in high technological industries. However, in the process of rapid development 
and commercialization of new products, since life cycle of high technology has recently 
decreased, the need for open innovation activity has increased (Ahn and Lee, 2011). From this 
trend, it can be predicted that open innovation has happened in the biochip industry due to its 
high and intensive level of technological research. For that reason, the biochip industry in 
Korea is selected as the target industry in the present study.  
The aim of this chapter is to investigate the start of open innovation and the switching cost 
during the initial stage of the new product development process. To achieve this aim and to 
ensure the validity of findings, a questionnaire survey is done, which is an established research 
technique for technology management studies (e.g. Al-Zu’bi and Tsinopoulos 2012; Pick and 
Eisend 2014, 2016).  
The questions to be addressed were designed as follows. The interviews to construct 
questions were carried out with CTO of two small biochip firms (BioDiatech and NSB Postech), 
CTO of one medium-size biochip firm (NanoEnTek), and a manager of the biochip team of a 
large firm (Samsung Advanced Institute of Technology). The data collection took place from 
October 10 to October 24, 2012. Furthermore, the discussion of open innovation activity in the 
implementation stage during new product development in biochip was held, with the specific 
focus on the factors affecting openness so that to find the relation of factors for openness and 
technology ability. In addition, the relation of technology ability to firm performance was 
discussed during open innovation action. The discussion results for open innovation activity 
during new product development of biochip were analyzed and the main variables were 
classified as two factors (technology novelty and technology complexity), openness, 
technology ability, and the perception of advantage of open innovation (see Table 3.1). 
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Table 3.1. Questions for openness in implementation stage during new product development 
(NPD). 
(1) How would you characterize the degree of technology novelty?  
1.1. How novel is the composition of the product on average? 
1.2. How novel is the structure of the product? 
1.3. How novel are the production processes on average? 
1.4. How novel is the layout of the production process? 
(2) How would you characterize the degree of technology complexity?  
2.1. Are different types of technologies used for the product? 
(3) How would you characterize level of openness? 
3.1. Our organization is active in working with others. 
3.2. Our organization regularly exchanges information with others. 
3.3. Our organization has active interaction with others. 
3.4. Our organization is flexible with the creation and abolition of organizations as 
needed. 
(4) How would you characterize the level of technology ability? 
4.1. How would you characterize level of overall R&D capability of your company 
compared with competitors? 
4.2. How would you characterize the number of patents of your company, as compared 
to competitors? 
4.3. How would you characterize the number of researchers of your company, as 
compared to competitors? 
4.4. How does level of your research experience with your research staff compare to that 
of competitors? (Limited to experience in related fields) 
4.5. How would you characterize research funding level of your company as compared 
to competitors? 
4.6. How would you characterize research equipment level of your company as compared 
to that of competitors? 
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(5) What is the level of firm performance? 
5.1. What is the level of increase of revenue? 
5.2. What is the level of increase of operating margin? 
5.3. What is the level of increase of competitive production cost? 
5.4. What is the level of increase of newly invested capital? 
5.5. What is the level of increase of number of newly developed products? 
5.6. What is the level of increase of royalty income? 
 
The scales used in the survey were seven as used in the literature (Son et al. 2014), and then 
the scales were later modified for this study. To ensure the validity of the questions and scales, 
a panel of experts consisting of three interviewees and two professors in Sogang University, 
Korea (major: biochip and biosensor) was asked to review them. This process allowed us to 
introduce modifications and clarification to the questions.  
The main question addressed in this chapter concerns the openness to start open innovation 
in the initial stage of new product development of biochip. Specifically, four aspects are of 
relevance here: (1) Does openness control firm performance? (2) Do factors such as technology 
novelty and technology complexity affect openness? (3) Does openness relate to technology 
ability? (4) Does technology ability relate to firm performance? The survey results obtained to 
the constructed questionnaire are described in the next section.  
 
(2) Survey Administration 
The survey in the Korean biochip firms, conducted from October 24, 2011 to November 17, 
2012, targeted decision makers in 70 firms. The respondents were contacted by e-mail and visit. 
At that time, the total number of bio-diagnostics firms in the Korean Association of Bio-
diagnostics was about 70. At first, from October 24, 2011 to February 24, 2012, the survey was 
done for 50 firms; the number of collected surveys was 35, which was not sufficient for data 
validation. Then, from August 17, 2012 to November 17, the survey was done for additional 
20 firms and the number of collected surveys was 15. Thus, the total number of collected 
surveys amounted 50 firms. Due to the long period of data collection (approximately one year), 
there may have a time-related bias, though all firms were alive during one year. Biochip firms 
included biosensor firms, biochip firms to produce DNA chip, protein chip, cell chip, biosensor 
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array firms, biochip fabrication firms including MEMS (microelectromechanical system), 
bioinformatics firms, and instrument firms (arrayer and detector). Through the survey, a total 
of 50 survey results were acquired, reaching the response rate of 71 %, and further analysis 
was carried out with 47 surveys (in 3 surveys, the responses were incomplete). 
 
(3) Demographic characteristics 
Demographic characteristics of the respondents are summarized in Table 3.2. 
Table 3.2. Characteristics of demography of sample 
Division Content Number Percentage (%) 
personal  
employment term 
below 5 years 16 32 
6~10 years 15 30 
11~15 years 13 26 
16~20 years 3 6 
21~25 years 2 4 
above 26 years 1 2 
Personal position 
CEO 23 46 
Research Director 4 8 
General Manager 11 22 
Deputy General 
Manager 
6 12 
Manager 4 8 
Missing value 2 4 
Personal age 
20~29 1 2 
30~39 14 28 
40~49 23 46 
50~59 11 22 
Missing value 1 2 
Firm's Age 
below 5 years 9 18 
6~10 years 14 28 
11~15 years 19 38 
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16~20 years 7 14 
Missing value 1 2 
Number of 
employees 
below 10 15 30 
11~50 16 32 
51~100 6 12 
101~200 5 10 
200~300 4 8 
1800 1 2 
Missing value 3 6 
Number of 
researchers 
1~10 24 48 
11~20 12 24 
21~50 5 10 
51~100 3 6 
above 100 3 6 
Missing value 3 6 
 
(4) Statistical analysis of variables 
The denotation of variables and measurement method of the variables in the research model 
are shown in Table 3.3. A seven-point scale was used for the variables. 
Table 3.3. Denotation and measurement of variables 
TN1 How novel is the composition of the product on average? 
TN2 How novel is the structure of the product? 
TN3 How novel are the production processes on average? 
TN4 How novel is the layout of the production process? 
OP1 Our organization is active in working with others. 
OP2 Our organization regularly exchanges information with others. 
OP3 Our organization has active interaction with others. 
OP4 Our organization is flexible with the creation and abolition of organizations as 
needed. 
TA1 Compared with competitors, level of overall R&D capability of your company 
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TA2 Compared with competitors, the number of patents of your company 
TA3 Compared with competitors, the number of researchers of your company 
TA4 Compared with your competitors, level of your research experience with your 
research staff (Limited to experience in related fields) 
TA5 Compared with competitors, research funding level of your company? 
TA6 Compared with competitors, research equipment level of your company? 
FP1 Level of increase of revenue 
FP2 Level of increase of operating margin 
FP3 Level of increase of competitive production cost 
FP4 Level of increase of newly invested capital 
FP5 Level of increase of number of newly developed products 
FP6 Level of increase of royalty income 
TC1 Number of different types of technologies used for the product 
TN: Technology novelty, TC: Technology complexity, OP: Openness, TA: Technology ability, 
FP: firm performance 
 
The classification of technology complexity is shown in Table 3.4. 
Table 3.4. Classification of technology complexity 
Type Subtype  Detail Classification 
Bio 
Fabrication 
Substrate material 
Glass 
Gold 
Silicon 
Polymer 
Coating 
Silanization 
Polymer matrix 
Bio material 
DNA 
Protein 
Cell 
Peptide 
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Small molecules 
Micro arraying 
Pin 
Inkjet 
Photolithography 
Electrical addressing 
Lab-on-a-chip 
Bio MEMS technology 
Silicon machining 
Plastic machining 
Bio MEMS device 
Micro channel 
Micro valve 
Micro fluidics 
Dispenser 
Reaction chamber 
Electric device 
Total integrated system 
Bioinformatics Bioinformatics 
Image analysis 
Visualization 
Database 
Data mining 
Clustering 
Detection 
Materials and instruments for 
detection 
Fluorescence material 
F.M. laser scanner 
F.M. Scattering 
F.M. Polarization 
Electrochemical 
SPR 
Mass Spec. 
Magnetic 
 
Based on the data acquired by the survey, analysis was performed using SPSS 18.0 program 
and PLS 2.0. The hypotheses were tested by applying the partial last square (PLS) method to 
the collected data. This study used PLS, rather than other SEM methods (i.e. LISREL, AMOS, 
etc.), because the PLS approach places minimal restrictions on sample size and residual 
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distribution (Phang et al. 2006). First of all, analysis of descriptive statistics quantity was 
accomplished and the results were investigated. To verify the reliability of the samples, items 
measuring each comprising concepts were investigated using Cronbach’s alpha test. Also, to 
verify the validity of the samples, factor analysis was performed in the hypothesis testing 
process. 
 
3.1.5. Results 
 
3.1.5.1. Validation  
To validate the model, three types of validity—content validity, convergent validity, and 
discriminant validity—were assessed. (1) Content validity was evaluated based on Cronbach 
alpha value (see Table 2.4). Cronbach’s alpha test to individual scale and the overall measures 
was used to assess internal consistency. The threshold value of Cronbach alpha is 0.7 (Nunally 
and Berstein 1994). As shown in Table 3.5, the Cronbach alpha values are 0.870 for technology 
novelty, 1.000 for technology complexity, 0.729 for openness, 0.896 for technology ability, and 
0.881 for firm performance. Thus, all variables are valid. 
Table 3.5. Confirmatory factor analysis 
 AVE Composite Reliability Cronbach’s Alpha 
TC 1.000 1.000 1.000 
FP 0.664 0.908 0.881 
TN 0.718 0.910 0.870 
OP 0.545 0.826 0.729 
TA 0.659 0.920 0.896 
*Average variable extracted 
 
(2) Convergent validity was assessed by composite reliability and average variance 
extracted (AVE) from the measures (see Table 3.5). The acceptable value of composite 
reliability for reliable construct is 0.7 (Chin 1988). The obtained composite reliability values 
were 0.910 for technology novelty, 1.000 for technology complexity, 0.826 for openness, 0.920 
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for technology ability, and 0.908 for firm performance. Thus, all variables are valid. The 
acceptable value of AVE is over 0.5 (Fornell and Larcker 1981). The AVE values in our results 
were 0.718 for technology novelty, 1.000 for technology complexity, 0.545 for openness, 0.659 
for technology ability, and 0.664 for firm performance. Thus, all variables are valid.  
 (3) Discriminant validity is verified by evaluating the square root of AVE (Fornell and 
Larcker 1981; Son et al. 2014). The square root of AVE for each construct in our results was 
greater than the levels of correlation involving the construct (see Table 3.6). Also, each 
construct showed a larger variance with its own measures than those with other measures (see 
Table 3.6). Threshold value of absolute value pairwise correlation is 0.6 (Nunally and Berstein 
1994); the highest absolute value of pairwise correlation in our data was 0.484, which is lower 
than 0.6. Variance inflation factors (VIF) is calculated to detect the multicollinearity among the 
explanatory variables. Threshold value of VIF is 10 (Nunally and Berstein 1994); in our results, 
the highest VIF value was 3.722, which is far lower than 10. Thus, all variables are valid. 
Table 3.6. Correlation between constructs 
 Complexity 
Firm 
performance 
Novelty Openness 
Technology 
ability 
TC 1.000     
FP 0.064 0.815*    
TN 0.234 0.065 0.848*   
OP 0.073 0.185 0.323 0.738*  
TA 0.244 0.447 0.367 0.484 0.812* 
* Square root of AVE 
 
The other analyses based on statistical results are as follows. The descriptive statistics 
including standard deviation are summarized in Table 3.7. Kaiser-Meyer-Olkin measure of 
sampling adequacy was calculated to amount to 0.754. The results suggest that 4 factors 
explain 67.933% of the total variance (Table 3.8). Since all 4 factors are well distributed over 
0.6 in factor analysis, the validity requirement was satisfied (see Table 3.9). 
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Table 3.7. Descriptive Statistics 
 N Min Max Mean Std. Deviation 
TN 1 47 1 7 5.19 1.296 
TN 2 47 1 7 4.72 1.363 
TN 3 47 1 7 4.72 1.314 
TN 4 47 2 7 4.60 1.313 
OP 1 47 1 4 2.13 1.055 
OP 2 47 1 4 3.06 .895 
OP 3 47 1 4 2.74 .943 
OP 4 47 1 4 1.81 1.014 
TA 1 47 1 7 4.72 1.542 
TA 2 47 1 7 3.77 1.709 
TA 3 47 1 7 3.30 1.743 
TA 4 47 1 7 4.38 1.675 
TA 5 47 1 7 3.91 1.717 
TA 6 47 1 7 4.26 1.738 
FP 1 47 1 7 3.32 1.795 
FP 2 47 1 7 3.74 1.725 
FP 3 47 1 7 4.74 1.621 
FP 4 47 1 7 3.15 1.732 
FP 5 47 1 7 4.00 1.655 
FP 6 47 1 7 2.45 1.515 
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TC 1 47 1 7 2.94 1.634 
Effective Number 47     
 
Table 3.8. Total Variance Explained 
Factor 
Initial Eigenvalues 
Extraction Sums of 
Squared Loadings 
Rotation Sums of Squared 
Loading 
Total 
% of 
Variance 
Cumul
ative 
% 
Total 
% of 
Variance 
Cum
ulativ
e % 
Total 
% of 
Variance 
Cumu
lative 
% 
1 6.193 32.594 32.594 6.193 32.594 
33.65
7 
3.986 20.980 
20.98
0 
2 3.253 17.121 49.715 3.253 17.121 
54.44
1 
3.564 18.759 
39.73
9 
3 1.919 10.098 59.813 1.919 10.098 
67.59
3 
3.118 16.412 
56.15
2 
4 1.554 8.180 67.993 1.554 8.180 
75.68
6 
2.250 11.841 
67.99
3 
5 .945 4.973 72.967       
6 .813 4.277 77.243       
7 .757 3.983 81.226       
8 .654 3.445 84.671       
9 .528 2.780 87.954       
10 .475 2.502 89.954       
11 .374 1.969 91.922       
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12 .324 1.704 93.626       
13 .270 1.423 95.049       
14 .236 1.242 96.290       
15 .211 1.109 97.400       
16 .174 .917 98.316       
17 .137 .721 99.038       
18 .117 .615 99.653       
19 .066 .347 
100.00
0 
      
Extraction Method: Principal Component Analysis 
 
Table 3.9. Rotated Component Matrix 
 
Component 
1 2 3 4 
TN 1 .107 .116 .778 .145 
TN 2 .141 -.034 .812 .181 
TN 3 .126 -.046 .880 .003 
TN 4 .126 -.096 .840 .077 
OP 1 .157 .050 .262 .672 
OP 2 .362 -.071 .144 .607 
OP 3 -.008 .140 .015 .787 
OP 4 .262 .055 .045 .742 
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TA 1 .830 .120 .080 .054 
TA 2 .837 .056 .082 .166 
TA 3 .754 .291 .078 .231 
TA 4 .687 -.012 .036 .163 
TA 5 .758 .252 .289 .107 
TA 6 .695 .281 .388 .171 
FP 1 .081 .912 -.024 .141 
FP 2 -.063 .881 -.100 .058 
FP 3 .355 .758 .099 .076 
FP 4 .253 .707 .060 .099 
FP 5 .109 .763 -.043 -.103 
Extraction Method: Principal Component Analysis, Rotation Method: Varimax with Kaiser 
Normalization. a. Rotation converged in 5 iterations 
 
3.1.5.2. Hypothesis testing 
 
To validate the model, the structural equation model was applied and Partial Least Square 
(PLS) was used. Since PLS requires minimal demands on sample size (Chin 1998) to validate 
a model and our data set had 47 questionnaires, the PLS method was used to evaluate the 
proposed model and hypotheses. When t-value is over 1.96, the hypothesis is significant at 5% 
level of significance (provided the number of surveys is sufficiently large). Cramer suggests 
that the approximation is usually good for samples larger than 30 (Cramer 1946) and, thus, 
statistical inference is appropriate for our dataset. As shown in Table 3.10, only t-values for the 
relation between technology novelty and openness, the relation between openness and 
technology ability, and the relation between technology ability and firm performance were over 
1.96 and thus only these three relations were satisfied. The values of path loadings were then 
calculated. Since R2 for openness, technology ability and firm performance was 0.104, 0.284, 
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and 0.200, respectively, the proposed model is acceptable, since minimum acceptable range of 
R2 is 0.1. The results of the analysis of the model with path coefficient, t-value, and R2 are 
shown in Figure 3.2.  
 
 
Figure 3.2. Model result for relation between technology characteristics and open innovation 
 
Table 3.10. Path Coefficients 
 
Original 
Sample 
Sample Mean 
Standard 
Deviation 
T Statistics P Values 
TC → OP -0.003 0.009 0.145 0.022 0.983 
TN → OP 0.324 0.358 0.132 2.454 0.014* 
TN → TA 0.235 0.215 0.141 1.660 0.097 
OP → TA 0.409 0.430 0.127 3.215 0.001** 
TA → FP 0.447 0.497 0.111 4.036 0.000*** 
*** p<0.001, ** p<0.01, * p<0.05 
 
The results reported in Figure 3.2 suggest the following. The technology novelty is 
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positively related to openness, meaning that, as technology novelty becomes higher, the degree 
of open innovation and openness increase as well. The result suggests that the firm becomes 
more open to get a new technology from outside to make a novel product if technology novelty 
is high and the new product is novel. Thus, Hypothesis 1 is confirmed. If only path coefficients 
in Table 3.10 are considered, the technology novelty is positively related to the change of 
technology ability of firm, meaning that, as technology novelty becomes higher, the technology 
ability of firm increases. However, since t value is not in the acceptable range, the relation 
between technology novelty and change of technology ability of firm is not established. Thus, 
technology novelty does not directly relate to technology ability of firm and Hypothesis 2 has 
to be rejected. 
If only path coefficient is considered, the technology complexity is positively related with 
openness, meaning that as technology complexity becomes higher, the openness increases. 
However, since t-value is not in the acceptable range, the direct relation between technology 
complexity and openness is not established. It is reported that a firm has to become more open 
to get complex technology from outside and then it can make new complex product with 
complex technologies (Bogers and West 2012; Nieto and Santamaria 2006). However, 
according to Mooty and Kedia (2014), the relation between complexity and performance has a 
reverse U-curve shape and, thus, it is difficult to make just a positive or a negative relation 
between technology complexity and openness, which is related to firm performance. In the case 
of biochip investigated in this study, to make biochips, many different kinds of technologies 
should be combined, since a biochip is basically a product of complex technology (Table 3.4); 
therefore, an increase of complexity cannot significantly affect the increase of open activity in 
firm due to the intrinsic high complexity of the biochip industry. Therefore, there is no positive 
relation between technology complexity and degree of open innovation in biochip production 
and Hypothesis 3 has to be rejected.  
The openness is positively related to technology ability, meaning that, as the degree of open 
innovation becomes higher, the technology ability in firm increases. The results suggest that, 
if the firm becomes more open and gets more new technology from the outside, the technology 
ability to make new product increases due to acquiring a new technology. Thus, Hypothesis 4 
is supported by our data analysis. 
The technology ability of firm is positively related to firm performance, meaning that, as 
level of technology ability in firm becomes higher, firm performance (such as revenue, 
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operating margin, competitive production cost, number of newly developed product, and 
royalty income) becomes better. The obtained results suggest that, if the firm becomes more 
open and gets more new technology from the outside, the technology ability to make new 
product increases due to the firm’s acquiring a new technology. Thus, Hypothesis 5 is supported 
by our data analysis. 
Although openness is reported to directly affect directly innovation performance (Vahter et 
al. 2014), in this study, openness is directly related to the change of technology ability and then, 
sequentially, technology ability is directly related to firm performance. The change of 
technology ability becomes a mediator factor between openness and firm performance, since 
the biochip is a technology-concentrated product. This constitutes a newly developed 
relationship in open innovation for high-tech products.  
 
3.1.6. Conclusion and Discussion 
The summary of the research results reported above is shown in Figure 3.3. 
 
 
Figure 3.3. Summary of model result for relation between technology characteristics and open 
innovation 
 
The purpose of this chapter was to investigate the factors affecting openness during 
implementation of open innovation. The factors, such as the technology characteristics, 
technology novelty and technology complexity, were investigated. We found that technology 
novelty has a positive relation with openness. If the technology novelty is high and new product 
is a very creative one, the degree of open innovation should be increased, meaning that the firm 
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should become more open to get more external technologies. However, due to the intrinsic 
nature of biochip technology, our results demonstrate that the technology complexity is not 
directly related to openness.  
A factor that affects the change of firm’s technology ability in new product development is 
openness. Our results show that the openness is positively related to firm’s technology ability. 
If the openness becomes high during the development of a new product and the degree of open 
innovation increases, more external technologies are necessary and should be acquired from 
the outside; thus, the technology ability to make a new product increases. As openness and 
inflow of external technologies increase, more technology ability inside the firm is achieved. 
As firms becomes more open and more inflow of external technologies occurs, more increase 
of technology ability inside firm is achieved. 
A factor that affects the change of firm’s technology ability in new product development is 
firm’s ability. Our results show that a firm’s technology ability has a positive relation to firm’s 
performance. If the firm’s technology ability increases because of openness increase, during 
the development of a new product, there is a corresponding increase of revenue, operating 
margin, competitive production cost, number of newly developed products, and royalty income, 
which positively affects firm’s performance. Thus, an increase of openness improves a firm’s 
technology ability and then, sequentially, an increase of technology ability causes an increase 
of firm’s performance.  
An innovation strategy is needed to effectively do innovation, since the problem with 
innovation improvement efforts is rooted in the lack of an innovation strategy (Pisano 2015). 
Based on the results from this study, the following strategy to manage open innovation during 
implementation of open innovation is suggested. At first, the novelty of technology for a new 
product is carefully examined. If the technology novelty is high, the degree of open innovation 
should be increased. If the technology novelty is very low, the firm should decide to decrease 
the open innovation activity with an external research partner. The technology complexity is 
not much considered to decide on the degree of open innovation and openness.  
As more open innovation is implemented due to novelty, the more technology flows in. By 
controlling the degree of open innovation, the technology flow can be controlled, which, in 
turn, affects the technology ability of firm to produce new products. As a second step, the 
degree of open innovation should be decided based on the level to which firm wants to increase 
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its internal research ability. Then, an increase of the research ability of firm causes the increase 
of firm performance, leading to more profit. As a third step, the balance between the expense 
of open innovation and profit of firm due to openness should be considered and then the degree 
of open innovation can be decided based on the balance. The relations among openness, 
technology ability, and firm performance should be simultaneously evaluated. 
In this study, the technology is center to value offering and can control the openness and 
firm performance. However, in the real world, to improve firm performance, a firm has to 
consider at least six factors, including technology, organization, environment, market, business 
model, and expansion in the innovation process (Henderson et al. 2016). The start of the process 
is often technology, from which we create value and then end with market – the source of need 
and place where value is realized (Henderson et al. 2016). Thus, to make strategy for open 
innovation, the above-mentioned variables should be considered simultaneously with the 
technology viewpoint. 
The results of this study are follows: (1) Influential factors affecting the degree of open 
innovation during the implementation process in new product development are identified; (2) 
The relations among influential factors including the technology characteristics to openness are 
clarified; (3) Strategy to control the openness is proposed to increase firm performance. 
Technology characteristics and technology ability in firm are key factors to decide on the 
degree of openness with external partners. Based on the insights regarding the relations of 
openness with firm performance from the technology point of view, the decision to control the 
degree of openness should be taken. 
Since, the extended period of data collection (ca. a year) could have caused a time-related 
bias in the present study (although all firms that responded to the survey were alive during one 
year), a reduction of time for the survey is recommended. 
 
3.2. Analysis of Influence Factors on Breadth and Depth in Open Innovation Activity 
 
3.2.1. Introduction 
 
After a conceptual introduction by Chesbrough (2003), open innovation has received a huge 
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attention from both academic research and firms. According to Chesbrough (2003, 2006a,b), 
open innovation is the methodology of innovation used by firms to open the innovation process, 
including research, development, and commercialization; in open innovation, external 
resources are used for reduction of innovation cost, increasing the possibility of success, and 
maximization of added value creation. Due to the globalization of firm’s market, open 
innovation has been widely used in various fields. The reason to believe that open innovation 
is important for efficient management of firm can be found in the rapid change of knowledge 
environment surrounding the firm. Following Chesbrough (2003), Kim et al. (2008) suggest 
the following three reasons for the emergence of open innovation in R&D). First, after the end 
of large firms’ monopoly on knowledge, sources of knowledge creation have been widened, 
including universities and venture firms. This means that big firm-cored monopolistic 
management becomes impossible, because creative knowledge is being developed in various 
fields. The second reason is mobility of human resources and the development of venture 
capital. The mobility of human resources here means that knowledge and know-how move with 
each other in a firm and the channel of technological commercialization is extended with the 
rapid development of venture capital. The last reason is the growth of cost for technological 
development and the minimization of product cycle. As the time of initiative for technology 
has been shorten, firms should invest resources into the development of follow-up technology.  
Specifically, in the case of Korea, the investment for R&D part has rapidly grown; however, 
most results of R&D have not been commercialized yet (Bock and Lee 2008). As mentioned 
by Bock and Lee (2008), 61.1 % of patents possessed by Korean firms are in the state of 
dormancy. Thus, the effort for innovation strategy is needed for an effective R&D investment 
and empowerment in Korea. Open innovation has been considered as an effective measure to 
solve the above problem (Kim et al. 2008). To apply open innovation to firms, the analysis of 
factors in innovation activity should be performed. Although open innovation is an important 
issue, studies on the factors affecting innovation activity remain scarce.  
Generally, in most previous studies, open innovation in firms has been investigated through 
case studies (Chiaroni et al. 2009). However, while various statistical studies have been 
conducted, due to the use of only the data related to open innovation from technological 
innovation activity, these studies, as suggested by Laursen and Salter (2006), have not 
considered various factors for tactical decisions of open innovation Therefore, further research 
on the various factors affecting innovation activity in open innovation should be undertaken. 
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In this chapter, the influential factors of the breadth and depth of external seeking are 
investigated with the aim of suggesting an appropriate strategy of open innovation to increase 
firm performance. The breadth and depth of external seeking are related to openness that affects 
firm’s performance. Factors affecting open innovation activity are classified as the follows: 
environmental characteristics surrounding firm, firm characteristics including research ability 
and organizational culture, and institutional characteristics for technological innovation activity. 
These three factors are investigated to see how they affect open innovation activity. To this end, 
a survey is conducted in the Korean biochip firms to analyze innovation activity in open 
innovation.  
 
3.2.2. Theoretical considerations 
 
3.2.2.1. Concept of open innovation activity 
 
 As shown in the introduction section, open innovation refers to the methodology of firm 
innovation that maximizes the value added by reducing the innovation cost and enhancing the 
possibility of success through opening a series of innovative processes in research, NPD 
development, and commercialization. According to Chesbrough (2006a,b), the open 
innovation is that a firm uses internal and external knowledge flow to accelerate inner 
innovation and to expand outer market of innovation. The open innovation process refers to the 
implementation of a system whereby which internal and external ideas are integrated and this 
open knowledge system is resonant with the company’s business models. Specifically, as a 
category of open innovation, all things regarding technology innovation that are in exchange 
with the outside of the firm are defined as open innovation. Besides, whether or not there is 
collaboration with the outside, only cooperative relationship in the process of technological 
innovation is open innovation. In a large category, open innovation exists as the outward and 
inward type of innovation activity. 
 In this regard, as proposed by Kim et al. (2008), technology purchase, collaborative 
research, research contract, cooperative venture foundation, venture investment, firm takeover, 
solution public participation, user innovation, and collective intelligence are classified as 
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activities of inward type, while technology sale and new dividing firm from inside are classified 
as activities of outward type (see Table 3.11). 
 
Table 3.11. Types and activities of open innovation 
Type Concept Example 
Inward 
Type 
Acquiring technologies or ideas of 
firm from outside during technology 
innovation process 
Technology purchase, collaborative 
research, research contract, 
cooperative venture foundation, 
venture investment, firm takeover, 
solution public participation, user 
innovation and collective intelligence 
Outward 
Type 
Letting technology to outside Technology sales, spin-off firm 
 
Furthermore, Gassman and Enkel (2004) classified open innovation as three models or core 
processes. First, inward process refers to the integration of supplier, customer, and outside 
knowledge. The knowledge inflow from outside organizations like universities and common 
laboratories is an example here. Second, outward process refers to the firm’s supplying ideas, 
selling intellectual properties to the outside, and knowledge transfer. Technology holding firm, 
new dividing firm, and licensing are relevant examples here. Third, integrated process is the 
process that integrates outward and inward processes and could be classified by mutual 
knowledge exchanges and joint investments for technology integration. 
 Laursen and Salter (2006) further analyze the effects of open search on the results with 
2707 manufacturing firms in the UK. Considering the open search as activities that accelerate 
open innovation, the authors measure how deeply and widely firm’s research was done among 
the 16 outside information sources. With these considerations, the authors find that the open 
search enhances the results of technology researches. Also, the depth of research enhances 
rapid innovation, while the breadth enhances gradual innovation. Furthermore, the effects of 
open action have limitations, because it shows a reversed U-shape when the activity of open 
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innovation is above some level. 
 
3.2.2.2. The research on the factors affecting open innovation 
 There are many reasons why firms conduct open innovation. In an analysis of the industrial 
characteristic effects in various cases, Kim et al. (2008) observe that the relation in the industry 
between position of firm, exclusive possession method of technology, maturity of industry, 
transition progress, and relief in industry affect open innovation. Furthermore, using the data 
of manufacturing business, Lee and Choe (2006) find that there is a decision factor of 
collaborate research related to business scale and technology knowledge inflow from 
universities or research centers. 
 Likewise, based on a thousand of Spanish manufacturing firms, Arranz and Arroyabe (2008) 
analyze decision factors of open innovation activity and conclude that the types of cooperative 
activities can be classified into vertical cooperation, horizontal cooperation, and cooperation 
with public institutions. In this research, the high-tech field, business scale, existence of R&D 
organization, and policy funds support are confirmed as decision factors for horizontal 
cooperation. Finally, James and Ropper (2002) note that the decision of cooperation type of 
R&D is based on facility scale, R&D investment cost, and market structure environment. 
 
3.2.3. Research model 
 
3.2.3.1. Research model and hypothesis 
 In order to analyze the factors of affecting open innovation activity, we divide them into 
firm’s internal and external factors. Ahn and Lee (2011) analyzed the decision factors of the 
open innovation by classifying them into environmental characteristics, business 
characteristics, and institutional characteristics. In the present research, the classification of 
fundamental independent variables is based on Ahn and Lee’s (2011) approach; however, some 
variables were added or edited based on industrial characteristics on the chip industry. 
Specifically, the factors are classified into environmental characteristics (novelty of technology, 
degree of market competition, and government support), industrial characteristics (research 
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capability, organization culture), and institutional characteristics (existence of dedicated group 
to derive open innovation and firm’s location in industrial cluster for business exchange). With 
the above classification, outside business environment factors, inside business capability 
factors, and institutional factors are considered using the integrated strategic view. The reason 
to make this classification is that effects of variables on open innovation can be found by 
investigating firm’s technical capacity and culture of firm that accepts open innovation. Also, 
by considering institutional system needed for open innovation, as well as technical capability 
and firm culture, an integrated view to analyze open innovation inside the firm can be proposed. 
 The variety of external networks of collaboration in open innovation is measured by breadth 
and depth of open innovation. Breadth of open innovation can be measured by the number of 
targets, while the depth is measured by the frequency of a single target. Laursen and Salter 
(2006) used the concepts of depth and breadth to measure the degree of open innovation by 
evaluating how much, or how closely, outside information sources cooperate on the basis of 
open innovation data. 
Based on the results of the studies overviewed above, it can be predicted how environmental, 
industrial, and institutional characteristic variables could affect depth and breadth of open 
innovation; furthermore, these variables can help decide whether or not to pursue cooperation 
with new objects or existing objects. With regard to this research model, the hypotheses 
outlined below can be formulated. 
 
(1) The relation between environmental characteristic factor and open innovation 
activity 
The degree of market competition among environmental characteristics refers to high 
uncertainty of the market (Einsenhardt and Schoonhoven 1996). As the existence of firm might 
be threatened if uncertainty of market becomes higher, to overcome this threat, cooperation 
through the open innovation is expected to increase. It appears that the more competitive firms 
are, the more technology from outside they can acquire. In other words, it means that open 
innovation would grow up more when the degree of market competition becomes higher. 
Stafford (1004) calls this taking a safety strategy when market is uncertain. Considering depth 
and breadth of open innovation activity, to enhance cooperation with the currently cooperating 
object is a safer strategy than finding another object. Therefore, the following hypothesis can 
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be formulated: 
H1-1: With an increase of the intensity of market competition, the depth of open innovation 
activity would increase. 
Normally, it is reported that governmental R&D support positively affects innovative degree 
of technology development. For example, Arranz and Arroyabe (2008) report that policy fund 
support meaningfully affects horizontal open innovation. Therefore, the following hypothesis 
can be formulated: 
H1-2: With an increase of the degree of government support, the depth of open innovation 
activity would increase. 
Appearance of new technology means that research about new knowledge is required. 
According to Belderbos et al. (2004), the cooperation with various research subjects to develop 
and introduce technology is increased with the transition of technology. Similarly, an increase 
of effort to find various knowledge sources is expected as a new technology is evolved. 
Therefore, the following hypothesis can be formulated: 
H1-3: With an increase of the novelty of technology, the breadth of open innovation activity 
would increase. 
 
(2) The relation between firm characteristic factor and open innovation activity 
The quality of researchers is an important factor for research cooperation. High technology 
capacity means that more advantages are expected in cooperation with outside subjects. High 
quality of research ability in firm makes cooperative research effective, rather than just 
facilitates importing or transferring the technology with outside (Link and Bauer 1987). Thus, 
by high quality researchers, it tends to maintain cooperation subjects narrowly and closely. 
Therefore, the following hypothesis can be formulated: 
H2-1: With an increase of the research capability based on the number of Ph.D. staff in R&D, 
the depth of open innovation activity would increase. 
Increase of research investment means an increase of research capacity of the firm. For a 
continuous increase of firm’s research capacity, aggressive investment should be done and the 
investment for development is related to seeking of new knowledge resources. During the 
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process of strategic investment of a firm, the factors affecting seeking of new knowledge 
resources should be investigated and the diversity of knowledge sources should be examined. 
Therefore, the following hypothesis can be formulated: 
H2-2: With an increase of the investment for R&D, the breadth of open innovation activity 
would increase. 
The factors related to openness of the organization culture could be found by open innovation 
example of P&G (Huston and Sakkab, 2006). Furthermore, openness and flexibility of the 
organization culture was suggested to be an important factor promoting wide open innovation 
activity. Therefore, the following hypotheses can be formulated: 
H2-3: With an increase of the flexibility in organization culture increase, the depth of open 
innovation activity would increase. 
H2-4: With an increase of the openness in organization culture, the breadth of open 
innovation activity would increase. 
 
(3) The relation between institutional characteristic factor and open innovation activity 
In the open innovation in Hyundai Motor Co in Korea, the organization to control open 
innovation is key in the success of innovation (Kim et al. 2008). To control open innovation 
activity the organization controls the management strategy for innovation, as well as planning 
for collaboration with external technology supplier. If a dedicated group to drive open 
innovation is established in a firm, this group acts as a facilitator that connects business units 
with potential sources of innovation (Noble et al. 2014). Thus, the establishment of a dedicated 
group for open innovation could be an effective way of management strategy for open 
innovation. Therefore, the following hypothesis can be formulated: 
H3-1: If dedicated group for open innovation exists, the depth of open innovation activity 
increases. 
Presence of technical and institutional system for information sharing is an important factor 
for open innovation, which can be correlated to firm’s location in industry cluster, since there 
are large chances for information sharing and collaboration with near external technology 
resources in the industrial cluster. Industrial cluster is defined as a manufacturing network of 
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independent firms including specialized suppliers for establishing productive facilities in the 
same location (Roelandt and Hertog 1999). In industry cluster, the chance for collaboration 
might increase due to the easiness of spatial and geographic cooperation. Networks between 
various firms for technology innovation may be developed and, thus, it will be easier to acquire 
the collaboration results. For example, in Osong Bioindustry Cluster of Korea, 9  various 
information exchanges and research cooperation has been done among biotechnology firms. 
H3-2: If firm is located in an industrial cluster, the breadth of open innovation activity 
increases. 
 
Based on the above relations the model for effect of influential factors on open innovation 
activity is proposed as shown in Figure 3.4. 
 
 
Figure 3.4. Model for effect of influential factors on open innovation activity 
 
 
                                           
9 For further detail, see http://www.osong-bio.kr/home/ 
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3.2.3.2. Variables and measurement 
 The definition of variables and measurement method of the variables in the research model 
are shown in Table 3.12. 
 
Table 3.12. Definition and measurement of variables 
Variable / dimension Definition 
Measure
ment 
Environmental 
characteristics 
Technology Novelty  
- The novelty degree in structure of product 
- The novelty degree in production process 
- The novelty degree in production process 
layout 
7 point 
metric 
Market competition 
- Market maturity degree 
- The degree of market competitor 
- Predictability degree of product demand 
7 point 
metric 
Government support 
- The degree of research project to receive 
from the government in the past three years 
5 point 
metric 
Firm 
characteristics 
Research 
capability 
R&D staff 
(Ph.D.) 
- Number of researchers to have Ph.D. 
Number 
metric 
Total R&D 
staff 
- Number of researchers in R&D 
Number 
metric 
R&D staff 
/ overall 
staff 
- R&D Staff / Total Staff 
Ratio 
metric 
R&D 
investment 
(2010) 
- logarithm value of R&D investment 
Money 
amount 
Organizat
ional 
culture 
Openness 
- Aggressiveness degree in cooperation with 
other departments 
- Information exchange degree with other 
departments 
7 point 
metric 
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- Personnel interaction degree with other 
departments 
Flexibility 
- Flexibility degree of creation or close of 
organization 
- Autonomy degree of recruitment and 
relocation of human resource 
7 point 
metric 
Institutional 
characteristics 
Presence of 
dedicated group 
- Presence of dedicated group for open 
innovation 
Nominal 
metric 
Presence of 
institutional system 
- Presence of technical and institutional 
system for information sharing 
Nominal 
metric 
Location in industrial 
cluster 
- Firm’s location in industrial clusters 
composed university and other 
technological firms 
Nominal 
metric 
Open 
innovation 
activity 
Depth of open 
innovation 
- Degree of frequency to collaborate with 
private research institutes / 
universities/national institutes / industrial 
associations/ competitors/ non-competitors/ 
equipment suppliers/ demand companies 
4 point 
metric 
Breadth of open 
innovation 
- Degree of collaborator number such as 
private research institutes/ universities/ 
national institutes/ Industrial associations/ 
competitors/ non-competitors/ equipment 
suppliers/ demand companies 
4 point 
metric 
 
3.2.4. Analysis 
 
3.2.4.1. Survey and analysis method 
(1) Survey 
A survey in Korean biochip firms was performed. Biochip industry, a high technology 
industry, derives from the fusion of various technologies, including biochip, nanotechnology, 
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biosensor, and bioinformatics. In general, due to secure competition for patent and intellectual 
property, open innovation activity has barely been accomplished in high technological industry. 
However, since life cycle of high technology has recently decreased, the need for open 
innovation activity has increased in the process of rapid development and commercialization 
of new products (Ahn and Lee, 2011). Based on these results, it can be predicted that open 
innovation has occurred in the biochip industry with a highly intensive degree of technology 
and, for that reason, the biochip industry in Korea is selected as the target industry in the present 
study.  
A survey was conducted to target decision makers in 50 firms from October 24, 2011, to 
November 17, 2012 by e-mail and visit. At that time, the total number of firms in the Korean 
Association of Bio-diagnostics was 50. Through the survey, a total of 45 survey results were 
acquired and further analysis was performed based on these results. 
(2) Method for analysis 
Based on the data acquired by survey, statistical analyses were performed using SPSS 18.0 
program. First of all, the analysis of descriptive statistics was accomplished and the results 
were investigated. To verify the reliability of the samples, items measuring each comprising 
concepts were investigated using Cronbach’s alpha value. Also, to verify the validity of 
samples, factor analysis was performed. In the hypothesis testing process, multiple regression 
analysis was used. 
 
3.2.4.2. Descriptive statistics quantity analysis 
(1) Demographic characteristics 
Demographic characteristics of the respondents are shown in Table 3.13. As to age 
distribution, 51.1 % of the respondents were in their forties, 28.9 % of the respondents were in 
their thirties, and 20.0 % of the respondents were in their fifties. As to the distribution by rank, 
47.7 % of the respondents were for directors, 20.0 % of the respondents were executive officers, 
8.9 % of the respondents were section chiefs, 6.7 % of the respondents were managers, 6.7 % 
of the respondents were assistant managers, and 4.4 % of the respondents were deputy heads. 
The rate of missing values was 6.7 %. Concerning the distribution by length of years in the 
position, 33.3 % of the respondents worked in their positions for under 5 years, 31.1 % between 
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6 ~ 10 years, 24.4 % between 11 ~ 15 years, 6.7 % between 16 ~ 20 years, and 4.4 % between 
21 ~ 25 years. 
 
Table 3.13. Characteristics of demography of sample 
Classification Frequency(number) 
Composition ratio 
(%) 
Age 
30s 13 28.9 
40s 23 51.1 
50s 9 20.0 
Total 45 100.0 
Rank 
Missing value 3 6.7 
manager 3 6.7 
section chief 4 8.9 
deputy head 2 4.4 
executive officer 9 20.0 
manager 3 6.7 
director 21 46.7 
Total 45 100.0 
Years of service 
Under 5 years 15 33.3 
6 - 10 years 14 31.1 
11 - 15 years 11 24.4 
16 - 20 years 3 6.7 
21 - 25 years 2 4.4 
Total 45 100.0 
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(2) Statistical analysis of variables 
The variables in this study include actual metrics and nominal metrics. Each descriptive statistic is 
shown in Tables 3.14 and 3.15. 
 Table 3.14. Descriptive statistic of actual metrics  
Classification No. Average 
Standard 
deviation 
Etc. 
Novelty of technique 45 4.67 1.19 
7point 
metric Degree of market 
competition 
45 4.54 1.26 
Degree of government 
support 
43 2.79 1.28 
5point 
metric 
R&D staff (Ph.D.) 42 5.60 15.44 
Metric 
value 
R&D staff 42 23.36 34.19 
R&D staff / overall staff 42 .53 .25 
R&D investment (2010) 38 1,176,946,549 1,753,929,021 
Openness 45 5.04 1.01 
7 point 
metric 
Flexibility 45 4.79 1.27 
Presence of organization 
for open innovation 
45 1.20 .40 
Nominal 
scale 
Presence of institutional 
system 
45 1.42 .50 
Presence of industrial 
cluster 
43 2.16 .81 
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Depth of open 
innovation 
45 1.15 1.90 
8 point 
metric Breadth of open 
innovation 
45 5.47 2.34 
 
Table 3.15. Descriptive statistic of nominal metric 
Presence of 
dedicated 
organization 
 Without dedicated 
organization 
With dedicated 
organization 
Total 
Frequency 36 9 45 
% 80.0 20.0 100.0 
 
Presence of 
institutional system 
 Without institutional 
system 
With institutional 
system 
Total 
Frequency 26 19 45 
% 57.8 42.2 100.0 
 
Presence of 
industrial cluster 
 
Inside 
industrial 
cluster area 
Near 
industrial 
cluster 
Outside 
industrial 
cluster 
Total 
Frequency 11 14 18 43 
% 24.4 31.1 40.0 95.5 
 
 
3.2.4.3. Reliability and validity of variables 
First, exploratory factor analysis was conducted to verify the validity. Principal component 
analysis was used to extract all the measured variables from structured factors, and orthogonal 
rotation was adopted to simplify factor loading. If the coefficient of reliability (Cronbach's 
alpha) was 0.6 or more, the reliability analysis was considered as a reliable measurement tool. 
In validity analysis, if the factor loading value is 0.4 or more, it is adopted as a meaning of a 
significant factor. Variables in this study include the metric measurement factor, nominal scale 
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factor, and multiple response factor. Accordingly, metric and nominal measurement factors do 
not need to take reliability and validity verification, the only multiple response factor needs to 
take the reliability and validity verification. 
The results are based on the validity and reliability verification (see Table 3.16). Total 
variance was found to be 72.91%. As the initial intention, four factors were extracted. The 
extracted factors were named novelty of technique, openness, degree of market competition, 
and the flexibility of the organization. Finally 11 questions were used for the analysis. However, 
flexibility of organization showed a rather low confidence value. 
Table 3.16. Reliability and validity analysis result of impact factor in open innovation 
 
factor analysis reliability 
novelty of 
technique 
openness 
degree of 
market 
competition 
flexibility of 
the 
organization 
Cronbach α 
TN_4 0.931    
0.856 TN_3 0.915    
TN_2 0.777    
CUL_2  0.897   
0.748 CUL_3  0.796   
CUL_1  0.745   
MU_2   0.917  
0.743 MU_5   0.834  
MU_4   0.599  
CUL_4     0.785 
0.481 
CUL_8    0.741 
Eigen- 
value 
2.392 2.050 2.034 1.545  
Variance 
(%) 
21.743 18.632 16.494 14.046  
Factor extracting method: Principal component analysis. 
Rotation method: Kaiser normalized VARIMAX. 
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3.2.4.4. Hypothesis Verification 
For hypotheses verification, multiple regression analysis method was used regarding ‘depth 
of open innovation' and 'breadth of open innovation' as dependent variables. Regression 
analysis and hypothesis verification were performed after separating the included variables 
from independent variables, such as environmental characteristics, firm characteristics, and 
institutional characteristics. 
(1) Environmental characteristic factors and open innovation activity 
For the analysis of the relationship between environmental characteristic factors and open 
innovation activity, multiple regression analysis was performed for 'depth and breadth of open 
innovation activity’ related to the technology novelty due to environmental characteristics, 
degree of market competition, and degree of government support. The independent variable 
measured as a parameter was introduced to the mean of the values as valid items. 
Table 3.17. Regression analysis result for environmental characteristic and depth of open 
innovation 
model 
unstandardized 
coefficient 
standardized 
coefficient 
t 
significance 
probability 
collinearity statistic 
B 
standard 
error 
β tolerance VIF 
(constant) -3.519 1.609  -2.188 .035   
novelty of 
technology 
.328 .234 .198 1.403 .169 .976 1.025 
degree of 
market 
competition 
.482 .213 .318 2.264 .029** .989 1.011 
degree of 
government 
support 
.475 .211 .317 2.254 .030** .986 1.014 
R2=0.239, Adjusted R2=0.198, F=4.084**, p=0.013 
**p<0.05 
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First, the results of a regression analysis on the depth of open innovation and environmental 
characteristic variables, the statistical significance was confirmed (R2 = 0.239, F = 4.084 **, p 
<0.05; see Table 3.17). In multicollinearity diagnostics, values of the tolerance limit are higher 
than 0.1 and, thus, there was no problem in our results. In the relationship between 
environmental characteristic variable and depth of open innovation, the degree of market 
competition and degree of government support showed a positive (+) significant relationship 
with a significance level of 0.05. The degree of effect of market competition was nearly the 
same as that of government support, since β value of market competition (0.318) and 
government support (0.317) are nearly identical.  
Table 3.18. Regression analysis result for environmental characteristic and breadth of open 
innovation 
model 
unstandardized 
coefficient 
standardized 
coefficient 
T 
significance 
probability 
collinearity statistic 
B 
standard 
error 
Β tolerance VIF 
(constant) 3.386 2.017  1.679 .101   
novelty of 
technology 
-.195 .293 -.101 -.665 .510 .976 1.025 
degree of 
market 
competition 
.466 .267 .264 1.746 .089 .989 1.011 
degree of 
government 
support 
.354 .264 .203 1.343 .187 .986 1.014 
R2=0.120, Adjusted R2=0.052, F=1.768, p=0.169 
Second, in the regression analysis on the breadth of open innovation and environmental 
characteristic variables, the statistical significance was not confirmed (R2 = 0.120, F = 1.768, 
p =0.169 (p >0.05); see Table 3.18). According to the above regression analysis results, the 
verification of hypothesis is evaluated for the relation of three influencing factors of 
environmental characteristic to the depth and breadth of open innovation activity. The degree 
of market competition and the degree of government support have a positive (+) significant 
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relationship with the depth of open innovation activity. Therefore, both hypotheses H1-1 and 
H1-2are confirmed are supported by our data analysis. 
On the other hand, the novelty of technology has shown that there is no statistical significance 
in relation to the breadth of open innovation. Therefore, hypothesis H1-3has to be rejected. 
This result indicates that the breadth of open innovation activity is not directly related to the 
introduction of new technologies in the Korean biochip industry. 
(2) Firm characteristic factors and open innovation activity 
To analyze the relationship between firm characteristic factor and open innovation activity, 
the multiple regression analysis was run separately for the organizational culture factor and the 
research capability factor. In the case of R&D investment, the analysis was done by taking the 
logarithm on R&D investment in 2010, because the collinearity statistics has the problem due 
to the big deviation and then the multiple regression analysis could not be done if the measured 
value is inserted without computation. For number of Ph.D. staff in R&D and the total number 
of R&D staff, the measured values without computation were used; however, for the ratio of 
number of R&D staff to the total number of staff in firm, measured values with computation 
were used. 
Table 3.19. Regression analysis result for research capacity and depth of open innovation  
model 
unstandardized 
coefficient 
standardized 
coefficient 
t 
significance 
probability 
collinearity statistic 
B 
standard 
error 
β tolerance VIF 
(constant) -6.731 5.365  -1.255 .219   
logarithm on 
R&D investment 
.896 .627 .290 1.428 .163 .489 2.044 
R&D staff 
(Ph.D.) 
.214 .082 .531 2.614 .014** .488 2.047 
total R&D staff -.011 .013 -.197 -.833 .411 .360 2.775 
total R&D staff / 
total staff in firm 
-.412 .953 -.062 -.433 .668 .988 1.013 
R2=0.354, Adjusted R2=0.273, F=4.383*** p=0.006 
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First, in the regression analysis of research capabilities and the depth of open innovation, 
the statistical significance was confirmed (R2= 0.354, F= 4.383 ***, p<0.01; see Table 3.19). 
In multicollinearity diagnostic, values of the tolerance limit are higher than 0.1, and thus there 
is no problem. In the relationship between 'research capabilities' and ‘depth of open innovation', 
the number of Ph.D. staff in R&D affects positive (+) at the significance level of 0.05. Degree 
of affecting is appeared as β = 0.531. Thus hypothesis H2-1, ‘As the research capability based 
on the number of Ph.D. staff in R&D increases, depth of open innovation activity increases', is 
confirmed. 
Second, in regression analysis on the breadth of open innovation and research capacity, the 
statistical significant was confirmed (R2= 0.282, F= 3.135 **, p<.05; see in Table 3.20). At 
multicollinearity diagnosis, the values of tolerance are larger than 0.1 and thus there is no 
problem. In the relationship between research capacity and the breadth of open innovation, the 
number of Ph.D. staff in R&D shows a significantly positive(+) effect and total number of R&D 
staff a shows negative(-) effect (p=0.05). In addition, it is confirmed that the logarithm value 
of R&D investment shows a significant positive (+) effect with the significance level of 0.1. 
Thus, Hypothesis H2-2 is confirmed. The level of degree to affect the breadth of open 
innovation is the number of Ph.D. staff in R&D (β = .552), investment in R&D (β = .432), and 
the total number of R&D staff (β = -. 731). 
 
Table 3.20. Regression analysis result for research capacity and breadth of open innovation  
Model 
unstandardized 
coefficient 
standardized 
coefficient 
t 
significance 
probability 
collinearity statistic 
B 
standard 
error 
β tolerance VIF 
(constant) -9.875 7.671  -1.287 .207   
logarithm on 
R&D investment 
(2010) 
1.809 .897 .432 2.017 .052* .489 2.044 
R&D staff (Ph.D.) .302 .117 .552 2.577 .015** .488 2.047 
total R&D staff -.053 .018 -.731 -2.928 .006** .360 2.775 
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total R&D staff / 
total staff in firm 
-.725 1.362 -.080 -.532 .598 .988 1.013 
R2=0.282, Adjusted R2=0.192, F=3.135**, p=0.028 
 
Third, in a regression analysis on the depth of organizational culture and open innovation, 
the statistical significance was confirmed (R2= 0.166, F= 4.177 **, p <0.05; see Table 3.21). In 
multicollinearity diagnostic, the values of tolerance are larger than 0.1, and then there is no 
problem. Therefore, Hypothesis H2-3 is confirmed. Flexibility in organization culture affects 
the depth of open innovation activity with β = 0.364 at p<0.05. 
 
Table 3.21. Regression analysis result in organizational culture and depth of open 
innovation 
model 
unstandardized 
coefficient 
standardized 
coefficient 
t 
significance 
probability 
collinearity statistic 
B 
standard 
error 
β tolerance VIF 
(constant) -2.257 1.555  -1.452 .154   
openness .229 .272 .122 .843 .404 .954 1.048 
flexibility .546 .216 .364 2.521 .016** .954 1.048 
R2=0.166, Adjusted R2=0.126, F=4.177** p=0.022 
 
Fourth, in regression analysis on the depth of organizational culture and open innovation, the 
statistical significance was confirmed (R2= 0.149, F= 3.672 **, p<0.05, see Table 3.22). In 
multicollinearity diagnostic, the values of tolerance are larger than 0.1 and, thus, there is no 
problem. The openness affects the breadth of open innovation activity with β = 0.299 at p <0.05. 
Thus, Hypothesis H2-4 is confirmed. 
 
 
 
108 
Table 3.22. Regression analysis result in organizational culture and breadth of open 
innovation 
model 
unstandardized 
coefficient 
standardized 
coefficient 
t 
significance 
probability 
collinearity statistic 
B 
standard 
error 
β tolerance VIF 
(constant) .305 1.933  .158 .875   
openness .694 .338 .299 2.051 .047** .954 1.048 
flexibility .348 .269 .188 1.292 .204 .954 1.048 
R2=0.149, Adjusted R2=0.108, F=3.672**, p=0.034 
 
(3) Institutional characteristic factors and open innovation activity 
In order to investigate the relationship between institutional characteristics and open 
innovation activity, multiple regression analysis was performed with relation to institutional 
characteristics factors, such as the existence of organization for open innovation, the presence 
of institutional system for open innovation, firm’s location in industrial cluster to depth and 
breadth of open innovation activity. Regression analysis was run for the three influential 
characteristics factors. 
First, in regression analysis of institutional characteristic factors and depth of open 
innovation activity, the statistical significant was confirmed (R2= 0.286, F= 5.216, p <0.01; see 
Table 3.23). In multicollinearity diagnostic, all VIF values are below 2.0 and thus it was 
confirmed that there is no problem. In the relationship between institutional characteristic 
factors and depth of open innovation activity, we found that the existence of a dedicated group 
to drive open innovation shows a significant positive (+) effect (p <.001).. However, the effects 
of the presence of an institutional system and firm’s location in industrial cluster were not 
significant. The existence of a dedicated group for open innovation affects the depth of open 
innovation activity with β= .471. Therefore, Hypothesis H3-1, ‘is confirmed. 
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Table 3.23. Regression analysis result in institutional characteristics and depth of open 
innovation 
model 
unstandardized 
coefficient 
standardized 
coefficient 
t 
significance 
probability 
collinearity 
statistic 
B 
standard 
error 
β tolerance VIF 
(constant) 
-
1.965 
1.296  -1.517 .137   
existence of 
dedicated group 
2.310 .744 .471 3.104 .004*** .795 1.258 
presence of 
institutional 
system 
.482 .587 .124 .820 .417 .795 1.258 
firm location in 
industrial cluster 
.035 .328 .015 .108 .914 .959 1.042 
R2=0.149, Adjusted R2=0.108, F=3.672**, p=0.034 
 
Second, in regression analysis of institutional characteristic and breadth of open innovation 
activities, with the coefficient of determination R2 = 0.066, F = 0.921, the statistical significance 
was not confirmed (R2 = 0.066, F = 0.921, p = 0.44 (p>0.05; see Table 3.24). Thus, Hypothesis 
H3-2 has to be rejected. This result might be due to the fact that there are very few biochip 
firms in an industrial cluster, like Osong Bioindustry cluster in Korea and, thus, the chances to 
do information sharing and collaboration might not dramatically increase, though the firm is in 
industrial cluster. 
Table 3.24. Regression analysis result in institutional characteristics and breadth of open 
innovation 
model 
unstandardized 
coefficient 
standardized 
coefficient 
t 
significance 
probability 
collinearity 
statistic 
B 
standard 
error 
β tolerance VIF 
(constant) 2.927 1.690  1.732 .091   
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existence of 
dedicated group 
.917 .971 .164 .945 .351 .795 1.258 
presence of 
institutional 
system 
.496 .766 .112 .648 .521 .795 1.258 
presence of 
industrial cluster 
.431 .427 .159 1.009 .319 .959 1.042 
R2=0.066, Adjusted R2=-0.006, F=0.921, p=0.440 
 
3.2.5. Conclusions and Discussion 
The summary of the research results is shown in Table 3.25 and Figure 3.5. 
 
Table 3.25. Relation with influential factors and open innovation activity 
Variable scope Contents of hypothesis 
Confirmed or 
Rejected 
Environmental characteristic 
H1-1: As the intensity of market 
competition increases, the depth of 
open innovation activity increases. 
Confirmed 
H1-2: As the degree of government 
support increases, the depth of open 
innovation activity increases. 
Confirmed 
H1-3: As the novelty of technology 
increases, the breadth of open 
innovation activity increases. 
Rejected 
Company 
characteristic 
Research 
capability 
H2-1: As the research capability based 
on the number of Ph.D. staff in R&D 
increases, depth of open innovation 
activity increases. 
Confirmed 
H2-2: As the investment for R&D 
increases, breadth of open innovation 
Confirmed 
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activity increases. 
Organizational 
culture 
H2-3: As the flexibility in organization 
culture increases, depth of open 
innovation activity increases. 
Confirmed 
H2-4: As the openness in organization 
culture increases, breadth of open 
innovation activity increases. 
Confirmed 
Institutional characteristic 
H3-1: If dedicated group for open 
innovation exists, depth of open 
innovation activity increases. 
Confirmed 
H3-2: If firm is located in industrial 
cluster, breadth of open innovation 
activity increases', is not adopted. 
Rejected 
 
 
 
Figure 3.5. Results of model for effect of influential factors on open innovation activity 
 
In this chapter, the factors affecting open innovation activity in the Korean biochip 
companies are investigated. The results of our analyses are as follows. First, the market 
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competition and governmental support show a statistically significant positive relationship with 
the depth of open innovation activity. This result suggests that the firm enhances the 
collaboration with external partner due to the reinforcement of competition, in the case of the 
necessity of strengthening competency. Therefore, a firm in high intensity of market 
competition should focus on the collaboration with the current external partner firm when the 
firm takes the open innovation. In addition, the firm focuses on collaboration with current 
collaborators if governmental support the firm is stronger, which leads the firm to enhance 
open innovation. 
Second, the higher number of doctoral researchers in R&D staff in firm, the higher depth of 
open innovation is achieved. This result is consistent with the results previously reported by 
Link and Bauer (1987) who suggested that the growth of the capacity of internal research 
promotes the cooperation while maintaining core technologies. Therefore, it is necessary to 
increase the number of doctoral researchers in order to enhance the depth of open innovation 
activity while pursuing core competencies. In this respect, the quality of the researchers is more 
important than their number. In addition, there is a statistically significant (+) positive 
relationship between the amount of R&D investment and the breadth of open innovation. Based 
on the cash flow in firm, our results show that more investment partners are sought as the 
research and development expenses are invested. In the biochip industry where human 
resources in R&D are essential, it is necessary to continuously invest and expand human 
resources to increase the breadth of open innovation activity. Of note, in the case of government 
investment as one of environmental characteristic variables, it increases the depth of open 
innovation, while the R&D investment is more related to the breadth of open innovation. 
 Third, the flexibility of organizational culture is positively related to the depth of open 
innovation activity, and the openness of organizational culture is positively related to the 
breadth of open innovation. Therefore, it is needed that the firm tries to make the flexible 
organizational culture, and how to act to other external collaborators should be considered 
based on organizational culture flexibility. In addition, open organizational culture makes the 
firm more open in open innovation activity. Therefore, in order to make a relationship with 
various external entities, at first, it will be necessary to make efforts to have openness in the 
organizational culture. 
 Fourth, our results confirm that the presence of the dedicated group for open innovation has 
a statistically significant (+) relation with the depth of open innovation activity. In order to 
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achieve open innovation, the presence of a dedicated group in firm is an important factor. If 
the research capacity of firm is higher than a level at which the firm can make commercial 
product by itself, it is strongly recommended to establish a dedicated group for open innovation 
to enhance open innovation activity.  
The significance of our results and the insights they provide for further research are as 
follows. First, in this chapter, a survey for open innovation is conducted for a single industry 
group, the biochip industry. Only few previous studies on open innovation have been conducted 
within a single industry group. Therefore, we assume that more detailed and accurate analyses 
have been done through the research on open innovation activity in just one (relatively small 
but innovation-intensive) industry. In particular, the analysis from the research plan to the 
research target to focus consistently on open innovation is very meaningful for practical 
application of open innovation. From the academic point of view, our results are meaningful in 
that the influential factors are depicted and the investigation for breadth and depth for open 
innovation activity related to these factors is undertaken.  
 Second, our results provide implications for the strategies that should be adopted to 
promote open innovation activity based on the analysis of the influential factors. From a 
practical point of view, where and how to get external knowledge from a new external 
collaborator through open innovation activity in real industrial field are shown to be 
strategically important questions that can be addressed by using the model proposed here. Our 
results are also meaningful for practitioners in firm, as this study suggests the strategic choice 
for open innovation through the analysis of the effects of the influential factors on the breadth 
and depth of open innovation activity. 
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Chapter 4. Management Strategy for Transition Phase of Open Innovation in New 
Product Development of Biochip 
 
Since open innovation is considered to be an effective innovation method for new product 
development (NPD) of biochip, it has been discussed in Chapter 2. At the final stage of new 
product development, the application of open innovation raises a number of questions, namely: 
(1) Do we still need open innovation, now that we have sufficient knowledge for new product 
development? (2) How can we decide if and when the transition to close innovation should be 
done? (3) If the transition to close innovation happens, which level of closeness is needed for 
the final stage of new product development? To answer the above questions, this chapter 
investigates the following aspects based on the technology point of view.  
At first, the firm should decide whether open innovation is still needed at the final stage of 
product development. Although the firm understands the advantages of close innovation, 
closeness and relations to enhance firm performance are not clearly understood, making it 
difficult to make the decision regarding the degree of closeness. Thus, in this chapter, the 
factors affecting the transition toward close innovation are investigated based on, first, the 
technology point of view, such as knowledge related to the product development stage and the 
product innovation stage, and second, to the non-technology point of view, such as the 
government approval stage. Furthermore, we investigate whether the transition to close 
innovation in the final stage of NPD causes an advantage, such as a decrease of cost for 
management process and prevention of leakage of technology to the outside. Structured 
interviews with three large firms and three small firms in the Korean biochip industry were 
conducted in order to analyze the factors related to the transition from open to close innovation. 
A model based on interview results is proposed.  
As a next step, the application of the proposed model is extended to the Korean bio-
pharmaceutical industry. The model is evaluated with the data from Korean bio-pharmaceutical 
firms and a strategy concerning the decision about close innovation transition with the aim of 
enhancing firm performance is investigated from the technology point of view. While the firm 
should decide about the time to start close innovation and the degree of close innovation activity, 
there is no guide for transition to close innovation. If a firm wants to implement a close 
innovation strategy, relations to enhance the close innovation activity should he understood, 
and then the decision to start close innovation can be made. Thus, in this study, factors affecting 
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the open-close innovation transition (based on the factors by technological point of view, such 
as the knowledge related to the product development and product innovation stages) are 
investigated. Hypotheses regarding factors affecting the open-close innovation transition are 
formulated and, based on the results of hypotheses evaluation with the data from bio-
pharmaceutical firms, a strategy concerning the decision about open-close innovation transition 
is proposed from the technology point of view.  
This study is the first to evaluate the effect of factors such as knowledge, product 
development stage, product innovation stage, and government approval stage on the open-close 
innovation transition. A model of the relationship between the open-close transition and 
perception of advantage of close innovation is proposed and then evaluated based on the survey 
results. 
 
4.1. Introduction 
Open innovation has been applied to the biochip industry due to the need for external 
knowledge for radical new product development. This is because of the characteristics, such as 
the need to combine various techniques and the limitation of existing resources in mastering 
the required techniques necessary for new product development (Fuji-Keizai 2008; Kim 2008; 
Impact Co 2013; Kim 2013; Hyun 2013; Kwon 2015). Since the biochip field results from a 
fusion of technologies developed in biotechnology, nanotechnology, and information  
technology, knowledge distribution should be recognized and the importance of knowledge 
integration should be considered, probably more than in any other areas in biotechnology. 
To achieve open innovation for products in the bio-pharmaceutical industry, it is necessary 
to develop a management strategy that takes into account their novel and complex 
technological characteristics (Fetterhoff and Voelkel 2006; Igartua et al. 2010; Pisano 2015; 
Slowinski and Sagal, 2010; Tidd and Bessant 2015; Vanhaverbeke et al. 2008). Since bio-
pharmaceutical industry includes the pharmaceutical industry and the biotechnology industry 
(with the latter including the biochip industry based on the industry sector classification), the 
management strategy for open innovation in the biochip industry can relate to that of the bio-
pharmaceutical industry. 
Fetterhoff and Voelkel (2006) suggest five key stage for open innovation: 1) seeking 
opportunities; 2) evaluating the market potential and inventiveness of a given opportunity; 3) 
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recruitment potential partners by building a convicting argument; 4) capturing value through 
commercialization; and finally 5) extending the innovation offering. Furthermore, Slowinski 
and Sagal (2010) suggest the following four stage stages in open innovation: (1) want phase; 
(2) find phase; (3) get phase; and (4) manage phase to success. In the present study, we propose 
the transition of innovation type in final stage of NPD as a part of the manage phase. Until now, 
an analysis of open innovation for the final stage of NPD has not been done and management 
strategy at that stage has not been suggested. In this study, the model for transition of innovation 
type in the final stage of NPD is proposed and then evaluated for validation.   
The transition stage is the stage when a firm may want to change from open innovation to 
close innovation. The transition stage occurs towards the new product development. Since the 
firm has acquired sufficient technology for commercial product at the final stage of new 
product development, the firm may want to reduce the inflow of technology from external 
partner by reducing the degree of open innovation. Thus, from the technology point of view, 
the change from open innovation to close innovation is motivated. However, collaboration with 
external partners for marketing and government approval process is still needed, although the 
reasons are non-technological. Thus, in the transition stage, a close innovation approach is 
implemented with regard to technology inflow, whereas open innovation is done in marketing 
and other legal aspects, which means that partial (mix of open and close) innovation is done 
overall. 
In view if the above, in order to develop a management strategy for the final stage of new 
product development, it is necessary as a first step to decide whether to close open innovation 
so that to control the technology inflow for value capture and success. In this study, the relation 
with knowledge, product development stage, product innovation stage technology 
characteristics, and government approval stage with the transition tendency to close innovation 
is investigated to provide the evidence for the decision to close. The transition tendency is the 
degree of move to close innovation by firm. The transition tendency relates to the perception 
of advantage of close innovation, including an increase of firm performance, which is 
investigated to see how close innovation affects firm performance. Structured interviews with 
experts in the Korean biochip firms are performed and a management strategy is suggested. 
Based on the interview results, a model for relations affecting transition tendency is proposed 
for the Korean biochip industry. As a second step, the proposed model is applied to the bio-
pharmaceutical industry. Hypotheses concerning the factors that relate to the open-close 
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transition are proposed and a survey is done in the Korean bio-pharmaceutical firms to evaluate 
the model. Finally, a strategy concerning the decision to close innovation in the transition stage 
is suggested with the aim of increasing firm performance based on the results of model 
evaluation.  
 
4. 2. Theoretical Considerations 
 
4.2.1. Open innovation in nanobiotechnology 
Biochip is an intrinsically an interdisciplinary technology that integrates various 
technologies such as electronics, material engineering, biotechnology, and nanotechnology. 
One of the key technologies for biochip is nanobiotechnology, which is an integration of 
nanotechnology and biotechnology (Thaxton and Mirkin 2004; Vega et al. 2007). Also, 
products in bio-pharmaceutical industry can be made by the integration of various technologies, 
such as chemistry, biology, biotechnology, and nanotechnology. Specifically, 
nanobiopharmaceutical technology has emerged for applications of biotechnology, while 
nanotechnology has emerged for drug discovery (Thaxton and Mirkin 2004; Vega et al. 2007). 
To evaluate the innovation process for biochip and biopharmaceutical products, the innovation 
in the nanobiotechnology and bio-pharmaceutical industries should be considered. This 
sections focuses on open innovation in nanobiotechnology (see Section 3.1.3 for a count of 
open innovation in the biotechnology industry). 
 At first, based on previous reports, the relation between open innovation and product 
development in nanotechnology area is reviewed to understand the managing methods in the 
nanotechnology industry. Social networks are pivot to understand the explosion of nanoscience 
knowledge and, therefore, management is needed to control the information flow among social 
networks (Aiman-Smith et al. 2006). Aiman-Smith et al. (2006) suggest that open innovation 
based on networks efficiently facilitates the emergence of fundamental nanotechnology to 
manufacture commercializable products. Also, open innovation is necessary to improve 
communication strategies, increase the impact of new knowledge, and accelerate innovation. 
In his study on open innovation applied to develop new products based on nanotechnology in 
Buckman, Anstey (2005) notes that partnerships help to turn the science of nanotechnology 
into a practicable technology and that management of open innovation in nanotechnology can 
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help nanotechnology to become a viable technology in order to make commercial product. 
Furthermore, in their investigation of the diversity of collaborative network in 
nanotechnology system, Pandza et al. (2011) report that the participating members need to 
manage research within diverse networks. Likewise, Miyazaki and Islam (2010) analyze the 
nanotechnology system in different countries based on industry and academic research 
activities and their findings are useful to inform the strategies for nanotechnology. Islam and 
Miyazaki (2010) also note regional strengths and weaknesses in nanotechnology domains for 
various countries. For example, the U.S. has notable strengths in the nanobiotechnology area, 
whereas other regions are stronger in nanomaterials. Thus, collaboration contributes to 
nanotechnology management across different regions. Furthermore, Rampersad et al. (2010) 
underscore the importance of managing innovation networks and the need of strategies for 
managing inter-organizational innovation incentives. Next, Shea (2005) reports the future 
management research directions in nanotechnology based on a case study approach (Shea 
2005). Taken together, these research results suggest that management strategy in 
nanotechnology is crucial for managing innovation networks related to open innovation activity.  
As a second step, the innovation management in the nanobiotechnology industry is 
investigated to understand the management strategies based on previous reports. In an analysis 
of two nanobiotechnology drugs, Maine et al. (2014) propose three kinds of innovation 
management strategies: importing ideas, creating environment, and technology-marketing 
match. Furthermore, in a study of how the university-industry collaboration network affects 
innovation in the nanobiopharmaceutical field based on the weighted patent-value as an index 
of innovation performance, Guan and Zhao (2013) find that the formation of stable platforms 
for collaboration and effective institutional arrangements should be done as a strategy for 
university-industry collaboration network. These research results suggest that management 
strategy in nanobiotechnology is related to managing importing ideas, creating environment, 
technology-marketing, and collaboration networks.   
Evolutionary path of technology fusion is investigated for nanobiotechnology case and the 
development trajectories of technology fusion is analyzed (No and Park 2010). By observing 
changes in the trajectory patterns of fusion through time, fusion pattern is evolved based on the 
following rules: (1) Technology development focuses more on niche technologies in fusion and 
(2) the technologies that do not join in fusion are eliminated during development process. 
Furthermore, in the analysis of the innovation trajectories of technology based on analysis for 
119 
patents and publications in nanobiopharmaceutical technology such as nano-enabled drug 
discovery, Kwon et al. (2016) report that analyzing research publications and patents 
simultaneously constitutes a good approach to understand the innovation trajectories. This 
contributes to the development of a strategy for innovation management. These research results 
suggest that management strategy in nanotechnology is related to technology characteristics 
such as evolution trajectories and innovation trajectories.  
Taken together, the results by previous studies overviewed above show that a management 
strategy for nanobiotechnology industry is needed to make nanobiotechnology more viable to 
manufacture commercial products. Such strategy should be based on the need to manage 
collaboration networks and technology characteristics, such as evolution trajectories and 
innovation trajectories. In this study, the management strategy for the biochip industry related 
to nanobiotechnology is investigated by considering the above suggestions. 
 
4.2.2. Open innovation and product development stage 
Since biochip products are usually made by combining technologies from different fields, 
in each step of product development, the kind and amount of knowledge vary for different 
product development stages. Thus, during new product development in biochip, the integration 
of various technologies is needed from the start to the end of the production process. In this 
section, by reviewing previous reports, the relation between open innovation to inflow of 
external technology and the product development stage are examined. 
First, Gronlund and et al. (2010) propose a new and revised model for new product 
development to help the application of open innovation to the stage-gate process and then 
related to the product development stage. The proposed model gives the strategy in 
transformation process towards a more open and systematic approach in new product 
development. Furthermore, Cooper (2016) suggests how a firm can do open innovation within 
the stage-gate model and shows the customized stage-gate to incorporated open innovation. In 
Cooper’s (2016) research, the process for stage-gate is divided into the ideation or discovery 
stage, building the business case, development stage, and launch or commercialization stage. 
The open innovation helps firms to redesign the idea-to-launch process and new product 
development process becomes more agile. In addition, Stosic and Milutinovic (2014) propose 
the ‘open stage-gate model’ by connection of basic elements of open innovation and stage-gate 
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model. The capability for applying open innovation to stage-gate model is investigated to make 
more flexible phase and gates in the new product development stage. These results suggest that 
the strategy of open innovation varies depending on the stage of new product development, 
which will be applied to construct a model for innovation in the present study.  
In a similar fashion, Caetento et al. (2011) investigate the relation of open innovation and 
the technology development process based on partnership establishment and note that a firm 
changes the technology development process based on the firm’s level of adequacy to open 
innovation. Dassault Systemes India (2016) shows that an open innovation strategy can be 
effectively used to accelerate product development and to make it smarter. In this research, the 
adoption of open innovation, together with product life cycle management, are reported to 
enable a higher profitability and a faster product delivery. These results suggest that the 
integration of open innovation with product management strategy for the technology 
development process and product life cycle makes the product production faster and more 
profitable. 
In addition, in their investigation of the application of open innovation to biopharmaceutical 
companies, Marcello et al. (2015) open innovation is shown to have high success in later-phase 
clinical trials, which is the last stage of the product development process. Likewise, with the 
focus on the action of open innovation practice according to the stage of new product 
development, Rubera et al. (2016) propose that open innovation activity can be classified into 
two types related to the product development stage (development-centric open innovation for 
development stage, and commercialization-centric open innovation for commercialization 
stage). Taken together, these results suggest that the open innovation is related to the stage of 
new product development and a different open innovation strategy is needed for each stage of 
new product development, which will be applied to construct a model for innovation in the 
present study. 
 
4.2.3. Open versus close innovation 
As discussed in the previous section, open innovation strategy should be different for each 
stage of new product development. Change between open and close innovation occurs based 
on the stage of new product development. In this section, we overview previous research on 
the advantages of open and close innovation so that to facilitate decision on the innovation type 
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needed for each stage of new product development.  
In this respect, in a study on the advantages afforded by open innovation as compared to 
close innovation, Almirall and Rammon (2010) demonstrate that open innovation is helpful for 
discovery in product development; however, if an external partner has divergent goals, open 
innovation makes it difficult for the focal firm to establish an effective technological trajectory 
for new product development. Since open innovation may cause problems in new product 
development, the focal firm should consider the advantages and disadvantages of open 
innovation when deciding on the innovation type. Cassiman and Valentini (2015) report that 
the inflow and outflow of knowledge in open innovation should be counted to understand the 
drivers of actual cost of open innovation.  Furthermore, Lowman and et al. (2012) suggest 
that open innovation faces risks in pharmaceutical new product development due to the 
emergence and rapid growth of Clinical Research Organization (CRO). With an increase of the 
role of CRO in clinical trials and clinical development process, firms increasingly depend on 
CRO in the drug development process. Thus, as the firm loses knowledge and a lack of ability 
occurs in drug development, the firm faces the risk of innovation management for integration 
of the new product development activity and basic technologies for future research. These 
results suggest that there are disadvantages of open innovation in new product development in 
the bio-pharmaceutical industry.  
Other studies suggest that the choice of open or close innovation depends on culture of units 
and governance forms. For instance, in their study of the differences between open innovation 
and close innovation based on the specificity of the problem to solve and governance forms, 
which are characterized by different benefits and costs, Felin and Zenger (2014) suggest four 
governance forms for open innovation (markets, partnerships, contests, and user or community) 
and two governance forms for close innovation (authority and hierarchy), providing thus the 
comparative framework for managing innovation. Herzog and Leker (2010) suggest that open 
and close innovation have different cultures for different strategies. In this research, the culture 
difference that exists between open and close innovation units and thus the management 
strategy and choice of innovation type are considered and linked to the culture of business units.  
Another group of previous studies shows that the choice of innovation type depends on 
science and non-technological factors, such as marketing and organization. For instance, in 
their investigation of the relation between open innovation and organizational boundaries based 
on task decomposition and knowledge distribution, Lakhani et al. (2012) find that task 
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decomposition and problem-solving knowledge distribution constitute strategic choice that 
influences the choice of innovation type, open or close. If modularity increases and 
communication cost decreases, open innovation is preferred; however, if modularity decreases 
and communication cost increases, close innovation becomes the preferred innovation choice. 
Likewise, Caraca et al. (2009) suggest that role of science has changed in the innovation 
process from a linear to a chain-linked model. In their research, though the key element to make 
high value product is scientific knowledge, the science is just one type of knowledge to create 
high value product. Understanding market and organization are also important factors to 
increase value of products; therefore, science and other factors are intrinsically related.  
When a new product is produced and comes to the commercial stage with open innovation 
activity in a biochip firm, the firm should decide on a continuation of current innovation type 
(open innovation) or a change of innovation type to close innovation. Since the choice about 
the innovation type depends on science and non-technological factors (Caraca et al. 2009), 
there are many factors affecting the decision at this stage. To clarify these factors, the opinions 
of experts, such as directors of research teams, CTOs and CEOs in biochip firms, are needed. 
In the present study, to obtain the opinions of experts in biochip firms, the structured interview 
is conducted. Furthermore, since the opinion of big and small firm like start-up companies may 
vary, we select as the interviewees the three largest firms in Korea (Samsung Electronics, LG 
Biotechnology, and SK Telecom) and three representative small firms in Korea (two start-up 
companies, BioDiatech and NSB Postech, and one mid-size company, NanoEnTeck). 
 
4.3. Research Method  
 
4.3.1. Structured interviews  
The structured interviews were conducted with the experts in the biochip industry from May 
6tto July 20, of 2013. The experts in three big firms including Samsung Electronics, LG 
Biotechnology, and SK Telecom and three small firms including BioDiatech, NSB Postech and 
NanoEnTeck were interviewed. Interview time was generally three hours for each firm.  
The interview questions were designed as follows. The discussion to construct interview 
questions were held with I (biochip major), a professor in Business School at Sogang University, 
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Korea (technology management major), and a former head of Bioanalysis Division in Samsung 
Advanced Institute of Technology (bioanalytical chemistry major). The discussion results for 
innovation type change in final stage of new product development in biochip were then 
analyzed and the main factors were classified as nine factors (see Table 4.1).  
Table 4.1. Interview questions for transition of innovation in biochip industry. 
(1) Does intellectual property (IP) for new product development (NPD) affect innovation 
type change? 
1.1. Does the firm have many patents needed for NPD? 
1.2. Does the firm have qualified patents needed for NPD? 
1.3. Does the firm have enough patents needed for NPD? 
(2) Does knowledge in firm for NPD affect innovation type change? 
2.1. Does the firm have enough research ability (mastering the technology) needed for 
NPD? 
2.2. Does the firm have the accumulated relevant technology needed for NPD? 
2.3. Does the firm have research competency needed for NPD? 
(3) Does product development stage affect innovation type change? 
3.1. Is New Product (NP) in commercial stage? 
3.2. Is NP in suboptimal stage? 
3.3. Is NP made for improvement after commercial stage? 
3.4. Is NP made for little modification for application after commercial stage? 
(4) Does government approval stage affect innovation type change? 
4.1. Is NP in clinical trial stage? 
4.2. Is NP in stage of approval process management? 
4.3. Is NP in post approval stage? 
(5) Does product innovation stage affect innovation type change? 
5.1. Is NPD done for emergence of total new product application? 
5.2. Is NPD done for expansion of current application? 
5.3. Is NPD done for new successive product? 
(6) How to measure transition tendency to close innovation? 
6.1. Does cost happen to change from open innovation to close innovation? 
6.2. Is it easy to change from open innovation to close innovation? 
6.3. Is system change needed to change from open innovation to close innovation? 
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(7) What is the process to quit collaboration? 
7.1. Is cost to quit collaboration high after producing NP? 
7.2. Is it easy to quit collaboration after producing NP? 
7.3. Is system change needed to quit collaboration after producing NP? 
(8) How to act for close innovation? 
8.1. Does technical knowhow of NP to outside close? 
8.2. Does information for marketing of NP to outside close? 
8.3. Does willingness to close increase? 
(9) What is the advantage of close innovation? 
9.1. Is technology leakage decreased due to close? 
9.2. Is cost for NP decreased due to close? 
9.3. Is management process decreased due to close? 
 
The main interview questions concerned the transition point between open and close 
innovation in new product development of biochip. The questions addressed the following four 
aspects: (1) Does innovation type change as product development stage changes? (2) Does a 
transition point exist between open and close innovation in new product development? (3) Is 
there a difference between big and small firm in the change of innovation type? (4) Does the 
repetition of innovation type change depending on the emergence of new innovative product 
based on the extension of previous technology? For example, the emergence of protein chip, a 
new innovative product based on the extension of previous DNA chip technology, causes open 
innovation and then closes innovation, as done in the DNA chip case. The answers and other 
opinions obtained in the interviews are described in Section 4.3.2.  
The interview questions were coded (see Table 4.2) as suggested elsewhere (Saunders et al. 
2003; Plowman et al. 2007). The coding scheme based on major factors was devised and then 
the interviews were conducted. Codes were allocated to subsequent factors to group them as 
nine major factors. The notification codes of each factor to be mentioned by each interviewee 
were listed for each interviewed firm. Based on the listed codes for the interviewee’s answers, 
the findings for innovation type change in final stage of new product development in biochip 
were extracted.  
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Table. 4.2. Coding scheme to classify interview questions 
Code Subsequent factors Grouping of factors 
1. Firm size 
General information 2. New product development 
3. Open innovation 
4. Total patent number 
Patent for new product 5. Qualified patent number 
6. Required number of patent 
7. Research ability 
Knowledge for new product 8. Accumulated relevant technology 
9. Research competency 
10. Commercial stage 
Stage of new product 
11. Suboptimal stage 
12. Improvement after commercial stage 
13. Modification for application 
14. Clinical trial stage 
Government approval 15. Approval process management 
16. Post approval stage 
17. Emergence of new application 
Product innovation stage 18. Expansion of current application 
19. New successive product 
20. Start of close innovation 
Transition tendency to close 21. Easy to change to close innovation 
22. System change for close innovation 
23. Cost to quit collaboration 
Process to quit collaboration 24. Easiness to quit collaboration 
25. System change needed 
26. Close of technical knowhow 
Way of close innovation 27. Close of marketing information 
28. Willingness to close 
29. Decrease of technology leakage Advantage of close innovation 
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30. Decrease of cost 
31. Decrease of management process 
 
To check the accuracy of the findings, the codes and findings were discussed with the experts 
involved in the construction of interview questions (a professor in Business School at Sogang 
University, Korea, and a former head of Bioanalysis Division in Samsung Advanced Institute 
of Technology). This led to a reinterpretation of answers and some corrections as to how the 
firms decide on the transition of innovation type.   
 
4.3.2. Interview results 
 
(1) Samsung Electronics 
The interview was conducted with a former team leader of biochip research lab in Samsung 
Advanced Institute of Technology supported by Samsung Electronics. The total number of 
codes was 27, including 3 codes for general information and 24 codes for 9 groups. Based on 
code classification, the interview results were analyzed. The interviewee suggested that there 
is change of degree of open innovation from the start to end of new product development. 
Therefore, big firm like Samsung Electronics start open innovation, since they control few of 
the needed technologies and, consequently, firms need to acquire technologies for new products. 
Thus, big farm start to work with external partner, like universities and small venture firms by 
investing in research and providing funds to them. Based on the intellectual property (IP) such 
as patent and know-how, the innovation change occurs. The innovation step can be divided in 
four stages similar to the four modules based on the IP (see Figure 4.1). Based on the initial IP 
that firm has, each module needs a different IP. To get IP, collaboration is done for IP licensing, 
cross IP licensing, IP acquisition, and right for IP execution. To get different types and amounts 
of IP, a different degree of openness is required in each step. In the second stage, open 
innovation activity increases to get more IP for product development. 
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Figure 4.1. Change of openness in new product development of biochip in Samsung 
Electronics 
 
In the third stage, a big firm has sufficient knowledge to make commercial product and then 
decreases open innovation activity. By decreasing open activity, the amount of research funds 
devoted to external partners decreases, which increases the profit of the firm. IP protection to 
prevent outflow of knowledge is very important in the commercial product stage. Thus, the 
firms do close innovation due to the perception of advantage of close innovation. In the fourth 
stage, the commercial product is made and then the government approval is needed before 
starting commercialization. To sell the biochip, for patient usage, a premarket approval (called 
510K) is needed based on the clinical trials from US Food and Drug Administration in the U.S. 
case. However, for usage as laboratory equipment, clinical tests and 510K are not needed. To 
get the government approval, collaboration with law firms or hospitals is needed to do the legal 
process, as well as clinical trials in collaboration with an internal research team, which 
increases the open activity of firm. In addition, the collaboration is needed for the improvement 
of product and wide modification of product for new application in the fourth stage. Thus, even 
in the third and fourth stages, there is a low degree of openness and, thus, there will be no 
completely close innovation. From the start stage to the final stage of product development, the 
degree of openness changes, causing a wave-type oscillation in the degree of openness.  
Based on the experience of the team leader in Samsung Electronics to do collaboration with 
small firms, in the first stage of the of product development process, a small firm fears leakage 
or outflow of its knowledge. Thus, small firms focus on developing their own IP and getting 
patents, and then start to do open innovation to get external technology. The other innovation 
process is the same as that of a big firm. 
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In the biochip technology, the first chip to emerge was the DNA chip, which exploited 
technologies based on DNA immobilization and the optical detection technique of DNA. The 
second chip to be developed was the protein chip. It was partly based on the DNA chip 
technology, with the addition of other technologies, such as protein immobilization and signal 
detection technology from protein. After protein chip, the cell chip technology emerged based 
on the DNA/protein chip technology and other technologies, such as cell immobilization and 
signal detection technology from cell. Finally, the organ-on-a chip emerged, which was based 
on the cell chip technology (see Figure 4.2). As new innovative biochip emerges based on the 
previous chip generation technology, the same pattern of innovation change can be observed 
(see Figure 4.3). The repetition of transition of innovation occurs in new innovative product 
development. 
 
 
Figure 4.2. The development of biochip 
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Figure 4.3. Change of openness by emergence of innovative product in Samsung Electronics 
 
(2) LG Biotechnology 
The interview was conducted with a former head of Sales Department to sell biosensor and 
biochip in LG Biotechnology. LG is the second largest conglomerate in Korea including LG 
Electronics and LG Biotechnology. The total number of codes was 26, including 3 codes for 
general information and 23 codes for 9 groups. Based on code classification, the interview 
results were analyzed. The interviewee agreed with the concept of transition of innovation type 
(see Figure 4.1), but the transition of innovation is mainly based on knowledge, not just IP. The 
interviewee insisted on the importance of collaborative innovation. He suggested that 
collaborative innovation is not just open innovation, since, in collaborative innovation, the 
collaboration starts from planning of a project. It means that mutual collaboration between 
internal researchers and external partners starts from the initial stage to the final stage. In the 
fourth stage, the commercial product is made and then the collaboration for marketing is needed 
before selling the product. Thus, to distribute the product to the market, collaboration with 
other firms is needed in marketing, which also increases the open activity of the firm. the 
interviewee agreed with the concept of innovation for new innovative product to be proposed 
for the same pattern of innovation change (see Figure 4.3). Since LG Biotechnology and 
Samsung Electronics are big firms and have sufficient knowledge due to the long history of 
biosensor and biochip development, it can be concluded that the experts in both firms converge 
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in their views on the transition of innovation for new product development. 
 
(3) SK Telecom  
The interview was conducted with a research fellow in Healthcare Group of SK Telecom. 
SK is the third largest conglomerate in Korea including SK Telecom and SK Energy. Healthcare 
Group does research for bioanalysis systems including biosensors. The total number of code 
was 21, including 3 codes for general information and 18 codes for 9 groups. Based on code 
classification, the interview results were analyzed. The interviewee insisted that the open 
innovation is the main research innovation activity for new product development in Healthcare 
Group of SK Telecom. From the planning to production of a product, collaboration innovation 
is carried out with external partners. Thus, there is no transition to close innovation in the firm’s 
overall innovation status, but just a slight decrease of openness due to the decrease of 
knowledge needed for commercialization (see Figure 4.4). As open innovation activity is 
performed for a long time since the initial stage, the internal research ability increases. Based 
on the interviewee’s experience with small firms, small firms keep closeness to prevent leakage 
of knowledge in the first step and then increase open innovation activity rapidly (see Figure 
4.4). After the third stage, small firms keep a high level of open innovation in their 
collaboration with external partners. When a new innovative product emerges, the repetition of 
innovation occurs, but, ion overall firm level, innovation is preserved open since the open 
innovation activity is preserved in each product (see Figure 4.5). These results suggest that 
there is no transition to close innovation in this firm.  
 
Figure 4.4. Change of openness in new product development of biochip in SK Telecom 
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Figure 4.5. Change of openness by emergence of innovative product in SK Telecom 
 
The pattern of innovation activity in Healthcare Group of SK Telecom is very different from 
those of Samsung Electronics and LG Biotechnology, though all three firms are big. The reason 
might be that the research history of Healthcare Group of SK Telecom is shorter and the firm 
wants more technologies, since this firm has insufficient knowledge from the start stage, as 
compared with the other two farms that have a long research history and many patents.  
 
(4) BioDiatech 
The interview was conducted with a former CEO and founder of BioDiatech, a venture 
company. The main product of BioDiatech is the biosensing device to detect myocardial 
infarction. The total number of code was 24, including 3 codes for general information and 21 
codes for 9 groups. Based on code classification, the interview results were analyzed. The 
interviewee agreed with the concept of transition of innovation type (see Figure 4.1), but the 
transition of innovation is mainly based on the understanding of technology perfectness to 
make commercial product, not just by IP from the first to the second stage. In the second stage, 
the change of the degree of openness is done based on knowledge for commercial product. In 
the third stage, the company has acquired sufficient knowledge for commercial product and, 
consequently, it decreases the degree of openness and starts to close the technology inflow. In 
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the fourth stage, the open innovation activity concerning marketing and government approval 
process increases rapidly (see Figure 4.6). These results suggest that there is transition tendency 
to close innovation in this firm.  
 
Figure 4.6. Change of openness in new product development of biochip in BioDiatech 
The interviewee agreed with the concept of innovation for innovative products (see Figure 
4.3). However, he indicated that the overall innovation status of a small firm is different from 
that of a large firm and open innovation level in a small firm is the same in the overall 
development process as shown in Figure 4.7. The reason might be that small firms want open 
innovation in technology for the product development stage and more open innovation in 
marketing and government approval process due to the shortage of infrastructure in marketing 
and law areas.  
 
Figure 4.7. Change of openness by emergence of innovative product in BioDiatech 
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(5) NSB Postech  
The interview was conducted with a CEO and founder of NSB Postech, a venture company. 
The main product of NSB Postech is the substrate used for immobilization of proteins in Protein 
Chip. The total number of code was 25, including 3 codes for general information and 22 codes 
for 9 groups. Based on code classification, the interview results were analyzed. The interviewee 
agreed with the concept of transition of innovation type shown in Figure 4.1. However, in the 
first stage, a small firm like NSB Postech does not adopt open innovation at all, since it wants 
to have exclusive ownership of the technology. In the second stage, open innovation starts for 
collaboration for clinical assay. The reason might be that the firm must work with customers, 
such as bioanalytical firms and hospitals, in developing the product. In the third stage, the firm 
wants open innovation for the government approval process, but does not want open innovation 
in technology inflow. Thus, overall, the degree of openness decreases (see Figure 4.8). 
According to the interviewee, in the fourth stage, open innovation is not needed, since 
improvement of a product or a modification for a new application for the product can be done 
inside the firm.   
 
 
Figure 4.8. Change of openness in new product development of biochip in NSB Postech 
 
The interviewee agreed with the concept of innovation for innovative products shown in 
Figure 4.3. However, he indicated that the overall innovation status of small firm is slightly 
different from that of large firm and open innovation is kept continuously in the overall level 
of degree of open innovation in the firm (see Figure 4.9). The reason might be the same as the 
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one proposed in the interview with BioDiatech. The inflow of external technology in early 
stage and collaboration for marketing and government approval process are needed.  
 
 
Figure 4.9. Change of openness by emergence of innovative product in NSB Postech 
 
(6) NanoEnTek  
The interview was conducted with a CEO and founder of NanoEnTek, a small technology 
company. The main product of NanoEnTek is the immunoassay analyzer consisting of lab-on-
a chip based on nano-scale Bio-MEMS (microelectromechanical system) technology. The total 
number of code was 26, including 3 codes for general information and 23 codes for 9 groups. 
Based on code classification, the interview results were analyzed. The interviewee did not agree 
with the concept of transition of innovation type shown in Figure 4.1. Instead, he suggested 
that the firm does not want to collaborate with external partners until all technology for product 
is developed internally in the first and second stages. The value of intellectual property (IP) is 
important, not just number of IP in a firm, since most IP in firm is not valuable. Research, 
technology development and production should be done inside the firm, i.e. close innovation. 
In the third and fourth stages, open innovation is needed for collaboration so that marketing 
and the government approval process increase value (see Figure 4.10). Thus, the transition of 
innovation should be done based on consideration of value chain and value calculation.  The 
interviewee also suggested that development of technology is made in a close innovation mode, 
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whereas activities such as marketing, service, government approval process and consulting may 
be carried out in an open innovation mode. Also, the interviewee suggested that the degree of 
openness is affected by the character of CEO and business area.  
 
Figure 4.10. Change of openness in new product development of biochip NanoEnTek 
The interviewee agreed with the concept of innovation for innovative products shown in 
Figure 4.3. In the emergence of each new innovative product, the repetition of innovation type 
change is observed (see Figure 4.11). The interviewee suggested that the repetition of 
innovation related to value creation occurs and, thus, if the value to be created in product 
development stage in firm is low, the degree of open innovation increases to increase the value. 
The interviewee suggested that, if a new innovative product is a very creative product to cause 
disruptive innovation, the degree of open innovation should increase to acquire more new 
knowledges from the outside.  
 
Figure 4.11. Change of openness by emergence of innovative product in NanoEnTek 
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(7) Relations of factors based on interview analysis 
The concept of change of innovation in the product development stage is well adopted by 
two large firms (Samsung Electronics and LG Biotechnology) and two small firms (BioDiatech 
and NSB Postech). However, SK Telecom’s approach is entirely open innovation-based, 
whereas NanoEntek is entirely based on close innovation. All interviewees agreed on the point 
that transition of innovation type occurs as shown in Figure 4.12. At first, a firm starts open 
innovation to get external knowledge. As time goes by, the focal firm acquires sufficient 
knowledge or more knowledge than the external partner, such as a university and other firms. 
At this point, the focal firm decides to decrease open innovation activity and moves to close 
innovation. The general pattern of innovation in the cases of DNA chip, protein chip, and cell 
chip was suggested by interviewees and all of them agreed on the point that repetition of 
transition of innovation type occurs as shown in Figure 4.13. 
 
 
Figure 4.12. Transition of innovation type in new product development of biochip 
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Figure 4.13. Repetition of transition of innovation type in new product development of 
biochip 
 
The interviews converged in the following general level points. Based on interview results, 
the product development stage and the product innovation stage are related to the emergence 
of new innovative product. Furthermore, knowledge and the government approval stage are 
related to transition tendency of innovation. Also, the product development stage is related to 
the knowledge possessed by the focal firm. Due to the change to close innovation, the firm can 
get a better performance, such as an increase of profit, which can be described as the perception 
of advantage of close innovation. Although marketing is a factor affecting the open-to-close 
transition, the proposed model is formulated taking into account only technological factors. 
Thus, six factors (product development stage, product innovation stage, knowledge, 
government approval stage, transition tendency to close innovation, and the perception of 
advantage of close innovation) are related in the final stage of new product development (see 
Figure 4.14).  
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Figure 4.14. Relationship between factors based on structured interview in biochip firm 
 
4.4. Research Model and Hypotheses 
For the bio-pharmaceutical industry, a model with hypotheses for transition tendency to close 
innovation is proposed based on the results of interviews. Although the model is based on the 
interviews carried out in the biochip industry, the model with hypotheses is tested in the bio-
pharmaceutical industry, as, largely speaking, the bio-pharmaceutical industry includes the 
biochip industry. The generality of the proposed model is evaluated by extension to the bio-
pharmaceutical industry. In the model, the transition tendency is affected by the following 
factors: (1) product development stage; (2) level of knowledge; (3) product innovation stage; 
and (4) the government approval process. Then, the transition tendency to close innovation is 
related to the perception of advantage of close innovation. The relationships between variables 
and related hypotheses are described below.  
(1) Product development stage 
The product development stage is related to the innovation type. For a new product 
development in the biochip technology, novelty is very high and, therefore, new technologies 
must be transferred from external partners. At the initial stage of new product development, 
the open innovation activity starts and a large amount of external knowledge flows into the 
firm. Thus, the product innovation stage is positively related to knowledge in the firm. The 
literature confirms that the import of know-how and technology should be carefully considered 
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in each stage of open innovation (cooperated stage-gate mode) of new product development 
(Gronlund et al. 2010; Cooper 2008). These studies demonstrate different levels of know-how 
and technology flow into the firm at each stage of new product development, suggesting that 
the product innovation stage is related to level of knowledge. To make a product commercial, 
more know-how and technology have to be accumulated in the firm as the stage of product 
development progresses increases. Based on the above, the following hypothesis is formulated. 
H1: There would be a positive relationship between product development stage and 
accumulation of knowledge. 
For the firm to have the capability to make the commercial product in the final stage of 
product innovation, the firm must have accumulated sufficient knowledge and hence it does 
not need external knowledge any longer. Thus, the firm starts to move towards close innovation, 
since no more external knowledge is needed. Rubera et al. (2016) report that the development-
centric open innovation (development stage of product) is related to high R&D, as well as an 
increase the technology and know-how in the firm. However, the commercialization-centric 
open innovation (commercialization stage of product) is related mainly to marketing, not with 
technology and know-how, i.e. knowledge. Thus, in the commercialization stage, close 
innovation is preferred from the technology point of view. Therefore, at the end of product 
development stage, the transition tendency to close innovation increases. Accordingly, the 
following hypothesis is formulated. 
H2: There would be a positive relationship between product development stage and 
transition tendency to close innovation. 
(2) Knowledge   
Knowledge is closely related with open innovation activity. Diversified knowledge affects 
the impact of technology innovation in drugs and technology industry (Rosenzweig 2016). In 
knowledge-based high-tech industry, the knowledge is the key source for firm’s 
competitiveness in technological innovation (Castro 2015). Especially the strategic decision to 
profit is needed to acquire external scientific knowledge, since knowledge acquisition from 
foreign countries causes an increase of performance and unblocks the innovation potential 
(Kafouros and Forsans 2012). Knowledge capability relates to asymmetric knowledge 
capabilities in open innovation (Cooke 2005). 
More technology and know-how, i.e. knowledge, are accumulated in the firm as 
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development goes on, since various technologies are combined to produce bio-pharmaceutical 
products. Inflow of various external technologies is needed to support relevant technologies to 
manufacture the product through open innovation; during open innovation activity, the degree 
of openness can control the amount of inflowing various technologies. As more knowledge is 
accumulated in the firm, the firm wants to stop the inflow of external knowledge, which causes 
the initiation of close innovation and increases the transition tendency to close. Therefore, the 
following hypothesis is formulated. 
H3: There would be a positive relationship between knowledge and transition tendency to 
close innovation. 
(3) Product innovation stage related to emergence of new innovative product  
Biochip has developed from DNA chip to protein chip, and cell Chip based on the emergence 
of new application and technology (Kafi and Choi 2014). As new innovative biochip emerges 
based on previous chip technology, the repetition of transition of innovation type occurs (see 
Figures 4.2 and 4.13). Kafi and Choi (2004) define that each stage of emergence of a new 
innovative product is called the product innovation stage. The product innovation stage is 
related only to the emergence of a new innovative product, not just to that of a modified product 
for a new application. In the bio-pharmaceutical industry, as new technology emerges based on 
previous knowledge and new knowledge, new innovative products emerge (Robbins-Roth 
2000). Since the new innovative product emerges, the firm wants to get new knowledge from 
external partners. Thus, the open innovation activity increases and the transition tendency to 
close innovation decreases. Thus, it can be predicted that the high product innovation stage and 
the high level of emergence of a new innovative product decrease close innovation. Therefore, 
the following hypothesis is formulated. 
H4: There would be a negative relationship between product innovation stage and transition 
tendency to close innovation. 
(4) Government approval stage  
In the government approval stage, such as clinical tests I, II, and III for FDA, open innovation 
between hospitals and firms is highly needed in bio-pharmaceutical firms (Bianchi et al. 2010; 
Chiaroni et al. 2009; Schuhmacher et al. 2013). The role of the government is very important 
in open innovation in other industries (Lee et al. 2012; Park et al. 2016). Although open 
innovation activity exists in target identification and validation, lead identification, and pre-
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clinical stage, in the clinical test stage, more and diverse types of open innovation are needed 
(Bianchi et al. 2010; Chiaroni et al. 2009). Furthermore, for legal process to get the 
governmental approval, the collaboration with law firm is needed. Thus, as the product arrives 
in the government approval stage, more open innovation activity is needed. Therefore, it can 
be predicted that the government approval stage decreases the tendency to close innovation. 
Therefore, the following hypothesis is formulated. 
H5: There would be a negative relationship between the government approval stage and 
transition tendency to close innovation. 
(5) Transition tendency to close innovation  
Although it has been reported that open innovation has many advantages, open innovation 
has adverse effect on firm’s R&D capability. The decrease of internal innovation potential, 
divergence of research goal, and increase of relevant costs for open innovation are suggested 
as disadvantages of open innovation (Almirall and Casadesuss-Masanell 2010; Kafouros and 
Forsans 2012; Cassiman 2015). Furthermore, there are differences in open and close innovation 
in terms of organizational culture, problem solving and the governance, and task decomposition 
and knowledge distribution (Herzog and Leker 2010; Felin and Zenger 2014; Lakhani et al. 
2012). Innovation risks of outsourcing in open innovation occur in pharmaceutical new product 
development (Lowman et al. 2012). Since the dependence on other organizations leads to 
knowledge loss and creates a lack of ability in integration of new product development 
(Lowman et al. 2012), the open innovation causes a decrease in firm’s profit. In the above cases, 
the decrease of open innovation (i.e. increase of transition tendency to close innovation) 
increases the advantage of close innovation activity, such as firm’s profit and increase of 
internal research capability. Thus, it can be predicted that the transition tendency to close 
innovation is positively related to the perception of advantage of close innovation activity. 
Therefore, the following hypothesis is formulated. 
H6: There would be a positive relationship between and transition tendency to close 
innovation and the perception of advantage of close innovation. 
Based on the above hypotheses and relations, the model is constructed (see Figure 4.15).  
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Figure 4.15. Model with hypotheses regarding factors affecting transition of innovation type in 
bio-pharmaceutical firm 
 
4.5. Research Method 
(1) Questionnaire Design 
The biotechnology industry, a high technology industry, is the fusion industry of various 
technologies, including biotechnology based drug (biodrug), nanobiotechnology, genetic 
engineering, and cell engineering. The pharmaceutical industry is mainly related to the 
development and production of new drugs or biosimilar drugs. In general, ue to the need to 
secure intellectual property, open innovation activity was barely accomplished in high 
technological industry. However, since life cycle of high technology has recently decreased, 
the need for open innovation activity has increased in the process of rapid development and 
commercialization of new product (Ahn and Lee, 2011). Based on these results, it can be 
predicted that open innovation will increasingly spread in the bio-pharmaceutical industry with 
a high intensive degree of technology. However, it can also be predicted that open innovation 
activity will decrease toward the end of new product development to reduce expenses and to 
avoid leakage of internal knowledge concerning innovative products. Thus, the bio-
pharmaceutical industry in Korea is selected in the present study as the target industry to 
investigate the change of innovation type.  
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The aim of this research is to investigate the transition of innovation type at final stage of 
new product development process. To meet this aim and ensure the validity of findings a 
questionnaire survey is done. Studies for pharmaceutical industry in past have done also 
questionnaire survey and questionnaire survey has been used as an established research 
technique for technology management studies (Fleuranceau-Morel 2002, Lotfi et al. 2015, Al-
Zu’bi and Tsinopoulos 2012)   
The questions were designed as followings. The interviews to construct questions were done 
with CTO of two medium-sized biotechnology firms, and manager of a team manager of large 
pharmaceutical firm in Korea, from October 10th to October 24th in 2012. Expert interviews in 
bio-pharmaceutical companies has been used as a method for open innovation analysis in bio-
pharmaceutical firm (Bianchi et al. 2011). The discussion for close innovation activity in final 
stage of new product development in biodrug was done. The findings in section 4.3.2 were 
used as the basic data to understand the transition of innovation type. Especially the factors to 
affect the transition of innovation type were discussed to clarify the transition tendency. And 
the relation of transition tendency to advantage of close innovation was discussed during action 
of innovation type change. The discussion results for close innovation activity in final stage of 
new product development were analyzed and the main variables were classified as four factors, 
openness, transition tendency, and perception of advantage of close innovation as depicted in 
Table 4.3.  
 
Table 4.3. Questions for transition to close innovation in final stage of new product 
development (NPD). 
(1) How is the degree of knowledge?  
1.1. We have enough research ability (mastering the technology) needed for NPD. 
1.2. We have the accumulated relevant technology needed for NPD. 
1.3. We have research competency needed for NPD. 
(2) How is the degree of product development stage?  
2.1. New Product is in commercial stage. 
2.2. New Product is in suboptimal stage. 
2.3. New Product is made for improvement after commercial stage. 
2.4. New Product is made for little modification for application after commercial stage. 
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(3) How is the degree of product innovation stage? 
3.1. New product development is done for emergence of total new product application. 
3.2. New product development is done for expansion of current application. 
3.3. New product development is done for new successive product. 
(4) What is important in change to close innovation? 
4.1. It is easy to change from open innovation to close innovation 
4.2. System change is needed to change from open innovation to close innovation. 
4.3. System change is needed to quit collaboration after producing new product. 
4.4. Cost to quit collaboration is high after producing new product. 
(5) What is the advantage of close innovation? 
5.1. Technology leakage is decreased due to close. 
5.2. Cost for new product is decreased due to close. 
5.3. Management process is decreased due to close. 
 
The scales used in the survey were seven as used in the literature (Son et al. 2014) but the 
scales were later modified for this study. To ensure the validity of question and scales I asked 
a panel of experts consisted of the above three interviewees and two professors in Sogang 
University, Korea (major: chemical-pharmaceutics and bio-pharmaceutics) to review them. 
This process made modification of questions and resulted in clarification of questions.  
The main question concerns the transition of innovation type in final stage of new product 
development of biodurg. Questions concern three aspects: (1) Does transition of innovation 
type happen? (2) Does factors such as knowledge, product development stage, government 
approval stage, and product innovation stage affect transition tendency to close innovation? (3) 
Does openness relate to technology ability? (4) Does transition tendency relate to perception 
of advantage of close innovation? Survey based on constructed questions is described in the 
following section.  
(2) Survey Administration 
The survey was conducted to target decision makers in 410 firms from November 3 to 
November 29, 2016, by fax, e-mail and assisting telephone by Telsearch Co. in Korea. Bio-
pharmaceutical firms include biotechnology firms, pharmaceutical firms, and bioanalysis 
instrument firms. Through the survey, a total of 54 survey results were acquired, reaching the 
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response rate of 13.2%; further analysis was done with 48 surveys with considerable values. 
However, the government approval stage in the model could not be analyzed, since the number 
of respondents was only 20 (out of 48).  
(3) Demographic characteristics 
Demographic property of respondents is shown in Table 4.4.  
Table 4.4. Characteristics of demography of sample 
Division Classification Number Percentage (%) 
Accumulated 
percentage (%) 
Firm Type 
Biotechnology firm 31 64.6 64.6 
Pharmaceutical firm 11 22.9 87.5 
Bioanalytical firm 6 12.5 100 
Firm size 
Venture firm 19 39.6 39.6 
Small firm 11 22.9 62.5 
Medium firm 17 35.4 97.9 
Large firm 1 2.1 100 
Personal position 
Staff 15 31.3 31.3 
Manager 25 52.1 83.4 
Director 5 10.4 93.8 
CEO 3 6.2 100 
 
(4) Statistical analysis of variables 
The definition of variables and measurement method of the variables in the research model 
are shown in Table 4.5. A seven-point scale was used for the variables. 
Table 4.5. Definition and measurement of variables 
KNW 1 We have enough research ability (mastering the technology) needed for NPD*. 
KNW 2 We have the accumulated relevant technology needed for NPD. 
KNW 3 We have research competency needed for NPD. 
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PDS 1 New Product is in commercial stage. 
PDS 2 New Product is in suboptimal stage. 
PDS 3 New Product is made for improvement after commercial stage. 
PDS 4 New Product is made for little modification for application after commercial stage. 
PIS 1 New product development is done for emergence of total new product application. 
PIS 2 New product development is done for expansion of current application. 
PIS 3 New product development is done for new successive product. 
TTC 1 It is easy to change from open innovation to close innovation. 
TTC 2 System change is needed to change from open innovation to close innovation. 
TTC 3 System change is needed to quit collaboration after producing new product. 
TTC 4 Cost to quit collaboration is high after producing new product. 
ACI 1 Technology leakage is decreased due to close. 
ACI 2 Cost for new product is decreased due to close. 
ACI 3 Management process is decreased due to close. 
*New product development 
 
Based on the data acquired by the survey, analysis was performed using SPSS 18.0 program 
and PLS 2.0. The hypotheses were tested by applying the partial last square (PLS) method to 
the collected data. This study used PLS, rather than other SEM methods (i.e. LISREL, AMOS, 
etc.), as the PLS approach places minimal restrictions on sample size and residual distribution 
(Phang et al. 2006). First of all, analysis of descriptive statistics was accomplished and the 
results were investigated. To verify the reliability of samples, the items measuring each concept 
were investigated using Cronbach’s alpha test. Also, to verify the validity of the samples, factor 
analysis was run in the hypothesis testing process. 
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4.6. Model Results 
 
4.6.1. Validation  
To validate the model, three types of validity—content validity, convergent validity, and 
discriminant validity—were assessed. (1) Content validity was evaluated based on Cronbach 
alpha value (see Table 4.6) Cronbach’s alpha test to individual scale and the overall measures 
to assess internal consistency were sued. The threshold value of Cronbach alpha is 0.7 (Nunally 
and Berstein 1994). As shown in Table 4.6., the Cronbach alpha values in our results were 
0.913 for knowledge, 0.868 for product development stage, 0.769 for product innovation stage, 
0.810 for transition tendency to close, and 0.850 for perception of advantage of close 
innovation. Thus, all variables are valid.  
 
Table 4.6. Confirmatory factor analysis 
 Cronbach’s Alpha 
Composite 
Reliability 
Average Variable 
Extracted(AVE) 
Knowledge (KNW) 0.913 0.945 0.852 
Product development Stage (PDS) 0.868 0.909 0.715 
Product innovation Stage (PIS) 0.769 0.817 0.607 
Transition tendency to close (TTC) 0.810 0.874 0.644 
Advantage of close innovation (ACI) 0.850 0.906 0.763 
 
(2) Convergent validity was assessed by composite reliability and average variance 
extracted (AVE) from the measures (see Table 4.6). The acceptable values of composite 
reliability for reliable construct is 0.7 (Chin 1988). The composite reliability values in our 
dataset were 0.945 for knowledge, 0.909 for product development stage, 0.817 for product 
innovation stage, 0.874 for transition tendency to close, and 0.906 for the perception of 
advantage of close innovation. Thus, all variables are valid. The acceptable value of AVE is 
over 0.5 (Fornell and Larcker 1981). The AVE values in our data were 0.852 for knowledge, 
0.715 for product development stage, 0.607 for product innovation stage, 0.644 for transition 
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tendency to close, and 0.763 for the perception of advantage of close innovation. Thus, all 
variables are valid.  
(3) Discriminant validity was verified by evaluating the square root of AVE (Fornell and 
Larcker 1981; Son et al. 2014). The square root of AVE for each construct was greater than the 
levels of correlation involving the construct (see Table 4.7.) Also, each construct showed a 
larger variance with its own measures than those with other measures (see Table 4.7). 
Acceptable threshold value of absolute value pairwise correlation is 0.6 (Nunally and Berstein 
1994) and the highest absolute value of pairwise correlation in our dataset was 0.606, which is 
very close to 0.6. Variance inflation factors (VIF) is calculated to detect the multicollinearity 
among the explanatory variables. Threshold value of VIF is 10 (Nunally and Berstein 1994) 
and the highest VIF value in our dataset was 6.139, which is considerably lower than 10. Thus, 
all variables are valid.  
Table 4.7. Correlation between constructs 
 
Advantage of 
close 
innovation 
Knowledge 
Product 
development 
Stage 
Product 
innovation 
Stage 
Transition 
tendency to 
close 
ACI 0.873*     
KNW 0.409 0.923*    
PDS 0.135 0.464 0.846*   
PIS 0.180 0.172 0.473 0.779*  
TTC 0.491 0.606 0.226 0.230 0.802* 
* Square root of AVE 
 
Other analyses that were performed are outlined below. The descriptive statistics including 
standard deviation is depicted in Table 4.8. Kaiser-Meyer-Olkin measure of sampling 
adequacy was calculated to amount to 0.671. Overall, 5 factors explained 78.756% of the total 
variance (Table 4.9). Since all 5 factors have well-distributed over 0.6 in factor analysis, the 
validity requirement was satisfied (see Table 4.10).  
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Table 4.8. Descriptive Statistics 
 N Min Max Mean Std. deviation 
KNW 1 48 2 7 5.02 1.211 
KNW 2 48 1 7 4.83 1.449 
KNW 3 48 1 7 4.94 1.522 
PDS 1 48 1 7 3.67 2.025 
PDS 2 47 1 7 3.91 1.976 
PDS 3 48 1 7 3.73 1.608 
PDS 4 47 1 7 3.79 1.429 
PIS 1 48 1 7 3.73 1.512 
PIS 2 48 1 7 3.69 1.446 
PIS 3 48 1 7 3.89 1.433 
TTC 1 48 1 7 4.04 1.414 
TTC 2 48 1 6 4.52 1.429 
TTC 3 48 1 6 3.67 1.3 26 
TTC 4 48 1 5 3.25 1.345 
Effective Number 48     
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Table 4.9. Total Variance Explained 
Factor 
Initial Eigenvalues 
Extraction Sums of 
Squared Loadings 
Rotation Sums of Squared 
Loading 
Total 
% of 
Variance 
Cumul
ative% 
Total 
% of 
Variance 
Cumul
ative% 
Total 
% of 
Variance 
Cumula
tive % 
1 5.926 34.858 34.858 5.926 34.856 34.856 3.238 19.047 19.047 
2 2.716 15.976 50.832 2.716 15.976 50.832 3.047 17.922 36.969 
3 1.877 11.041 61.873 1.877 11.041 61.873 2.532 14.896 51.865 
4 1.482 8.720 70.592 1.482 8.720 70.592 2.471 14.538 66.402 
5 1.388 8.164 78.756 1.388 8.164 78.756 2.100 12.354 78.756 
6 .779 4.583 83.339       
7 .577 3.396 86.735       
8 .529 3.113 89.849       
9 .417 2.455 92.303       
10 .355 2.088 94.392       
11 .256 1.509 95.900       
12 .200 1.178 97.078       
13 .162 .950 98.028       
14 .115 .679 98.707       
15 .106 .625 99.333       
16 .063 .371 99.704       
17 .050 .296 100.00       
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Extraction Method: Principal Component Analysis 
Table 4.10. Rotated Component Matrix 
 
Component 
1 2 3 4 5 
KNW 1 .182 .907 .116 .156 .098 
KNW 2 .224 .838 .132 .000 .137 
KNW 3 .353 .760 .104 .302 .029 
PDS 1 .871 .138 .099 -.043 .145 
PDS 2 .878 .222 .053 -.078 .020 
PDS 3 .887 .080 -.068 .140 .135 
PDS 4 .685 .231 .220 .132 .256 
PIS 1 .055 .164 -.109 .038 .871 
PIS 2 .384 -.047 .388 .045 .635 
PIS 3 .187 .070 .064 .130 .845 
TTC 1 .103 .408 .774 -.020 .018 
TTC 2 -.079 .542 .698 .153 .057 
TTC 3 .177 -.164 .793 .165 .050 
TTC 4 -.002 .472 .588 .331 .019 
ACI 1 .105 .248 .080 .860 -.054 
ACI 2 -.018 .063 -.005 .881 .282 
ACI 3 .014 .080 .438 .784 .022 
Extraction Method: Principal Component Analysis, Rotation Method: Varimax with Kaiser           
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Normalization, a. Rotation converged in 5 iterations  
  
4.6.2. Hypothesis testing 
To validate the model, the structural equation model was applied and Partial Least Square 
(PLS) was used. Since PLS requires minimal demands on sample size (Chin 1998) to validate 
a model, and our data set is 48, the PLS method was used to evaluate the proposed model and 
hypotheses. When t-value is over 1.96, the hypothesis is significant at 5% level of significance 
if the number of samples is sufficiently large. Cramer (1946) suggests that the approximation 
is usually good for samples larger than 30; thus, statistical inference is appropriate for this study 
with our 48 data set. However, Hypothesis 5 could not be tested, since the number of 
respondents was only 20 (out of 48). As shown in Table 4.11, only t-values for the relation 
between knowledge and transition tendency to close innovation, the relation between product 
development stage and transition tendency to close innovation, and the relation between 
transition tendency to close innovation and the perception of advantage of close innovation 
were over 1.96; thus, only these three relations were satisfied. Furthermore, the values of path 
loadings were calculated. Since R2 for knowledge, product development stage, and the 
perception of advantage of close innovation amounted to 0.215, 0.401, and 0.241, respectively, 
the proposed model is acceptable, since minimum acceptable range of R2 is 0.1. The results of 
the analysis of the model with path coefficient, t-value and R2 are shown in Figure 4.16.  
 
Figure 4.16. Model result for relation between transition tendency and advantage of close innovation 
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Table 4.11. Path Coefficients 
 
Original 
Sample 
Sample Mean 
Standard 
Deviation 
T Statistics P Values 
KNW → TTC 0.650 0.650 0.104 6.266 0.000*** 
PDS → KNW 0.464 0.485 0.112 4.127 0.000*** 
PDS → TTC -0.169 -0.156 0.166 1.016 0.310 
PIS → TTC 0.198 0.172 0.201 0.989 0.323 
TTC → ACI 0.491 0.499 0.130 3.777 0.000*** 
*** p<0.001, ** p<0.01, * p<0.05 
 
The results in Figure 4.3 suggest the following. Since t-value and p-value are within an 
acceptable range, the product development stage is positively related to knowledge, meaning 
that as product develops more and becomes into commercial status, the degree of knowledge 
in firm increases. This result indicates that the firm acquires more knowledge accumulation 
through open innovation activity from the initial stage of product development, since, due to 
open innovation, new technologies from outside flow into firm to make the product as time 
goes by. Therefore, Hypothesis 1 is substantiated by our data analysis.  
When t-value and p-value are considered, the relation between the product development 
stage and transition tendency to close innovation is not established. When t-value is over 1.96, 
the hypothesis is significant at 5% level of significance. However, t-value was 1.06 for relation 
between the product development stage and transition tendency and thus this relation was not 
confirmed. As the acceptable range of p-value is lower than 0.05 and p-value of this relation is 
0.301, this relation was not confirmed. Therefore, Hypothesis 2 has to be rejected. The results 
suggest that the product development stage is not directly related to change of innovation type 
of firm. By evaluating Hypothesis 3, it can be tested that the relation between the product 
development stage and change of innovation type of firm can be established only with 
knowledge as a mediator.  
Since t-value and p-value are within an acceptable range, knowledge is positively related to 
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transition tendency to close innovation, meaning that the more knowledge, such as patent and 
know-how, has been accumulated in commercial stage of product, the more a firm may want 
to change the innovation type from open to close. Since the firm has sufficient knowledge, 
closing the relationship with its open innovation partners can reduce product development 
expenses, leading to more profit. The results suggest that, if a firm starts to get more knowledge, 
like new technology from outside, and the knowledge accumulation increases, the firm may 
not need more inflow of knowledge from the outside, since the firm has sufficient knowledge 
to make commercial product and, thus, wants to close the relation with external partners. Thus, 
Hypothesis 3 is supported by our results.  
When path coefficient and t-value are considered, the relation between the product 
development stage and transition tendency to close innovation is not established. When t-value 
is over 1.96, the hypothesis is significant at 5% level of significance. However, t-value is 0.989 
for the relation between the product development stage and transition tendency and, thus, this 
relation is not achieved. As the acceptable range of p-value is lower than 0.05 and p-value of 
this relation is 0.198, this relation was not confirmed. The results suggest that, although the 
emergence of related new product or new application of current product occurs, the transition 
tendency to close innovation is not affected by the emergence of those in bio-pharmaceutical 
firms. The results in the bio-pharmaceutical industry are different from those in the biochip 
industry. The reason might be that the newly emerged product in the pharmaceutical industry 
is not directly connected from previous products and technology that is not an extended 
technology of the previous product. Thus, Hypothesis 4 has to be rejected. 
The government approval stage could be analyzed, since the number of respondents was 
only 20 (out of 48). Therefore, Hypothesis 5 was not evaluated.  
Since t-value and p-value are within an acceptable range, the transition tendency to close 
innovation is positively related to the perception of advantage of close innovation, meaning 
that as the tendency to close innovation becomes higher, the perception of advantage of close 
innovation increases. As firm closes the relation with external partner, i.e. there is a lower 
degree of open innovation, the expenses regarding collaboration with external partner and 
outflow of know-how decrease, causing the firm to make more profit. Thus, Hypothesis 6 is 
supported by our data analysis. 
However, our results of structured interviews in the biochip industry show that the product 
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development stage directly affects the transition tendency to close innovation, product 
development stage does not directly affect the transition tendency to close innovation. Product 
development stage is directly related to knowledge in firm and then, consequently, knowledge 
is directly related with the perception of advantage of close innovation performance in the bio-
pharmaceutical industry. Level of product development stage becomes a control factor to 
manipulate the change of innovation type and even the increase of firm performance in bio-
pharmaceutical industry. This is a newly developed relation in open innovation for high-tech 
products.  
 
4.7. Conclusions and Discussion 
The results of structured interviews in the biochip industry based are shown in Figure 4.14. 
And the summary of the research result in bio-pharmaceutical industry is shown in Figure 4.17. 
 
 
Figure 4.17. Summary of model result for relation between transition tendency and advantage of close 
innovation in bio-pharmaceutical firms 
 
The purpose of this study was to investigate the factors affecting the transition of innovation 
type during the final stage of product development. Structured interviews were conducted with 
6 firms: 3 large and 3 small. At first, based on structured interviews for the biochip industry, 
the factors were elucidated for the product development stage, knowledge, product innovation 
stage, and government approval stage. We found that the transition tendency to close 
innovation affects the profit of firm as the perception of advantage of close innovation. Based 
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on the above relations, the model for the transition tendency to close innovation during final 
stage of product development was proposed for the biochip industry. 
To test the generality and extend applications of the proposed model, the model to be used 
in the biochip industry was first applied to analyze the bio-pharmaceutical industry in Korea. 
The model was analyzed based on the survey data of 48 bio-pharmaceutical firms. However, 
the government approval stage in the model could be analyzed, since the number of respondents 
was only 20 (out of 48).   
We found that the level of product innovation stage shows a positive relation with 
accumulated knowledge related to technology. If the level of product innovation stage is near 
commercialization, knowledge accumulation for product inside firm increases, meaning that 
the firm has sufficient knowledge for technology for commercialization of a new product. Our 
results demonstrate that the knowledge accumulation of technology has a positive relation with 
transition tendency to close innovation. As level of knowledge in firm becomes high and firm 
has sufficient knowledge for a new product, the firm wants to move to close innovation, since 
the firm does not need more external knowledge. Thus, closeness in innovation should be 
increased, meaning that the firm becomes less open to get external technologies. However, our 
results also show that, due to the intrinsic nature of bio-pharmaceutical technology products, 
the product innovation stage is not directly related to transition tendency to open innovation. 
As making a new drug, which is the main work of a pharmaceutical firm, is not generally an 
extension of a previous product, a new innovative product is not much related to knowledge 
accumulation in a previous innovative product.  
The factors affecting the perception of advantage of close innovation and transition 
tendency were then investigated. It was found that the transition tendency to close innovation 
has a positive relation with the perception of advantage of close innovation. If transition 
tendency and the perception of advantage are high, the firm starts to close and, consequently, 
gets less knowledge from external collaborator, meaning that the technology-sharing and -
transfer from external partner decreases. This means that, if the close innovation increases and 
open innovation decreases during the final production stage of a new product, the decrease of 
operating cost, expense for collaboration, cost for management of open innovation, and royalty 
payment can be achieved and, thus, various perceptions of advantages of close innovation can 
be obtained. If transition tendency is too low and, due to this, the perception of advantage of 
close innovation is low as well, the firm should continue to use the open innovation strategy. 
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Moreover, the increase of product development stage positively affects the knowledge of 
technology in firm and then the knowledge in firm has a positive relation with the transition 
tendency to close innovation. Thus, an increase of the knowledge due to the increase of 
production development stage causes an increase of the transition tendency, after which an 
increase of transition tendency causes an increase of the perception of advantage of close 
innovation (see Figure 4.17). 
Since the problem with innovation improvement efforts is rooted in the lack of innovation 
strategy (Pisano 2015), the innovation strategy to effectively do innovation is urgently needed. 
Based on the results of this study, a strategy to manage open innovation in the final stage of 
new product development was suggested. At first, the current stage of product development for 
new product was carefully examined. If the level of product development stage becomes high, 
then the knowledge of technology in the firm should increase. The state of knowledge was 
carefully evaluated as to whether or not there is sufficient knowledge for final product in the 
firm. Then the firm should decide to decrease the open innovation activity with external 
research partner. As a second step, the decision to decrease or stop open innovation in the final 
stage of new product development should be made based on the consideration of status of 
accumulation knowledge of technology to close innovation and the perception of advantage of 
close innovation. If the amount of knowledge accumulation in the firm is high when 
commercial stage is achieved in firm, the firm wants to close the inflow of external knowledge, 
the transition tendency to close becomes high, and, thus, the firm should stop open innovation. 
If the transition tendency is within an acceptable range, the firm should decide to start close 
innovation with new external research partners, but most of collaboration with current external 
partners should be maintained to improve the current product or to modify the current product 
for new applications. If the transition tendency is too low, the firm should decide to keep current 
open innovation with new external partners.  
As a third step, the decision to stop open innovation in the final stage of new product 
development should be made based on the consideration of both transition tendency to close 
innovation and the perception of advantage of close innovation. The balance between the 
expense to keep open innovation and profit of firm due to closeness should be considered and 
then the degree of close innovation can be decided upon based on the balance. To increase 
transition tendency to close causes the acceleration of reducing the degree of open innovation, 
as the perception of advantage of close innovation increases due to an increase of firm profit 
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and a decrease of collaboration expenses. The relations among knowledge, transition tendency, 
and the perception of advantage of close innovation should be simultaneously evaluated. 
Taken together, the results of this study provide the following insights. Product development 
stage and level of knowledge in firm are key factors affecting transition tendency to close 
innovation, i.e. the degree of close innovation with external partners. Based on the insights 
about the relations of closeness with firm performance as the perception of advantage of close 
innovation, the decision to control the degree of close innovation should be made. 
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Chapter 5. Conclusions and Recommendations 
 
5.1. Conclusions 
 
This research has sought to establish management strategies for open innovation in new 
product development of biochip. The open innovation activity was analyzed according to three 
phases: (1) the switching phase, when open innovation starts in the initial stage of NPD; (2) 
the implementation phase in the middles stag of NPD; and (3) the transition phase, when open 
innovation changes into close innovation in the final stage of NPD. The factors affecting open 
innovation activity in each phase were evaluated and a model (based on the relation between 
factors) was proposed for each phase. The proposed models were then applied to analyze open 
innovation activity in the new product development of biochip. The models were evaluated by 
conducting surveys and analyzing their results in the context of the Korea biochip firms. The 
models were shown to be well adopted for the open innovation activity in each phase. Other 
factors affecting openness in each phase were verified based on both the technology and the 
non-technology points of view. These achievements lay the foundation for further research on 
open innovation in the bio-pharmaceutical industry, which can help analyze open innovation 
in other high-tech industries in the future. 
 
5.1.1. Management strategy for the switching phase of open innovation in new product 
development of biochip 
The factors affecting the decision to start open innovation in the initial stage of new product 
development were investigated in this section. The switching cost refers to the cost for change 
from close innovation to open innovation. If the switching cost is high, firm is reluctant to enter 
open innovation. These factors relate to the switching cost (cost to start open innovation with 
new partner) by considering the perception of advantage of open innovation and how these 
affect the decision on whether or not to start open innovation. A model as proposed based on 
the relations of factors and then evaluated by conducting surveys of the Korean biochip firms 
and analyzing their results. We found that the switching cost has a negative relation with the 
perception of advantage of open innovation. If the switching cost is low and the perception of 
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advantage of open innovation is high, the firm starts to open and get knowledge from external 
collaborators, meaning that technology-sharing and -transfer from the current external partner 
(not a part of new open innovation for new product development) and internal research team 
decrease. If the current external partner already exists before NPD, the current external partner 
relates to production of old existing product and has knowledge for old product. Therefore, it 
is difficult to think of the current external partner as a partner of NPD in a newly starting open 
innovation in new precut development. If the switching cost is too high and the perception of 
advantage of innovation decreases due to the high switching cost, the firm will not want to 
open the technology flow between inside and outside. The trust to the current external partner, 
as well as the level of research capacity in the firm, is found to influence the switching cost. 
Our results demonstrate that the trust to the current external partner and the level of research 
capacity in the firm have is positively related to the switching cost.  
Based on the results of the model, the following strategy to manage open innovation is 
suggested as following. The decision to start open innovation or not in the initial stage of new 
product development should be done based on the consideration of the switching cost and the 
perception of advantage of open innovation. At first, factors such as trust to the current external 
partner and the internal research capacity to affect the switching cost should be considered. If 
any of these is high, the switching cost is too high and, thus, the firm should keep the current 
external partner and internal research team in close innovation.  
If the switching cost is within an acceptable value, the firm should decide to start open 
innovation with new external research partners. The relation with the current external partner 
should be reduced to reduce the switching cost. The research capacity should be reduced by 
reducing the number of researchers or Ph.D. level researchers, which causes a decrease of the 
switching cost. However, the internal research capacity should be kept over the medium level, 
since the internal research capacity affects the performance of open innovation activity. Internal 
research team with a good research capacity can efficiently manage the technology transfer 
from the outside. Due to reducing the switching cost, the perception of advantage of open 
innovation increases, which leads to an acceleration of implementation of open innovation. 
The results of this study suggest the following insights. The current internal research capacity 
and external partner are important factors that inform the decision to start open innovation by 
introducing new partners. Based on the insights about the relationship between the current 
situation (research capacity and presence of external partners) and the switching cost and 
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between the switching cost and the perception of advantage of open innovation, the decision 
of the firm to start open innovation should be made. It can be concluded that the switching cost 
and the perception of advantage of open innovation are used to decide whether or not to start 
an open innovation activity in the initial stage of NPD. 
 
5.1.2. Management strategy for implementation phase of open Innovation in new product 
development of biochip  
In this section, the factors controlling the degree of openness in the middle stage of new 
product development were investigated based on the technology characteristics, technology 
novelty, and technology complexity in this section. The model was proposed based on the 
relationships of a certain number of factors and then was evaluated by carrying out surveys in 
the Korean biochip firms. We found that the technology novelty has a positive relation with 
openness in new product development. If the technology novelty is high and thus new product 
is a very creative one, the degree of open innovation should be increased, meaning that the firm 
should become more open in order to get more external technologies. We also established that 
technology complexity is not directly related to openness due to the intrinsic nature of the 
biochip, which is a very complex technology-based product.  
The factor affecting the change of firm’s technology capability was then investigated together 
with openness affecting the firm’s technology capability in new product development. We saw 
that the openness has a positive relation with firm’s technology capability. If openness becomes 
higher during production of a new product and the degree of open innovation increases, then 
more external technologies flow in the firm. Consequently, the technology capability related to 
design and production of new products is increased. More openness and a higher inflow of 
external technologies cause an increase in the technological capability of the focal firm.  
The factors affecting firm’s performance were also investigated. We found that the firm’s 
technology capability shows a positive relation with firm’s performance. If the firm’s 
technology capability due to openness increase is increased during NPD, then a higher increase 
of revenue, operating margin, competitive production cost, number of newly developed product, 
and royalty income should be achieved and, consequently, the firm’s performance is increased. 
Thus, an increase of openness causes an increase of technology capability in firm; then an 
increase of technology capability in firm causes an increase of firm performance.  
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Based on these results, a model of the strategy to manage open innovation during 
implementation of open innovation was suggested. At first, the novelty of technology for new 
product was carefully examined. If the technology novelty is high, the degree of open 
innovation should be increased. If the technology novelty is very low, the firm should decide 
to decrease the open innovation activity with external research partner. The results suggest that 
the technology complexity is not related to the degree of open innovation and openness.  
As more open innovation is implemented due to novelty, more technologies flow into the firm. 
By controlling the degree of open innovation, the technology flow can be controlled, which, in 
turn, controls the technology capability of firm to produce new products. As a second step, the 
degree of open innovation is decided upon based on the level to which firm wants to increase 
its internal research ability. Then, an increase of the research capability of the firm causes an 
increase of firm’s performance, which, in turns, increases profitability. As a third step, the 
balance between the expense of open innovation and profit of firm due to openness should be 
considered and then the degree of open innovation should be decided upon based on the balance. 
The relations among openness, technology capability, and firm performance should be 
simultaneously evaluated. 
Therefore, it can be concluded that technology characteristics and technology capability of 
the focal firm are key factors to decide on the degree of openness with external partners. Based 
on the insights of the relations between openness and firm performance (evaluated from the 
technology point of view), the decision to control the degree of openness should be made. 
In this study, which is based only on technological considerations, the technology is the center 
to the value offering. It determines openness and firm’s performance. However, in the real 
world, to increase firm performance, there are other sources of opportunity, such as 
organization, environment, market, business model, and expansion to other products. Of note, 
these factors are interdependent (Henderson et al. 2016). The process for creating a new 
product starts with technology, from which we create value, but ends with market – the source 
of need and place where we realize value (Henderson et al. 2016). Therefore, to develop a 
strategy for open innovation, the variables outlined above should be considered together with 
technology. Consequently, non-technological factors such as the market, organization, and 
environment should also be evaluated. 
The factors affecting open innovation activity, such as institutional-, environmental-, and firm 
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characteristics, were investigated to enhance the technological innovation activity. Survey data 
of Korean biochip firms for open innovation activity were used for empirical verification. The 
results yielded by the analyses are as follows. First, the market competition and governmental 
support show a statistical positive relationship with the depth of open innovation activity. This 
result suggests that the firm enhances the collaboration with external partner due to the 
reinforcement of competition, in the case of the necessity of strengthening competency. 
Therefore, a firm under an industry group related to the high intensity of market competition 
focuses on the collaboration with the favorable external partners when the firm takes the open 
innovation strategy. Also, the firm focuses on collaboration with current collaborators if the 
government supports the firm more, meaning that the government supports the firm to enhance 
open innovation. 
Second, the higher the number of doctoral researchers in R&D staff in a firm, the higher the 
depth of open innovation. This result is consistent with the results reported by Link and Bauer 
(1987) who suggest that the growth of the capacity of internal research promotes cooperation 
while maintaining core technologies. Therefore, it is necessary to increase the number of 
doctoral researchers in order to enhance the depth of open innovation activity while pursuing 
core competencies. Furthermore, as shown by our results, the quality of the researchers is more 
important than their number. In addition, there is a statistically significant (+) positive 
relationship between the amount of R&D investment and the breadth of open innovation. Due 
to a larger cash flow into the firm, more investment to find new partners and then more R&D 
investment to collaboration with external partners are needed. In the biochip industry where 
human resources in R&D are essential, it is necessary to continuously invest and expand human 
resources to increase the breadth of open innovation activity. Of note, governmental investment 
in the above environmental characteristic variables is used to increase the depth of open 
innovation, while the R&D investment is more related to the breadth of open innovation. 
 Third, the flexibility of organizational culture is found to be positively related to the depth of 
open innovation activity, and the openness of organizational culture is positively related to the 
breadth of open innovation. Therefore, it can be suggested that the firm should make an effort 
to increase the flexibility of its organizational culture. With this flexibility, it should be decided 
how to act to other external collaborators. In addition, an open organizational culture makes 
the firm to be more open in open innovation activity. Therefore, in order to establish a 
relationship with various external entities, at first, it will be necessary to make an effort to have 
openness in the organizational culture. 
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 Fourth, our results also demonstrate that the presence of a dedicated group for open 
innovation proves to have a statistically significant impact and has a positive relation with the 
depth of open innovation activity. Thus, in order to achieve open innovation, the presence of a 
dedicated group in the focal firm is an important factor. If the research capacity of firm is higher 
than the level on which the firm can make commercial product by itself, it is strongly 
recommended to establish a dedicated group for open innovation in the firm to enhance open 
innovation activity.  
The significance of this study and suggestions for further research are as follows. First, a 
survey for open innovation was conducted for a single industry group—the biochip industry, 
which was rare in previous research. Therefore, this study provides more detailed and accurate 
analyses through the research on open innovation activity in just one industry, which is 
characterized by a relatively small size, but nonetheless requires open innovation activity. Our 
results provide significant practical implications related to the strategy and implementation of 
open innovation. From the academic point of view, this study identifies and links influential 
factors in the model, which are then linked to the investigation of breadth and depth of open 
innovation activity.  
 Second, our study provides important implications for the strategy to be followed in open 
innovation activity. This strategy is based on the analysis of influential factors. From the 
practical point of view, the question whether or not to establish a relationship with new external 
collaborators is shown to be an important issue to be solved in a real industrial context. With 
regard to firm practitioners, our results offer a strategic choice for open innovation, since the 
effects of factors affecting the breadth and depth of open innovation activity are analyzed. 
It can be concluded that the influential factors related with technology point of view and non-
technology point of view are evaluated together to affect the degree of openness; furthermore, 
the management strategy for implementation of open innovation is proposed based on the 
relations among influential factors. 
 
5.1.3. Management strategy for the transition phase of open innovation in new product 
development of biochip  
The factors controlling the transition to close innovation in the final stage of new product 
development were investigated in this section. Structured interviews were carried out with 6 
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firms, 3 large firms, and 3 small firms. At first, based on structured interviews, the factors for 
innovation transition were elucidated as the product development stage, knowledge, the 
product innovation stage, and the government approval stage. Our results demonstrate that the 
transition tendency to close innovation affects the profit of firm as the perception of advantage 
of close innovation. Repetition of transition of innovation is therefore proposed based on the 
emergence of new innovative product. Based on the above relations, the model for the transition 
tendency to close innovation during the final stage of product development is proposed in the 
biochip industry. 
To test the generality and to extend applications of the proposed model, the model constructed 
in the biochip industry was first applied to analyze the bio-pharmaceutical industry in Korea. 
The model was analyzed based on survey data of 48 bio-pharmaceutical firms. However, the 
government approval stage in the model could be analyzed, since only 20 out of 48 expected 
responses were obtained in the government approval stage. 
Our results show that the level of product innovation stage shows a positive relation with 
accumulated knowledge of technology know-how and patents. If the level of product 
innovation stage is near commercialization, knowledge accumulation for product inside the 
firm increases, meaning that the firm has sufficient knowledge for commercialization of a new 
product. We also observe that the knowledge for technology for commercialization of new 
product has a positive relation with transition tendency to close innovation. As level of 
knowledge in firm becomes high and firm has sufficient knowledge for a new product, the firm 
wants to move to close innovation, since it does not need more external knowledge. Thus, 
closeness in innovation should be increased, meaning that the firm becomes less open to get 
external technologies. However, according to our results, due to the intrinsic nature of bio-
pharmaceutical technology products, the product innovation stage is not directly related to the 
transition tendency to open innovation. Since making a new drug, which is the main work of a 
pharmaceutical firm, is not generally an extension of a previous product, the new innovative 
product is not much related to knowledge accumulation in the production of previous 
innovative products.  
The factors affecting the perception of advantage of close innovation were then investigated 
and transition tendency to close innovation was found to affect the perception of advantage of 
close innovation in new product development. Our results show that the transition tendency to 
close innovation has a positive relation with the perception of advantage of close innovation. 
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If both transition tendency and the perception of advantage of close innovation are high, the 
firm starts to close and, consequently, gets less knowledge from external collaborators, 
meaning that the technology-sharing and -transfer from external partner decreases. Therefore, 
if the close innovation increases and open innovation decreases during the final production 
stage of a new product, the decrease of operating cost, expense for collaboration, cost for 
management of open innovation, and royalty payment can be achieved; as a result, various 
perceptions of advantages of close innovation can be obtained. By contrast, if both the 
transition tendency and the perception of advantage of close innovation are low due to low 
tendency, the firm should continue to keep the open innovation strategy. Moreover, an increase 
of product development stage positively affects the knowledge of technology and then the 
knowledge in firm has a positive relation with the transition tendency to close innovation. Thus, 
as times goes by, an increase of knowledge due to an increase of production development stage 
causes an increase of the transition tendency which, in turn, causes an increase of the perception 
of advantage of close innovation. 
Based on the results of this study, we propose a strategy to manage open innovation in the 
final stage of new product development. At first, the current stage of product development for 
a new product should be carefully examined. If the level of product development stage becomes 
high, then the knowledge of technology in the firm should increase. The state of knowledge is 
carefully evaluated as to whether or not there is sufficient knowledge for final product in the 
firm. Then the firm should decide to decrease the open innovation activity with external 
research partners. As a second step, the decision whether or not to decrease or stop open 
innovation in the final stage of new product development should be made based on the 
consideration of the status of accumulation knowledge of technology to close innovation and 
the perception of advantage of close innovation. If the amount of knowledge accumulation in 
the firm is high in the commercial stage, the firm wants to close the inflow of external 
knowledge, the transition tendency to close becomes high, and, thus, the firm should stop open 
innovation. If the transition tendency is within an acceptable range, the firm should decide to 
start close innovation with new external research partners, but most of collaboration with 
external partner is kept to improve the current product to have a better performance or to modify 
the current product for new applications. If the transition tendency is too low, the firm should 
decide to keep current open innovation with new external partners. The product innovation 
stage related to the emergence of new innovative products by extension of the current new 
product should not be considered to decide on the transition tendency to close innovation, the 
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reverse of the degree of open innovation. 
As a third step, the decision to stop open innovation in the final stage of new product 
development should be taken based on both the consideration of transition tendency to close 
innovation and the perception of advantage of close innovation. The balance between the 
expense to keep open innovation due to high transient tendency to close innovation and profit 
of firm due to closeness should be considered; thereafter, the degree of close innovation can be 
decided based on the balance. To increase the transition tendency to close causes an 
acceleration to reduce the degree of open innovation, because the perception of advantage of 
close innovation increases due to an increase of firm profit and a decrease of expense for 
collaboration. The relations among knowledge, transition tendency, and perception of 
advantage of close innovation should be simultaneously evaluated. 
Taken together, our results demonstrate that product development stage and level of 
knowledge in firm are key factors to decide on the transition tendency to close innovation, i.e. 
the degree of close innovation with external partners. Accordingly, the decision to control 
degree of close should be accounted for based on the insights about the relations of closeness 
with firm performance as the perception of advantage of close innovation. 
 
5.2. Perspectives and Recommendation for Further Research 
 
In this study, three phases of open innovation were examined. In addition, the phases of open 
innovation were analyzed based on influential factors related mainly to the technology-point 
of view, though influential factors based on the non-technology point of view were found to be 
also very important in open innovation activities. Thus, in future research, other phases of open 
innovation (e.g. recruiting, evaluating, marketing, and so on), as well as an analysis focused on 
the non-technology point of view (e.g. marketing, environment, organization, firm culture, 
institutional characteristics, and so on) should be considered to better understand open 
innovation activities and to suggest appropriate management strategies for open innovation.  
A new model to explain product development in the biochip industry is needed to increase 
our understanding of NPD. In addition, a new model for organization behavior on the macro 
level related to open innovation is needed to better understand open innovation activity on the 
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whole bio-pharmaceutical industry level. Concepts of such models are proposed in the 
following sections. In the future, if the analyses are performed based on these models and the 
models are validated, open innovation in high tech industry will het more comprehensively 
verified and, consequently, more effective strategies will be developed. 
 
5.2.1. Recombinant technology model for new product development 
If teach segment of technology characteristics for fusion technology are clearly understood 
by decomposition and the model to describe this action is made, the NPD for fusion product 
can be clearly clarified. When a new NPD product is made, if product technology for a product 
is very complex (see Table 3.4), it is difficult to predict which direction the research will go in.  
To better understand the characteristics of fusion technology, an NPD process of biochip by 
decomposition is needed to develop relevant strategies that would enable the import of external 
knowledge in open innovation. Biochip, an innovative product in the biotechnology area, is 
made by the integration of various technologies. In new product development of biochip, a new 
model for technology generation can be developed by mimicking recombinant DNA 
technology. Such model can be called the recombinant technology model. The aim of this 
model is to develop a systematic combination of the techniques in the fusion technology area. 
The key technologies needed to develop products are decomposed into segments and are 
described as genes. The product development stages in the model can be related to influential 
factors, which can then be applied to develop the management strategy based on the 
characteristics of fusion technology.  
 
5.2.1.1. Model formulation 
The innovative product of fusion technology, like the biochip area, can be made by the 
combination of various technologies (see Table 3.4). The new model for technology generation 
based on recombinant DNA technology, called the recombinant technology model, was 
proposed here to develop systematical combination of the techniques in the fusion technology 
area. Assume that each technology to make biochip (see Table 3.4) is decomposed and then 
more than 30 kinds of technology characteristics are obtained. Let us define each technology 
as a gene, like a human gene to make the human body through gene translation and transcription. 
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Similarly to this process, key technologies needed to develop a product are decomposed into 
segments and are described as genes. The fusion of technology can be described as a 
recombination of each technique, called gene (see Figure 5.1). The original technology in 
biotechnology can be described as a full gene map. To make a product in nanobiotechology, 
the genes, i.e. techniques of biotechnology, should be changed by the foreign genes, i.e. the 
technique of nanotechnology. For example, protein has its reaction characteristics, but cannot 
be immobilized on a solid surface. That is original biotechnology character, called an original 
gene. If the nanoparticle is introduced into protein and the protein/nanoparticle hybrid is made, 
in which nanoparticle is introduced, it is called a foreign gene. By combing two technologies, 
a protein/nanoparticle hybrid is made and can be immobilized on solid surface, chip; therefore, 
we can make protein chip. Do a recombination of technologies is similar to making a protein 
chip. 
 
 
  Figure 5.1. Recombinant technology model for NPD of biochip 
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After the new recombinant gene map for product is achieved, it should be processed in a 
manufacturing factory to produce products. In this case, the manufacturing factory can be 
thought of as a cell. For technology evolution as compared to other products, there will be two 
ways: a totally new product based on the new fundamental principle and a new slightly 
modified product through changing of the product manufacturing process. First, to design a 
totally new product, the gene map should be changed by the insertion of a new gene, i.e. a new 
technique. Second, by a slight change of the manufacturing system (called new cell), the 
modification of the product can be done, meaning process innovation. By these process 
evolutions, a new product can evolve from a slightly modified product or improved product. 
The differences between the proposed model and previous concepts for technology 
development are as follows. Previously, the recombination of technologies has been thought of 
as an assembly of previous technologies (Hargadon 2003). In addition, the technology fusion 
was considered to be an equal combination of current technologies (Gassmann 2006). In 
recombinant technology, to achieve an innovative product, the insertion of outside technology 
to the fundamental core technology should be accomplished, in which the backbone technology 
concept is used. 
For example, the technology for biochip can be divided into bioinformatics, biomarker 
development and production, surface immobilization of biomarker, reaction and detection 
technique, and microscale chip fabrication. For the production of biochip, the surface 
immobilization technique and the chip fabrication technique should be changed by the 
nanoscale immobilization and nanoscale chip fabrication, respectively. Insertion of a gene, i.e. 
two kinds of nanotechniques, into the original gene (i.e. biotechnology techniques) should 
enable for the production of biochip. Since biotechnology companies generally have only 
techniques for biochip, nanotechniques should be supplied from external resources so that open 
innovation could be applied to supply the nanotechniques to the biotechnology companies. To 
make more advanced products as the next stage, the new chip process technology, such as 
nanoimprinting, can be applied, which can be called the evolution of process innovation. 
Alternatively, making new products using the new detection- and fabrication- technology, such 
as the electrical detection in application of scanning tunneling microscope and nanogap 
electrode, should be applied for a lower detection range, which can be called as evolution of 
product. 
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5.2.1.2. Chimera open innovation process in nanobiotechnology 
To achieve the distributed innovative product development, the strategy for the managing 
open innovation is needed in nanobiotechnology. Since the innovative product of fusion 
technology can be achieved through the recombinant technology method proposed in the 
previous section, the initiative work, such as design of fusion technology and decision of 
technology to be imported from external resource, should be done at first by internal source. 
Since the only use of external source from design of technique to accomplish the final 
commercial product can cause s loss of the core competency technique of company, the design 
of the fusion technique and assembly of collected techniques should be done by internal source, 
and thus the internal execution of part of core technique in original technology (see Figure 5.1) 
is recommended. We call this kind of the hybridization of internal source and external resources 
in technology development structure based on company initiative the chimera open innovation 
process. This process requires a change of organization, such as a structural change of R&D 
group and a cultural change to adapt a new idea from the outside is needed.  
For a successful adaptation of innovative product development by the chimera strategy of 
open innovation in fusion technology, such as nanobiotechnology, the following structure is 
can be suggested. 
(1) Idea of new product: The idea of a new product can be obtained from an internal or an 
external source.  
(2) Design of technology: The core techniques should be segmented and analyzed based 
on the recombinant technology method.  
(3) New organization: an Open Innovation Initiative R&D group (hereafter called OII) 
should be made that would design the product technology, collect the internal 
information in all R&D departments, distribute the ideas to the rest of the firm, and 
collect the technologies from external resources. OII would consist of members to be 
educated or trained in fusion technology, such as in different fields of engineering and 
science. All members should have knowledge for a business and market 
(4) Formation of technology supply chain: OII should play the key role in designing the 
fusion technology, contact external resources such as lead users, customers, and other 
scientists for open innovation. To open innovation, the following strategies should be 
used. First, the OII meets lead users and technology developers, and then collects their 
ideas for a product. Second, a website for open innovation should be created. The 
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website would consist of two categories, the fully open system to receive the ideas and 
products of customer and external researchers, on the one hand, and the controlled open 
system to receive the response of the lead users and friendly experts by suggesting 
problems of firm and receiving the solution, as well as giving internal knowledge and 
information, on the other hand Third, OII would make national non-profit society for 
the firm’s research field, creating open collaboration between external expert and other 
firms. For example, the national nanobiotechnology society should be made and the 
experts in that society would join open innovation to propose future technology 
breakthroughs with R&D groups of related firms. Fourth, the appropriate reward 
should be offered to external contributors. Fourth, OII should do the design of product 
technology based on the recombinant technology concept and decide which technique 
should be imported from external resources. Fifth, the collection of information and 
techniques from the technology supply chain should be done by push and pull. The 
continuous and stable technology supply would be needed to accomplish the 
development of innovative product. 
(5) Product production: OII would control the recombinant technology in internal R&D 
groups. If the R&D of firm depends too much on external resources, the firm’s own 
R&D capability may be weakened. Thus, OII should encourage the recombinant 
technology by giving other internal department’s information and external information 
to internal members of new product development department. The manufacturing of 
product should be done based on the application of the recombinant technology to the 
manufacturing process. 
(6) Future trend: The leading-edge technology for future should be encouraged and be 
evaluated for future asset by OII. The spin-off of false negative technology should be 
done by OII for the future unexpected success and collaboration. OII should regularly 
report to senior management group, including CEO, and the strategy change by CEO 
should be prepared based on the dynamic changes of the market and product due to 
open innovation. 
Since the nanobiotechnology field is a fusion of biotechnology and nanotechnology; therefore, 
here, knowledge distribution should be recognized and the importance of knowledge 
integration should be considered. The interactive innovation between internal and external 
experts should become important, since the sources of knowledge are wide-spread and, unlike 
specialists in kits one technology, experts in fusion technology are rare. Thus, the innovation 
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in nanobiotechnology should be done based on the recombinant technology concept, network 
learning, technology supply chain, and combination of internal and external resources in the 
chimera open innovation circumstances. The innovative product development with 
hybridization of internal and external resources in technology development structure should 
play the key role in innovation in nanobiotechnology and other fusion technology markets.  
In the future, the proposed recombinant technology model should be evaluated with structure 
interviews and surveys in bio-pharmaceutical industry so that to analyze open innovation in 
product development stage. The expected analysis results would yield relevant management 
strategies of open innovation in biochip, a product of nanobiotechnology. 
 
5.2.2. Macroscopic organization evolution in bio-pharmaceutical industry by open 
innovation 
As reported in section 1.5.1., the alliances between intra-biotechnology companies or 
biotechnology company-to-pharmaceutical firms are among the major factors to be considered 
for organization evolution in the biotechnology industry. Alliance is a major activity of open 
innovation. In the future, to construct the strategies for open innovation for a firm, the 
organization evolution related to alliances should be considered. In this section, a model for 
organization evolution is proposed based on the alliances among pharmaceutical firms and 
biotechnology firms. 
The alliance including mergers and acquisitions (M&A) greatly affects the evolution and 
competitiveness of organization in the biotechnology industry. The alliance becomes just 
another cooperate reorganization strategy, since biotechnology companies continue to look for 
ways to accelerate growth and to gain access to sales and marketing talent and market, and 
large pharmaceutical companies are looking forward to ways to increase revenue, to expand 
their pipelines of products, and to obtain critical mass in R&D. In this study, the organization 
evolution in the bio-pharmaceutical industry, including pharmaceutical-and biotechnology- 
industry due to alliance, are examined.  
The competition among major big pharmaceutical companies and biotechnology continues to 
exist. In addition, alliance in terms of licensing between major big pharmaceutical companies 
and biotechnology companies has been done. Thus, the organization evolution and 
competitiveness by the alliance among intra-pharmaceutical companies, among 
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pharmaceutical companies and biotechnology companies, and among intra-biotechnology 
companies should be analyzed together. The competition and collaboration among intra-
pharmaceutical companies and intra-biotechnology companies are described in Figure 5.2. 
 
 
Figure 5.2. Competition and collaboration among major big pharmaceutical firms and 
biotechnology firms. 
 
In this section, the macro-level relation in the entire big pharmaceutical companies and 
biotechnology is proposed (see (see Figure 5.3). Also, the organization revolution of 
biotechnology companies due to the reorganization by M&A among biotechnology companies 
should be elucidated based on alliance as mesoscopic relation. The microscopic relation the 
organization evolution of single biotechnology company should be explained based on 
technology-adoption cycle and entrepreneur-associated factors. Each macroscopic-, 
mesoscopic-, and microscopic relation affecting organization ecology has been analyzed by the 
proposition of various models.  
175 
 
Figure 5.3. Relations among major big pharmaceutical companies and biotechnology 
companies.  
 
In the future, the relationships in Figures 5.2 and 5.3 should be evaluated with structure 
interviews and surveys in bio-pharmaceutical firms so that to analyze open innovation on 
macroscopic level. The analysis results on the macroscopic level can yield relevant 
management strategies in open innovation for the entire bio-pharmaceutical level. 
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